RESTENOSIS: A GUIDE TO THERAPY
Dedicated to my wife, Monica, and to my children, Nathaniel and Kimberly, for all of their support
RESTENOSIS: A GUIDE TO THERAPY Edited by
David P Faxon MD Chief Section of Cardiology The University of Chicago Chicago IL USA
MARTIN DUNITZ
© 2001 Martin Dunitz Ltd, a member of the Taylor & Francis Group First published in the United Kingdom in 2001 by Martin Dunitz Ltd, The Livery House, 7–9 Pratt Street, London NW1 0AE This edition published in the Taylor & Francis e-Library, 2003.
Tel.: Fax.: E-mail: Website:
+44 (0) 20 7482-2202 +44 (0) 20 7267-0159
[email protected] http://www.dunitz.co.uk
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. A CIP record for this book is available from the British Library. ISBN 0-203-21303-3 Master e-book ISBN
ISBN 0-203-27013-4 (Adobe eReader Format) ISBN 1 85317 897 7 (Print Edition)
Composition by Wearset, Boldon, Tyne and Wear
iv
Contents
Preface Contributors
vii ix
8
Drug-coated stent for restenosis Marco A Costa
9
Gene transfer for coronary restenosis 129 Ripudamanjit Singh and Robert D Simari
1
Defining the clinical problem Thomas Feeney and David P Faxon
1
2
Pathophysiology of restenosis John D Altman, Antoni Bayes-Genis and Robert S Schwartz
9
3
4
5
6
7
Clinical presentations and noninvasive assessment of restenosis 21 Joel W Heger and Sanjeev D Ravipudi Clinical, biochemical, angiographic and intravascular ultrasound predictors of restenosis 39 Stefan Verheye and Glenn Van Langenhove Importance of physiologic assessment pre- and post intervention Michael D Eisenhauer and Morton J Kern
113
10 Stenting to prevent restenosis J Aaron Grantham and David R Holmes, Jr
145
11 Debulk/ stenting Antonio Colombo and Evangelia Karvouni
159
12 Management of in-stent restenosis 179 Richard A Howard and Alice K Jacobs 13 Management of restenosis through radiation therapy Ron Waksman
203
55
The role of intravascular ultrasound in the prevention and treatment of restenosis 77 Shinichi Shimodozono, Yasuhiro Honda, Heidi N Bonneau and Peter J Fitzgerald Pharmacological approaches to prevent restenosis 97 Vatsal H Mody, Alex Durairaj and Anil O Mehra
14 Radiation for restenosis Paul S Teirstein
221
15 Radioisotope stents Tim A Fischell
241
16 Restenosis in the peripheral vasculature Manu Rajachandran and Robert Schainfeld Index
251
273
v
vi
Preface
When Dr Andreas Grüntzig initially performed coronary angioplasty more than twenty years ago, it was estimated that no more than five percent of patients would be suitable for the procedure. Clearly, this has not been the case, with more than one and a half million patients undergoing the procedure each year in the United States. Despite enormous advances in technology that have resulted in increased success and reduced complications, restenosis has remained the Achilles’ heel of angioplasty. Over the past twenty years, there have been major advances in our understanding of the pathophysiology of restenosis that have allowed new and effective treatments for restenosis. This book addresses the major issues of restenosis, from clinical presentation and pathophysiology to current therapy. Specifically, the role of stents and
new interventional devices in the treatment of restenosis are discussed. In addition, several chapters have been devoted to the emerging technologies of intravascular radiation therapy and drug eluding stents, as both have shown considerable promise in reducing the incidence of restenosis. The chapters in this book are written by internationally recognized authorities in each of their respective areas of expertise. We have attempted to provide not only a thorough review of the topic, but also the most current information relative to it. We hope you find this book of value in understanding this rapidly advancing field and that this knowledge will be a foundation for future research that ultimately leads to an effective treatment for restenosis. David P Faxon
vii
viii
Contributors
John D Altman, MD
Michael D Eisenhauer, MD
Center for Applied Vascular Biology Mayo Clinic ROCHESTER MN 55905-0001 USA
Chief, Cardiology Service William Beaumont Army Medical Center El Paso TX 79920 USA
Antoni Bayes-Genis, MD
David P Faxon, MD
Mayo Clinic ROCHESTER MN 55905-0001 USA
Chief, Section of Cardiology University of Chicago Chicago IL 60637 USA
Heidi N Bonneau, MS, RN Stanford University Medical Center Stanford CA 94305-5637 USA
Marco A Costa, MD, PhD Department of Interventional Cardiology Institute Dante Pazzanese of Cardiology Ibirapuera Sao Paulo Brazil
Antonio Colombo, MD Director, Cardiac Catheterization Laboratory EMO Centro Cuore Columbus 20145 Milano Italy
Alex Durairaj, MD Medical Center Division of Cardiology Los Angeles CA 90033 USA
Thomas Feeney, MD Pasadena CA 91107 USA
Tim A Fischell, MD, FACC Director of Cardiovascular Research Heart Institute at Borgess Medical Center Kalamazoo MI 49001 USA
Peter J Fitzgerald, MD, PhD Associate Professor of Medicine Stanford University Medical Center Stanford CA 94305-5637 USA
J Aaron Grantham, MD, FACC Division of Cardiovascular Disease and Cardiac Catheterization Laboratory Mayo Clinic Rochester MN 55905 USA
ix
CONTRIBUTORS
Joel W Heger, MD
Morton J Kern, MD, FACC
Division of Cardiology University of Southern California School of Medicine Los Angeles CA 90033 USA
Director, JG Mudd Cardiac Catheterization Laboratory St Louis University School of Medicine St Louis MO 63110 USA
David R Holmes, Jr, MD
Anil O Mehra, MD
Consultant in Cardiovascular Diseases and Internal Medicine Mayo Clinic Rochester MN 55905 USA
Yasuhiro Honda, MD Assistant Director, Cardiovascular Care Analysis Laboratory Stanford University Medical Center Stanford CA 94305-5637 USA
Richard A Howard, MD Senior Fellow in Cardiology Section of Cardiology Boston Medical Center Boston MA 02118 USA
Alice K Jacobs, MD Professor of Medicine, Director, Cardiac Catheterization Laboratory and Interventional Cardiology Section of Cardiology Boston Medical Center Boston MA 02118 USA
Evangelia Karvouni, MD Columbus Hospital 20145 Milano Italy
x
Medical Center Division of Cardiology Los Angeles CA 90033 USA
Vatsal H Mody, MD Medical Center Division of Cardiology Los Angeles CA 90033 USA
Manu Rajachandran, MD Medical Director, Comprehensive Vascular program, Deborah Heart and Lung Center Assistant Professor of Medicine Division of Vascular Medicine SMC4DVM St Elizabeth’s Medical Center Boston MA 02135-2997 USA
Sanjeev D Ravipudi, MD Division of Cardiology University of Southern California School of Medicine Los Angeles CA 90033 USA
CONTRIBUTORS
Robert Schainfeld, MD
Paul S Teirstein, MD
Assistant Professor of Medicine, Tufts University School of Medicine and Director, Noninvasive Vascular Laboratory Division of Vascular Medicine St Elizabeth’s Medical Center Boston MA 02135-2997 USA
Director, Interventional Cardiology Scripps Clinic and Research Foundation La Jolla CA 92307-1027 USA
Robert S Schwartz, MD Consultant in Cardiovascular Diseases and Internal Medicine Mayo Clinic Rochester MN 55905-0001 USA
Stefan Verheye, MD Cardiovascular Translational Research Institute, Middelheim, Antwerp, Belgium and Interventional Cardiology Middelheim Hospital 2020 Antwerp Belgium
Glenn Van Langenhove, MD, PhD Shinichi Shimodozono, MD Stanford University Medical Center Stanford CA 94305-5637 USA
Middelheim Hospital 2020 Antwerp Belgium
Ron Waksman, MD, FACC Robert D Simari, MD Associate Professor of Medicine Mayo Clinic Rochester MN 55905-0001 USA
Ripudamanjit Singh, MD
Professor of Medicine (Cardiology), Georgetown University Director of Experimental Angioplasty Cardiology Research Foundation Washington Hospital Center Washington DC 20010 USA
Department of Cardiology Mayo Clinic Rochester MN 55905-0001 USA
xi
1 Defining the clinical problem Thomas Feeney and David P Faxon
Introduction Andreas Grüntzig first introduced percutaneous transluminal coronary angioplasty (PTCA) in 1977, however, 15 years earlier Charles Dotter conceived the idea of angioplasty and performed the initial clinical studies in peripheral vessels.1 Since its inception, the technique has become the most commonly performed coronary revascularization procedure in the world, with an estimated one million procedures per year. While the technique initially used only balloon catheters to enlarge the vessel lumen, today, atherectomy, laser, and stents complement the technique, with nearly 70% of procedures utilizing stents.2 Accordingly, the technique is more commonly referred to today as percutaneous coronary intervention or PCI to reflect these changes. Although major advances in equipment, pharmacology and techniques have led to wider application and improved success with reduced complications, restenosis remains the primary limiting factor in long term vessel patency (Table 1.1). Restenosis, or renarrowing of the treated vessel segment, occurs in approximately 30% of patients within 9 months of the procedure and accounts for significant morbidity and health care expenditures. Numerous clinical and experimental trials have studied mechanical and pharmacological approaches to the problem, but nearly all have been unsuccess-
ful. Pharmacological trials have evaluated platelet inhibitors, thrombin inhibitors, lipid lowering, fish oil, steroids, angiotensin converting enzyme (ACE) inhibitors, antiinflammatories and gene therapy to inhibit smooth muscle cell proliferation, antioxidants, and antiproliferative agents.3 Despite the advances in interventional techniques and pharmacotherapy, restenosis remains the Achilles heel of angioplasty. The formidable challenge ahead is to better understand restenosis and develop a mechanistic approach to its treatment.
Mechanism of angioplasty In an effort to gain further insight into the restenotic process, the mechanism of percutaneous coronary intervention (PCI) must be understood.4 At the time of PCI, the balloon stretches the arterial wall and produces tears in the atherosclerotic plaques in order to produce a larger luminal area. The vessel then progresses through a complex process consisting of initial elastic recoil, subsequent thrombosis and later, intimal thickening and vascular remodeling. Elastic recoil is defined as the difference between inflated balloon diameter and minimal lumen diameter upon balloon deflation. The degree of elastic recoil depends on the viscoelastic properties in the atherosclerotic plaque and the arterial wall. Most of the elastic recoil occurs within 30
1
DEFINING THE CLINICAL PROBLEM
Variable Years No. of patients New devices % MVD Angiographic success Clinical success In hospital Death (%) MI (%) CABG (%) Restenosis TVR
Grüntzig 1977–80 169 No 42 79 – 0 7 2.9 30 16
NHLBI-I 1977–81 1156 No 25 68 61 1.2 4.9 5.8 32 21
NHLBI-II 1985–86 1802 No 53 91 78 1.0 4.3 3.4 – 30
MCD 1990–94 3787 Yes 51 89 86 0.4 5.2 2.7 – 23
NHLBI-III 1997–98 2700 69% 66 93 93 0.6 2.5 0.7 – 20.3
PCI, percutaneous coronary intervention; NHLBI, National Heart, Lung and Blood Institute; MCD, multivessel coronary disease; MVD, mitral valve disease; MI, myocardial infarction; CABG, coronary artery bypass graft; TVR, target vessel revascularization.
Table 1.1 Changes in PCI practice and outcomes.
minutes after balloon deflation but may also occur up to 24 hours after the procedure. This elastic recoil can result in as much as a 50% decrease in cross-sectional area. This recoil is more common after PCI, especially when performing interventions on eccentric and ostial lesions. In terms of device predilection, elastic recoil is greatest after PCI, intermediate after directional coronary atherectomy (DCA) and does not significantly occur after stenting. Angiographic analysis suggests that the early recoil is associated with a greater incidence of restenosis. A partial explanation for the benefits of stenting in reducing restenosis may relate to the elimination of this elastic recoil. PCI works by stretching and thus, injuring the vessel wall. In the process of injuring the wall, the endothelial lining is completely removed. Almost immediately following an intervention, with any device, the subendothelial structures are exposed to circulating blood elements. Platelets are immediately laid down
2
through adhesion of the platelet glycoprotein (GP)-1a receptor to collagen and von Willebrand’s factor. Aggregation ensues and can in some cases lead to thrombotic occlusion or abrupt closure of the vessel. Over the next few days, a significant inflammatory response leads to infiltration of polymorphonuclear cells initially, and subsequently, monocytes and macrophages. These blood elements (including platelets), as well as injury to the smooth muscle cells, result in release of a number of growth factors and cytokines that stimulate smooth muscle cell migration and proliferation into the injured area. The fibroblast within the adventitia is felt by many to be an important component of this cellular proliferation process, as well. Finally, the late stages of healing involve remodeling of the extracellular matrix with the production of collagen and this process may lead to generalized geometrical remodeling of the vessel, with either enlargement or constriction. This further
CLINICAL COURSE
aggravates the restenosis process. Clinical studies have supported the concept that remodeling is the most dominant factor in restenosis, accounting for ⬎ 60% of ultimate lumen loss.
Definition of restenosis Initially the field was hampered by a wide variety of angiographic and clinical definitions that led to widely disparate incidences of the problem (Table 1.2).5 Grüntzig proposed that restenosis be defined as the loss of 50% of the gain in initial lumen diameter. The National Heart Lung and Blood Institute (NHLBI) proposed four definitions, which included Grüntzig’s initial definition. The Thorax Center proposed a loss of more than 0.72 mm in lumen diameter, measured by quantitative methods, at follow-up. However, Dr Grüntzig subsequently proposed that restenosis be defined as more than a 50% stenosis at the time of follow-up angiography, a definition that is now widely accepted as the angiographic definition of restenosis. While this definition is practical and easy to use, it does not accurately reflect the biological process that results in restenosis. It has been demonstrated by Serruys et al that when restenosis is defined as the absolute decrease in lumen diameter, the majority of patients show as least some degree of restenosis and the distribution follows a Gaussian curve.6 In addition, it was shown by Kuntz and Baim that the absolute loss in lumen diameter (late loss) was inversely related to the acute gain in lumen diameter.7 It was also demonstrated that the ratio of late loss to acute gain approximated 50% with nearly all interventional techniques. Late loss ratio is therefore, a much better index of the biological process, since it takes into account the degree of initial
change in lumen diameter, presumably a measure of the damage to the vessel wall. Clinical restenosis has also been defined in various ways. Currently, the most accepted definition of clinical restenosis is target vessel or target lesion revascularization, defined as the recurrence of symptoms with angiographic evidence of restenosis in the same vessel or in the same lesion and a subsequent PCI or surgery of that lesion. Earlier definitions had not required a revascularization and therefore, a large number of patients who had medically managed borderline lesions were also defined as having restenosis. Defining restenosis as target vessel revascularization (TVR) is most relevant to the patient, since it accurately reflects his or her risk of needing another procedure as a result of restenosis. The incidence of TVR or target lesion revascularization (TLR) is approximately half that for angiographic restenosis. However, because TVR closely parallels angiographic restenosis, it is commonly used as a surrogate endpoint in clinic trials.
Clinical course The time course of restenosis is variable, but usually occurs within the first 9 months, with the median time at 3 months. It had been previously felt that restenosis occurred within the first 6 months of the procedure based on angiographic studies. However, since early angiographic restenosis is often silent, clinical restenosis or TVR occurs later, but usually before 9 months. Also, it rarely, if ever, occurs in the first month and recurrence of symptoms in this time period usually reflects either late subacute thrombosis or as a result of disease in other vessels that were not dilated. Restenosis can occur after 9 months and has been reported to occur up to 7 years after the procedure at a rate of 1–2% per year, the same as for progression of disease. It is doubtful that
3
DEFINING THE CLINICAL PROBLEM
Associated Clinical Diabetes Unstable angina Variant angina Dialysis Tobacco use Primary PCI Hypercholesterolemia Male gender Previous MI Hypertension Age Previous restenosis Long lesion (⬎ 20 mm) Multivessel Multilesion SVG (prox & body) Chronic total occlusion Collaterals to dilated vessel Ostial stenosis Angulation (⬎ 45°) Eccentricity Calcification Bifurcation lesion Thrombus Proximal location LIMA SVG (distal lesion) Procedural Pressure gradient ⬎ 20 mmHg Residual stenosis ⬎ 30% Balloon inflation variables Number of inflations Inflation time Balloon material Maximum inflation Inflation technique
Possibly associated
No association
x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
x x x x x
PCI, percutaneous coronary intervention; MI, myocardial infarction; SVG, saphenous vein graft; LIMA, left internal mammary artery.
Table 1.2 Clinical, angiographic, and procedural variables identified as risk factors for restenosis.
4
STENTS AND RESTENOSIS
the biological process resulting in this late recurrence is the same as that responsible for restenosis and is more likely due to progression of atherosclerosis.
Predictors of restenosis A number of clinical studies have identified clinical and angiographic predictors of restenosis (Table 1.2).3 Clinical factors have included male gender, diabetes, unstable angina, variant angina, prior myocardial infarction (MI), dialysis, and prior restenosis. Angiographic variables have included long lesions, multivessel procedures, saphenous vein graft angioplasty, chronic total occlusion, ostial lesions, and bifurcation lesions. Procedural variables have included acute gain, final minimal lumen diameter (MLD), final percent stenosis, absence of a dissection, and thrombus. In large data banks, multivariate analysis has identified only a few of these variables to have independent influence.8 By far, the most potent predictor is the final MLD or percent stenosis. Other variables include lesion length, saphenous vein graft (SVG) lesions, instent restenosis, and unstable angina. However, these variables only explain 20–30% of restenosis, underscoring the poor understanding of the cause of restenosis.
Stents and restenosis In order to understand the process of restenosis, the trends in coronary intervention over the last 23 years should be analysed. One report from the Society of Cardiac Angiography and Interventions examined contemporary trends in percutaneous coronary procedures performed from 1996 to 1998.9 Nineteen thousand, five hundred and ten coronary procedures were performed during this time in 33 separate institutions. The most striking feature
is the dramatic increase in coronary stent implantation and a decrease in the use of balloon angioplasty. The overall use of ablative devices in general practice remained modest, with rotational atherectomy use increasing and directional atherectomy use decreasing. The use of platelet receptor antagonists remained modest, at 13% overall. In terms of the frequency of device selection, by 1998, stents were used 71% of the time. Other databases, such as the NHLBI PTCA Registry, also support these observations.10 Stent implantation has been shown to improve both short and long term results of coronary interventions.11 The use of these endoluminal scaffolds has dramatically increased since their introduction, as indicated above. One of the most compelling reasons for their widespread use is the favorable acute angiographic and clinical outcomes that result from their use. A comparison of overall hospital outcomes between balloon angioplasty and stent use from the NHBLI PTCA Registry showed a reduction in the frequency of emergency bypass surgery and the combined rates of death and emergent bypass surgery in the stent population. Two clinical trials, STRESS and BENESTENT, were instrumental in demonstrating the benefits of stenting in reducing restenosis and were largely responsible for the tremendous growth in their use. The mechanism for the reduction of restenosis by stents is the prevention of recoil and remodeling rather than a reduction in intimal hyperplasia. In fact, stents increase the amount of intimal hyperplasia due to the larger lumens achieved by the procedure. Despite the success of stents in preventing restenosis, recurrence following stenting occurs in approximately 15–20% of patients.12 The rates of restenosis are significantly higher in subgroups of patients with less favorable anatomy, ranging from 30% to 50%. Once
5
DEFINING THE CLINICAL PROBLEM
restenosis has occurred within the stent, treatment is difficult and re-restenosis is very high, ranging from 40% to 60%. Angiographic patterns of in-stent restenosis range from focal to diffuse (⬎ 10 mm) and may be only within the stent or on the edges (within 5 mm). The angiographic predictors of in-stent restenosis are prior restenosis, long lesion, multiple stents, small vessels, and high-pressure inflation (⬎ 16 atm).13 Patients with diabetes have a significantly higher restenosis rate independent of the device used, but within the diabetic subgroup, stents reduce the rate of restenosis.14 The mechanism of in-stent restenosis is entirely due to intimal hyperplasia, as remodeling is prevented by the stent. The treatment of in-stent restenosis is difficult, as nearly all devices are ineffective in reducing its incidence.15 The greatest potential treatment appears to be intravascular radiation. Recently, several devices have been approved for use. Although recent advances in stent deployment techniques and the use of aspirin and anti-platelet medications have improved the safety and reduced the length of stay and vascular complication rates, studies performed during the era of reduced anticoagulation suggest that the economic impact of stenting is not substantially different from earlier data obtained from the STRESS trial. It is likely
6
that the overall 1-year costs of stent deployment will remain $500 to $1000 higher compared with balloon angioplasty.16 Whether the issue of ‘routine’ vs ‘provisional’ stenting becomes a cost-effective strategy remains in question. Eventually, however, the in-hospital costs of stenting may decrease sufficiently to the point where the long-term costs of stenting are similar to balloon angioplasty. This, of course, will be dependent on the degree of reduction in restenosis.
Conclusion The field of interventional cardiology has made enormous advances over the past 20 years. However, to be able to provide an effective and long lasting treatment to patients with symptomatic coronary disease, it will be essential that the problem of restenosis be solved. This book, written by authoritative leaders in the field, addresses the current status of restenosis and the means to prevent it. New therapies, including pharmacological, gene, mechanical, and radiation, now offer considerable hope of reducing restenosis below 10% and perhaps even to the 5% range. Achieving this would provide a durable revascularization procedure that would have an early failure rate equal to coronary bypass surgery.
REFERENCES
References
1. 2. 3.
4. 5.
6.
7. 8.
9.
Grüntzig AR, Senning Å, Siegenthaler WE. Nonoperative dilation of coronary-artery stenosis. N Eng J Med 1979; 301:61–68. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98:1802–1820. Hillegass WB, Ohman ME, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd edn. Philadelphia: WB Saunders Company, 1993, 415–435. Schwarz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998; 81:14E–17E. Beatt KJ, Serruys PW, Renseing BJ, Hagennoltz PR. Restenosis after coronary angioplasty: new standards for clinical studies. J Am Coll Cardiol 1990; 15:491–498. Serruys PW, Luitjen HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77:361–371. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation 1993; 88:1310–1323. Rensing BJ, Hermans WR, Vos J et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993; 88:975–985. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report
10.
11.
12.
13.
14.
15. 16.
from the registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv 2000; 49:19–22. Cohen HA, Jacobs AK, Yeh W et al. Does therapy with GP IIb/IIIa receptor antagonists improve late clinical outcome following percutaneous coronary intervention? A report from the NHLBI PTCA Dynamic Registry. J Am Coll Cardiol 2000; 35:31A (abst). Kimura T, Yokai H, Tamara T et al. Three years clinical and quantitative angiographic follow-up after the Palmaz–Schatz coronary stent implantation. J Am Coll Cardiol 1995; 25:375A (abst). Holmes DR Jr, Hirshfeld J Jr, Faxon D et al. ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol 1998; 32:1471–1482. Klugherz BD, Meneveau NF, Kolansky DM. Predictors of clinical outcome following percutaneous intervention for in-stent restenosis. Am J Cardiol 2000; 85:1427–1431. Van Belle E, Bauters C, Hubert E et al. Restenosis rates in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96:1454–1460. Mintz GS, Mehran R, Waksman R et al. Treatment of in-stent restenosis. Semin Interv Cardiol 1998 Jun; 3:117–121. Cohen DJ, Breall JA, Ho KKL et al. The economics of elective coronary revascularization: a comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting, and bypass surgery. J Am Coll Cardiol 1993; 22:1052–1059.
7
2 Pathophysiology of restenosis John D Altman, Antoni Bayes-Genis, Robert S Schwartz
Introduction In 1999, more than 400 000 coronary angioplasties were performed in the United States and more than 1 000 000 world wide. In the treatment of flow-limiting stenosis, a high pressure angioplasty balloon is inflated within the lesion causing fractures in the plaque, the internal elastic membrane, media, and adventitial structures. The subsequent arterial healing response begins immediately, and eventually is essential for restoring normal arterial function. However, in 30–40% of patients this normal response is exaggerated, resulting in restenosis. The process of restenosis is complex, involving many separate mechanisms including elastic recoil, mural thrombus, neointimal formation, and arterial remodeling.
Elastic recoil and thrombus Elastic recoil is defined as the difference in vessel cross-sectional area during and shortly after balloon inflation. Elastic recoil is an acute event impacting procedural success rate rather than long-term restenosis rate. The most potent predictor of long-term lumen diameter is post procedural lumen diameter. The elastic components of the arterial wall, the media, adventitia, and internal and external elastic membranes, have memory and can cause significant acute recoil after balloon
deflation. Debulking with the removal of medial and adventitial tissue reduces elastic recoil and results in larger post procedural luminal areas compared to angioplasty alone. However, debulking does not improve longterm clinical event rates except to the extent that carefully performed atherectomy results in a larger lumen.1 The use of intravascular stents has dramatically increased procedural success rates by limiting elastic recoil. However, acute stent recoil of 15–30% is routinely observed, especially in calcific and densely fibrotic lesions. Thrombus formation is common following angioplasty but rarely causes clinical symptoms of abrupt vessel closure. The extent of nonocclusive mural thrombus is proportional to the degree of vessel injury and occurs despite the aggressive use of antiplatelet and antithrombin agents. In a healthy artery, the endothelial lining regulates platelet activation and thrombus formation through the release of nitric oxide, prostacyclin, and antithrombin III. Disruption of the endothelial lining is the first sign of injury following angioplasty and results in the acute loss of these inhibitory functions. Similarly, denudation exposes the highly thrombogenic subendothelial matrix and collagen. Tissue factor, known as thromboplastin, binds factor VII/VIIa and leads to thrombin activation and fibrin deposition. Platelets are recruited to the injured vessel through interactions with collagen and the
9
PATHOPHYSIOLOGY OF RESTENOSIS
platelet glycoprotein lalla complex. This interaction is strengthened by subendothelial von Willebrand factor binding. Adherent platelets are activated by thrombin and release alpha granule contents including serotonin, thromboxane A2 and platelet-derived growth factor (PDGF). Activation also leads to conformational changes in the platelet glycoprotein IIb/IIIa receptor, allowing for fibrin crosslinking to occur. The resulting fibrin-platelet rich thrombus is a potent stimulus for neointimal formation (Fig. 2.1). Thrombin, fibrin degradation products, platelet substances including PDGF and cytokines released from recruited inflammatory cells can cause the migration and proliferation of neointimal cells. The fate of the mural thrombus in humans is that it most likely organizes into neointima. In porcine coronary arteries, a layer of endothelium covers the mural thrombus 4 days after injury. A mononuclear inflammatory infiltrate occurs and by 21 days has actively resorbed the thrombus material. In the meantime, ␣-actin positive cells migrate into
the thrombus using it as scaffolding for neointimal formation.
Neointimal formation The intima is the region of the artery bordered by the luminal surface and the internal elastic membrane. At birth the intima consists of only endothelial cells sitting on the internal elastic membrane. With increasing age, smooth muscle cells begin to appear within the intima. Their longitudinal orientation, compared to the circular orientation in the media, suggests a response to changes in wall stress. In atherosclerotic heart disease, lipid rich deposits accumulate at these sites, accelerating the intimal thickening process. Stenosed arteries are routinely treated with angioplasty and the healing response that follows can be dramatic with further intimal thickening, called neointima (Fig. 2.2). The process of neointima formation includes mural thrombus formation and the proliferation and migration of myofibroblasts and smooth muscle cells. Endothelial, inflam-
Neointima Chronic Thrombus Lumen Acute Thrombus
Plaque
10
Figure 2.1 Thrombus formation is common following angioplasty and is proportional to the degree of vessel injury. The artery shown is from a patient that died in a motor vehicle accident 10 months after balloon angioplasty. The insert identifies acute and chronic thrombus formation. Inflammatory cells are seen infiltrating the chronic thrombus and beneath, neointimal formation is apparent.
NEOINTIMAL FORMATION
Neo intima Lumen
Figure 2.2 Restenosis of the left anterior descending artery 3 years post percutaneous transluminal coronary angioplasty in a 70-year-old male. Neointimal hyperplasia is found overlying the areas of medial tear (arrows) and also covering the atherosclerotic plaque.
Plaque
matory and smooth muscle-like cells are the key players in these processes.
Endothelial cells Disruption of the endothelial lining is the first stage of arterial injury following balloon angioplasty. Endothelial cells rapidly enter the replication cycle to restore endothelial continuity, a process of 1–2 weeks. Even after complete reendothelialization, endothelial function may not be restored for many months. Acute loss of the endothelial barrier exposes subendothelial collagen to circulating thrombin and platelets. Small amounts of mural thrombus form and although not occlusive, are a potent stimulus for neointima formation. In addition to its well known role in regulating vessel tone and platelet aggregation, the endothelium appears to directly modulate
the proliferative activity of the underlying smooth muscle cells (SMCs). Nitric oxide is a potent inhibitor of SMC proliferation and migration in cell culture.3,4 Nitric oxide also balances the biological effects of endothelin-1. Endothelin-1, released by the endothelium in response to many stimuli including mechanical injury, is a potent vasoconstrictor and mitogen for SMCs. These effects are mediated by endothelin-1 receptor A (ETA) located on SMCs.3 In healthy endothelium, the effects of endothelin-1 are balanced by endothelin-1 receptor B (ETB) mediated increases in nitric oxide and prostacyclin release. Angioplasty disrupts this balance. Following angioplasty, coronary sinus endothelin-1 levels are elevated and ETA expression is increased within the neointima while nitric oxide release remains depressed for many weeks. The role of endothelin-1 is validated in animal models by
11
PATHOPHYSIOLOGY OF RESTENOSIS
demonstrating the efficacy of endothelin-1 antagonists in reducing neointimal thickening.5 Previous investigations have underscored the principle of cross-talk between endothelial cells and SMCs.4 Neointimal thickness is closely related to the presence of a regenerated endothelium, although the extent of medial injury plays a greater role in determining the magnitude of neointimal formation. Large areas of endothelial denudation without trauma to the media lead to mild neointimal thickening.6 In contrast, focal endothelial denudation with substantial medial trauma, including rupture of the internal elastic lamina and/or external elastic lamina, is associated with marked neointimal thickening, despite prompt endothelial regeneration.7 This latter type of injury is induced in animals by placing a soft silicone catheter around the artery. A significant neointimal response occurs with minimal endothelial disruption indicating that endothelial injury alone is not sufficient to produce significant neointimal thickening.
Smooth muscle-like cells Since the introduction of coronary angioplasty over two decades ago, most of the hypotheses of the mechanisms of restenosis had a similar life cycle: initial enthusiasm followed by subsequent revision. The current understanding is that SMCs are activated after balloon injury and shift from contractile to synthetic phenotype that leads to proliferation, migration, and extracellular matrix formation.8 The importance of SMC proliferation is still controversial in human neointimal hyperplasia. Two studies of human restenotic lesions using directional atherectomy showed conflicting results. Pickering et al9 found cellular proliferation rates of about 20%, while O’Brien et al4 reported less than 1%.9,5 As a result, cell
12
migration through the internal elastic membrane has emerged as a distinct and active mechanism in the genesis of neointimal hyperplasia. There are multiple ways to explain the complexity of neointimal formation after balloon injury. this overview attempts to simplify the issue, by discussing three different perspectives of neointimal growth according to the origin of the cells: medial, adventitial, and luminal. Although the animal models and the methodology used are different, taken together they provide a reasonable understanding of cell kinetics in neointima formation. The medial origin of neointimal cells was suggested by experiments performed in the rat and rabbit peripheral arteries.4 Fogarty catheters were used to gently rub the endothelial cells off the surface of the artery with minimal medial damage. In this model, a first wave of cell proliferation begins in the media within 24 hours after injury and is mediated by basic fibroblast growth factor (bFGF).10,11 Administration of a bFGF neutralizing antibody limits early medial SMC replication after injury but has no effect on the resulting neointimal thickening.12 This study also questions the significance of SMC proliferation in neointimal formation. Hormonal factors released at the site of injury also play a role in the response of SMCs to balloon injury. Infusion of angiotensin II in rats is followed by marked SMC proliferation in the intima.13 Powell et al reported that inhibitors of angiotensin converting enzyme (ACE) suppress myointimal proliferation after vascular injury.14 The actions of ACE inhibitors are probably not solely related to an effect on angiotensin II levels, but may be caused in part by an effect on bradykinin metabolism or by effects mediated by aldosterone. Nonetheless, two large placebo-controlled trials showed no benefit of ACE inhibitors in human restenosis rates.15,16 The second wave of the response to injury in
NEOINTIMAL FORMATION
rat arteries involves migration of SMCs from their normal position in the tunica media to the intimal layer. PDGF is a critical signal for this migration.17 Although PDGF is a potent mitogen for SMCs in cell culture, its action in injured rat arteries appears to be chemoattraction. Most studies in injured porcine coronary arteries are consistent with the medial origin of neointimal cells. Porcine coronary arteries are injured with rigid, non-compliant angioplasty balloons that cause breaks in the medial wall exposing the outer elastic. Neointimal formation occurs in the region between the broken ends of the media and is thought to consist of SMCs migrating from the injured medial segment. Similarly, porcine and human post angioplasty restenosis lesions are thought to consist of SMCs originating from the media, since the majority of neointimal cells are ␣-smooth muscle actin positive by immunostaining (Fig. 2.3).18,19 However, there is evidence that non-muscle cells may express ␣-smooth muscle actin with the appropriate stimulation.20 Myofibroblasts are specialized
fibroblast-like cells that show induced expression of ␣-smooth muscle actin.21 These cells have the ultrastructural features intermediate between a fibroblast and a SMC. Myofibroblasts typically lack markers of highly differentiated SMCs such as desmin, h-caldesmon, and smooth muscle myosin, but show induced expression of ␣-smooth muscle actin.22 Recent work by Wilcox suggests that myofibroblasts in the adventitia proliferate after angioplasty and migrate into the neointima where they appear as smooth muscle ␣-actin containing cells.23,24 Three days after injury of the porcine coronary artery the highest cellular proliferation is observed in the adventitia near the site of medial tear. Two weeks later these cells are found within the neointima. Additional work must be done in order to establish the exact percentage of neointimal cells with adventitial origin. Schwartz et al suggest that blood borne cells capable of ␣-smooth muscle actin expression play a significant role in neointimal formation.25 Deposition of nonocclusive mural thrombus following angioplasty is a potent chemoattractant for inflammatory cells. Three
Lumen
Neointima
Media Adventitia
Figure 2.3 Neointimal hyperplasia observed 28 days after radio frequency-induced injury in a pig coronary artery. This model of vessel injury is characterized by medial necrosis and voluminous neointimal hyperplasia. Note the thick neointima made of actin-positive cells and extracellular matrix. Left panel: elastic von-Gieson stain. Middle panel: hematoxylin-eosin stain. Right panel: ␣-smooth muscle actin stain. Magnification 25⫻.
13
PATHOPHYSIOLOGY OF RESTENOSIS
to 8 days after porcine coronary artery injury an intense cellular infiltration is evident. The infiltrate consists of monocytes transitioning to macrophages, neutrophills, and lymphocytes. The inflammatory infiltrate develops from the luminal side of the injured artery, with cells migrating progressively deeper into the mural thrombus. Inflammatory cells release cytokines and growth factor and 8 days after injury actin-positive cells are observed forming a ‘cap’ across the top of the mural thrombus. The observation that smooth muscle-like cells are first seen at the luminal surface suggests a blood origin. The SMC migration and proliferation into the degenerated thrombus creates substantially increased neointimal volume, much greater than that of the thrombus alone. The influence of elastin on migration and proliferation of SMCs in the restenosis process is under intense investigation since it appears that elastin degradation facilitates SMC migration. Oho et al26 showed that following arterial injury, elastase activity is increased and associated temporally with the development of neointima. They suggest that this may be prevented with the administration of serine proteinase inhibitors, thereby reducing elastase activity. Similarly, the dramatic neointimal formation associated with closure of the ductus arteriosus is initiated by internal elastic membrane digestion with subsequent SMC migration. Lastly, studies in mice where the elastin gene was deleted indicated the key role elastin plays in maintaining normal artery architecture.
Extracellular matrix Two observations indicate that the production of extracellular matrix (ECM) proteins by activated neointimal cells significantly contributes to the development of restenosis.27
14
First, the time course of restenosis does not correlate with cellular proliferation. The restenotic process appears to plateau at 3–6 months while cellular proliferation rapidly declines after a few weeks. Secondly, only 11% of the neointima consists of cellular material; the vast majority is myxoid tissue.25 the major ECM components include fibrous proteins of two functional types (structural collagens and elastin) and cell adhesive or antiadhesive molecules such as fibronectin, vitronectin, laminin; and proteoglycans hyaluran. In a rabbit model of restenosis, the synthesis and net content of collagen, elastin and proteoglycans were significantly increased at 1, 2 and 4 weeks after angioplasty in iliac arteries.28 Increased synthesis of proteoglycans (biglycan and decorin) and collagen types I, III and IV has also been described in primary atherosclerotic and restenotic human coronary arteries.29 Moreover, hyaluronan along with its receptor CD44 is upregulated in the neointima.30 CD44 has also been shown to play a role in migration of cells into fibrin or osteopontin.31 Rasmussen et al32 found that administration of neutralizing anti-transforming growth factor (TGF)-1 antibody to cultured rat SMC from injured arteries inhibited the production of proteoglycan synthesis. The direct transfer of TGF-1 gene into porcine arteries is associated with increase of collagen and proteoglycan synthesis accompanied by intimal and medial hyperplasia.33 Together, these findings suggest that TGF-1 may be a major mediator of abnormal ECM protein expression in the pathology of vascular restenosis. Little has been done to identify the matrix proteins involved in SMC migration into the intima. Osteopontin is of special interest because it is characteristically expressed in sites where tissues are undergoing marked remodeling. Cells can attach to osteopontin
REMODELING
via ␣V3, which appears to be the major migration promoting receptor in vitro.34 this may be true in vivo as well since antagonists directed at the ␣V3 inhibit formation of the intima after balloon injury.35 Another integrin seen in the vascular tissue in vivo is ␣11, which may be the major integrin involved in SMC migration on collagen. The influence of ECM proteins on SMC migration in the onset of restenosis is not clear, although degradation of matrix protein by proteases may facilitate SMC migration.36 This hypothesis is supported by the observation that administration of a protease inhibitor significantly inhibited SMC migration in the rat. Given the abundance of ECM in restenotic lesions, one alternative ‘antirestenosis’ strategy would be to directly reduce the matrix volume surrounding each cell, either by reducing synthesis or by increasing proteolysis.
Remodeling Remodeling is defined as a change in artery size over time, as measured in area of the internal or external elastic membrane.37 Favorable or adaptive remodeling is the outward expansion and unfavorable or pathological remodeling is the inward shrinkage of an artery. Adaptive remodeling is observed in early coronary artery disease. Vessel enlargement keeps pace with the increases in plaque burden thereby preventing luminal stenosis. However, in many individuals, plaque volume outpaces the remodeling capacity of the artery and stenosis ensues. This occurs after the plaque volume occupies greater than 40% of the vessel although animal studies do not indicate a limit to the amount of favorable remodeling that can occur. Autopsies performed in marathon runners and African Masai tribesmen have shown coronary arteries 2–3 times the normal size indicating a great capacity of the artery to expand.38,39
Remodeling following balloon angioplasty can be favorable or unfavorable (Fig. 2.4). In the setting of restenosis, artery shrinkage is often to blame and may account for up to 805 of lumen loss. Artery shrinkage in response to injury was first hypothesized in animal models as an explanation of the discrepancy between large lumen loss and the small amount of neointima formed. Autopsy studies, in patients whom had undergone angioplasty at some time point in life, illustrate the importance of remodeling in the restenosis process. Artery size, measured as the area of the external elastic membrane, was decreased in restenotic lesions and increased in lesions without significant luminal narrowing. Neointimal thickness in restenotic and nonrestenotic lesions was nearly identical (1.74 ⫾ 1.0 mm2 vs 1.70 ⫾ 0.9 mm2) confirming the pivotal role of remodeling in restenosis. Utilizing serial intravascular ultrasound after angioplasty, Mintz et al40 identified two groups of patients at 6 months. One group showed compensatory enlargement while the second group showed shrinkage of the treated segment. Favorable remodeling was associated with a much lower 6-month restenosis rate (28% vs 60%). Surprisingly, 87% of the lumen loss between 1 and 6 months was owing to artery shrinkage. The only predictor or unfavorable remodeling was the arc of calcium within the vessel. Unfavorable remodeling occurs after balloon angioplasty and with other coronary devices including rotational atherectomy and eximer laser angioplasty. Controversy exists regarding the role of artery shrinkage in restenosis following directional coronary atherectomy (DCA).41 Nearly 80% of all percutaneous coronary interventions involve coronary artery stenting. Coronary stents limit acute recoil, improve procedural success rates, increase post procedural lumen diameter, and decrease overall
15
PATHOPHYSIOLOGY OF RESTENOSIS
Normal
No remodeling
Favorable remodeling
Unfavorable remodeling
Figure 2.4 Favorable or adaptive remodeling is the outward expansion and unfavorable or pathological remodeling is the inward shrinkage of an artery. Favorable remodeling is observed in early coronary artery disease and can keep pace with the increases in plaque burden to prevent luminal narrowing. Remodeling following balloon angioplasty is often unfavorable, accounting for up to 80% of late lumen loss.
incidence of restenosis. The stent crosssectional area does not change significantly over time. Remodeling, both favorable and unfavorable, does not occur within the stent. However, at stent borders and articulation sites remodeling does occur. Unfavorable remodeling at these sites accounts for up to 88% of the lumen loss being greatest at the articulation sites.43 The mechanisms responsible for favorable remodeling in response to increases in plaque burden are markedly different than those for unfavorable remodeling following angioplasty. Blood flow and shear stress are powerful stimuli for artery enlargement. Dramatic increases in arterial size occur after the cre-
16
ation of an atriovenous fistula or use of the internal mammary artery as an arterial bypass conduit. Increases in blood flow are also cited as the mechanism of coronary collateral maturation. In coronary artery disease, positive remodeling occurs to normalize luminal shear. Arterial mechano-receptors in the endothelium sense changes in shear with increases in blood flow. The signal generated by the endothelium must then be transferred to the adventitia where lumen enlargement occurs. Possible mediators include nitric oxide, prostacyclin, endothelial hyperpolarizing factor, adenosine S⬘-triphosphate ATP, and substance P, all increased by shear. The mechanisms responsible for artery con-
CONCLUSION
traction following angioplasty are unknown but may be analogous to wound contraction. Adventitia myofibroblast are likely to be involved in unfavorable remodeling as these cells are found encircling the artery. Three days after angioplasty, adventitial myofibroblasts show the highest rate of proliferation, nearly 30%.23,24 Proliferation is concentrated at the site of injury and circumferential even at sites without medial injury. PDGF and its receptor are increased in the adventitia after injury and may mediate this proliferative response. Injured myofibroblasts also change phenotypes and begin expressing smooth muscle ␣-actin, a protein usually confined to SMCs. A similar phenotype change is observed in cutaneous wound healing and in response to the cytokines TGF- and ␥-interferon.
Conclusion More than 20 years after Andreas Grüntzig performed the first angioplasty, restenosis following coronary intervention continues to be problematic. Restenosis involves acute recoil, mural thrombus, neointimal formation, and unfavorable remodeling. The mediators are the endothelial, smooth muscle-like, and inflammatory cells. The role of adventitial myofibroblast is currently under investigation. Unfavorable remodeling is the main component in restenosis following balloon angioplasty, rotational atherectomy, and laser angioplasty. Its role in DCA is controversial. Intravascular stents reduce restenosis by limiting acute recoil and preventing unfavorable remodeling. However, in-stent restenosis is commonly 15–30%, attributable solely to neointimal formation.
17
PATHOPHYSIOLOGY OF RESTENOSIS
References
1.
Tsuchikane E, Sumitsuji S, Awata N et al. Final results of the stent versus directional coronary atherectomy randomized trial. J Am Coll Cardiol 1999; 34:1050–1057. 2. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998; 81:14E–17E. 3. McKenna CJ, Burke S, Opgenroth TJ et al. Selective ET-A receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998; 97:2551–2556. 4. Reidy MA. Endothelial regeneration VII. Interaction of smooth muscle cells with endothelial regrowth. Lab Invest 1988; 59:36–43. 5. O’Brien ER, Alpers CE, Stewart DK et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res 1993; 73:223–231. 6. Fingerle J, Tina AUYP, Clowes AW et al. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 1990; 10:1082–1087. 7. Walker LN, Ramsay MM, Bowyer DE. Endothelial healing following defined injury to rabbit aorta: depth of injury and mode of repair. Arteriosclerosis 1983; 47:123–130. 8. Schwartz SM, Campbell CR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986; 58:427–444. 9. Pickering JG, Weir L, Jekanowski J et al. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993; 91:1469–1480. 10. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 86:III43–III46. 11. Lindner V, Lappi DA, Baird A et al. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68:106–113. 12. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by
18
13.
14.
15.
16.
17.
18.
19.
20.
an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88:3739–3743. Dzau VJ. Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc Pharmacol 1984; 6 Suppl 2:S377–S382. Powell JS, Muller RKM, Kuhn H et al. Inhibitors of angiotensin-converting enzyme prevents myointimal proliferation after vascular injury. Science 1989; 245:186–188. Does the new angiotensin-converting enzyme inhibitor, cilazapril, prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86:100–110. Faxon DP. Effect of high dose angiotensinconverting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double blind, placebo-controlled trial of cilazapril. the Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Occlusion and Restenosis (MARCATOR) Study group. J Am Coll Cardiol 1995; 25:362–369. Fingerle J, Johnson R, Clowes AW et al. Rose of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86:8412–8416. Schwartz RS, Murphy JG, Edwards WD et al. Restenosis after balloon angioplasty, a practical proliferative model in porcine coronary arteries. Circulation 1990; 82:2190–2200. Karas SP, Gravanis MB, Santoian EC et al. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992; 20:467–474. Leslie KO, Taatjes DJ, Schwartz J et al. Cardiac myofibroblasts express alpha smooth
REFERENCES
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
muscle actin during right ventricular pressure overload in the rabbit. Am J Pathol 1991; 139:207–216. Skalli O, Schurch W, Seemayer T et al. Myofibroblast from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989; 60:275–285. Lazard D, Sastre X, Frid MG et al. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci USA 1993; 90:999–1003. Scott NA, Martin F, Simonet L et al. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. FASEB J 1995; 9:A845. Scott NA, Ross CE, Dunn B et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury in porcine coronary arteries. Circulation 1996; 93:2178–2187. Schwartz RS, Holmes Dr Jr, Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20:1284–1293. Oho S, Koo E, Gotlieb A, Rabinovitch M. Increased elastolytic activity associated with intimal proliferation in the porcine aortic organ culture. FASEB J 1993; 7:A491. Macleod DC, Struss BH, deJong M et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994; 23:59–65. Strauss BH, Chisholm RJ, Keeley FW et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994; 75:650–658. Riessen R, Isner JM, Blessing E et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144:962–974. Jain M, He Q, Lee WS et al. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. J Clin Invest 1996; 97:596–603.
31. Weber GF, Ashakar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin. Science 1996; 271:509–512. 32. Rasmussen LM, Wolf YG, Ruoslahti E. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor- activity. Am J Pathol 1995; 147:1041–1048. 33. Nabel EG, Shum L, Pompili VJ et al. Direct transfer of transforming growth factor 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90:10759–10763. 34. Hoshiga M, Alpers CE, Smith LL et al. ␣V3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77:1129–1135. 35. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90:2203–2206. 36. Dollery CM, McEwan JR, Henney AM. Matrix metalloprotinase and cardiovascular disease. Circ Res 1995; 77:863–868. 37. Schwartz RS, Topol EJ, Serruys PW et al. Artery size, neointima, and remodeling. Time for some standards. J Am Coll Cardiol 1998; 32:2087–2094. 38. Mann G, Spoerry A, Gray M, Jarashow D. Atherosclerosis in the Masai. Am J Epidemiol 1972; 95:26–37. 39. Glagov S, Weisnberg G, Zarins C et al. Compensatory enlargement of artery segments in response to enlarging atherosclerotic plaques. N Engl J Med 1987; 316:1371–1375. 40. Mintz GS, Popma J, Pichard A et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94:35–43. 41. Birnbaum Y, Fishbein MC, Luo H et al. Regional remodeling of atherosclerotic arteries: a major determinant of clinical manifestations of disease. J Am Coll Cardiol 1997; 30:1149–1164. 42. Degwa T, Mitsuo K, Tsunoda T et al. Differential mechanisms of late lumen loss after Palmaz-Schatz stenting; evaluation by serial intravascular ultrasound study. Circulation 1996; 94 suppl 1:1–200.
19
3 Clinical presentations and noninvasive assessment of restenosis Joel W Heger and Sanjeev D Ravipudi
Introduction Restenosis has been recognized as the Achilles’ heel of coronary angioplasty.1 It is a limiting factor that occurs in 12–48% of patients who undergo a successful percutaneous coronary intervention.2 The scope of this vexing problem is staggering; of the 500 000 coronary interventions performed in the United States each year, more than 150 000 patients develop restenosis (based on 1997 American Heart Association statistics).
Mechanisms of restenosis Much has been learned about the mechanism of restenosis with the advent of new intracoronary devices (such as stents and atherectomy) and with new intracoronary imaging modalities (such as intravascular ultrasound (IVUS) and angioscopy). Elastic recoil usually occurs within minutes to hours of an intervention and is usually asymptomatic. Approximately 15% of successful percutaneous transluminal coronary angioplasty (PTCA) develop a ⬎ 0.5 mm luminal loss at 24 hours due to recoil and thrombus.3 One-half of these will proceed to restenosis.4 Most of the time there is little lumen change between day 1 and 1 month. The vast majority of cases occur between 1 and 3 months owing to neointimal hyperplasia and negative remodeling. Recur-
rence of clinical or angiographic restenosis after 6 months is rare.2,3,5–7
Clinical restenosis Reported ranges of chest pain recurrence within 6 months are as low as 25% to as high as 93%. The average rate is approximately 50%. It is estimated that the positive predictive value of symptoms alone is 60%.6,7 It is difficult to establish a clinical definition of restenosis given the limitations of symptoms and stress testing. Estimating the incidence of clinical restenosis by composite endpoints of target vessel revascularization, myocardial infarction (MI), and death has some clinical relevance. Patients with restenotic lesions rarely present with acute MI (⬍ 2%) or death (⬍ 1%) presumably due to the soft fibromuscular process that rarely ruptures.5,8–10 Estimating restenosis by target vessel revascularization in studies with longer follow-up is confounded by disease progression and incomplete revascularization. Combining data from the large randomized trials of PTCA vs coronary artery bypass graft (CABG), the rate of repeat revascularization among the PTCA group averages approximately 40% over 2 years.11 The main clinical predictors of restenosis include diabetes, chronic dialysis, variant angina, and unstable angina.6,7
21
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
Angiographic restenosis Numerous definitions of restenosis have been reported. The most commonly accepted angiographic definition is a ⱖ 50% luminal diameter stenosis at 6-month follow-up.5 Differing methods of assessment (visual, calipers, computer-assisted edge detection) account for considerable reporting variability. Despite these issues, angiographic restenosis rates vary from 30–50%. IVUS has proven valuable, but still has limitations because the ‘reference site’ for comparison is often diffusely diseased.3,7 Angiographic assessment still remains the standard for most clinical trials of restenosis. A number of indices have been measured and described with regard to the mechanics of angiographic restenosis. Acute gain is the change in minimal luminal diameter (MLD) from baseline to immediately after PTCA. The late loss is the difference between the immediate post procedure MLD to that measured at 6 months. The net gain is the difference between follow-up MLD from baseline (acute gain-late loss). The loss index refers to the percentage of early gain which is ultimately lost (late loss/acute gain). These indices vary depending on what devices are used for intervention. The acute gain is greatest with stenting as is the net gain. In aggressive directional atherectomy, the net gain may approach that of stenting. Balloon angioplasty, laser atherectomy, and rotational atherectomy usually have only moderate net gain. The major angiographic predictors of restenosis are long lesions, chronic total occlusions, ostial lesions, angulated lesions (⬎ 45°), and saphenous vein graft proximal and body lesions.6,7 Asymptomatic angiographic stenosis occurs in upwards of 15% of angioplasty patients. The significance of ‘silent restenosis’ is
22
unknown. Limited data suggests a favorable outlook for patients with silent restenosis regardless of inducible ischemia.
Clinical presentation Owing to the myriad of clinical, histologic, and angiographic variables involved in restenosis, the timing and presentation of symptoms can vary. Clinical restenosis refers to the incidence of clinical events that ultimately lead to repeat revascularization of the index lesion. Studies of restenosis have used a composite endpoint of death, MI, and target vessel revascularization to assess clinical outcomes from coronary interventions.12 Retrospective analysis of Emory University data showed that restenotic patients, when compared to patients without restenosis, had a higher incidence of angina (71% vs 39%) and target vessel reintervention (at 6 months, 56% vs 4%), a lower freedom from MI (at 6 months, 0.88 vs 0.97 and at 6 years, 0.85 vs 0.93) and coronary artery bypass surgery (at 6 months, 0.94 vs 0.99 and at 6 years, 0.78 vs 0.91), and a poorer survival rate (at 6 years, 0.93 vs 0.95).13 Highlighting the unfavorable outcomes associated with restenosis has led to the importance of recognition, appropriate diagnosis, and treatment.
Timing Analysis of data from early registries investigating restenosis suggested a strong relationship existed between the incidence of restenosis and the timing of occurrence after angioplasty. Holmes et al5 reported from the PTCA registry of the National Heart, Lung, and Blood Institute (NHLBI) on the prevalence of restenosis in 557 patients who underwent follow-up angiography after successful angioplasty. With a definition of restenosis
CLINICAL PRESENTATION
being a loss of at least 50% of the gain achieved at PTCA, restenosis was documented in 32.8% of the patients. A definite relationship existed between the timing of follow-up angiography and the occurrence of restenosis, with the highest incidence during the first 5 months. Restenosis was rarely observed at 9–12 months or beyond 12 months.5 Nobuyoshi et al3 confirmed an associated ‘time course’ with restenosis in a prospective study of 546 patients undergoing successful PTCA. Follow-up angiography in 229 patients was performed at day 1, 1 month, 3 months, 6 months, and 1 year. As early as 24 hours post procedure, an appreciable loss in lumen diameter of ⬎ 0.5 mm was detected in 16% of the patients, thought to be consistent with lesion recoil or thrombus formation. Using a definition of restenosis as ⱖ 50% loss of the gain in the absolute stenotic diameter, actuarial restenosis rates at 1, 3, 6, and 12 months were 12.7%, 43%, 49.4%, and 52% respectively (Fig. 3.1). The greatest change occurred between 1 and 3 months with a modest increase observed from 3 to 6 months. No significant increase in actuarial restenosis rate or decrease in stenosis diameter was observed from 6 months to 1 year.3 There has been widespread agreement that restenosis is a relatively early phenomenon that presents within 6 months of angioplasty, and is extremely rare after 12 months.2,3,5 In an angiographic follow-up study 5 years after PTCA Ormiston et al14 confirmed a lack of late progression involving index lesion restenosis and also demonstrated that vascular remodeling might even result in late lesion regression. Studies performed using various percutaneous coronary revascularization devices have observed an alike ‘time course’.15 Given the available data, it is evident that the majority of restenoses occurs during the first 3 months
following angioplasty, and that occurrence after 6 months is rare; patients who are free of restenosis at 6 months will likely continue to observe success of their index lesion angioplasty.6
Symptomatic restenosis Following successful angioplasty, clinicians are watchful of signs and symptoms associated with abrupt vessel closure, restenosis, and other possible complications of PTCA. In this setting, chest pain is the most sensitive clinical finding. Unfortunately, this symptom has considerable overlap with multiple pathologic processes that can occur during the post angioplasty setting. Local coronary artery trauma can cause chest pain minutes to hours following PTCA.16 Elastic recoil, also occurring minutes to hours following PTCA, can lead to restenosis and its associated symptoms.17 Additionally, platelet deposition at the site of endothelial denudation early after angioplasty (minutes to days) can induce spasm and the formation of a mural thrombus, which may cause acute chest pain, induce abrupt vessel closure, or subsequently organize and lead to restenosis.2 Abrupt vessel closure occurs minutes to weeks following angioplasty in 1–8% of patients and produces symptoms of acute infarction.5,8 Thus, from a practical standpoint, a clinician cannot rely solely on symptoms to direct appropriate therapy. The restenotic process has been described as a ‘healing’ response to vascular injury with lesion development occurring gradually over a period of weeks to months.18 Events late after angioplasty (7–150 days) include the release of platelet-derived growth factor and other humoral and hemostatic factors. In the setting of restenosis, these factors induce an excessive intimal fibroproliferative response comprised
23
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
100 90 80 70 60 49.4
50
52
43
40 30 20 12.7
10 0 1
3
6
12
Months after PTCA
Figure 3.1 Actuarial restenosis rate following successful PTCA: In a prospective study of 546 patients undergoing successful PTCA, follow-up angiography was performed in 229 patients at day 1, 1 month, 3 months, 6 months, and 1 year. 219 patients completed follow-up angiography for ⱖ 3 months. Mean stenosis diameter was 1.91 ⫾ 0.53 mm immediately after coronary angioplasty, 1.72 ⫾ 0.52 mm on day 1, 1.86 ⫾ 0.58 mm at 1 month, and 1.43 ⫾ 0.67 mm at 3 months. 149 patients completed follow up angiography for ⱖ 6 months with a mean stenosis diameter of 1.66 ⫾ 0.58 mm at 3 months and 1.66 ⫾ 0.62 mm at 6 months. 73 patients went on to complete follow-up with a mean stenosis diameter of 1.65 ⫾ 0.56 mm at 6 months and 1.66 ⫾ 0.57 mm at 1 year. Actuarial restenosis rates at 1, 3, 6, and 12 months were 12.7%, 43%, 49.4%, and 52% respectively. The greatest change occurred between 1 and 3 months with a modest increase observed from 3 to 6 months. No significant increase in actuarial restenosis rate or decrease in stenosis diameter was observed from 6 months to 1 year. Data from Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12:616–623. PTCA, percutaneous transluminal coronary angioplasty.
mostly of smooth muscle cells. Progressing over a period of weeks to months, the fibromuscular overgrowth histologically comprises the majority of the restenotic lesion, unlike the typical lipid laden coronary plaque.2,18 As a result, the majority of patients who develop symptomatic restenosis experience a
24
gradual return of their typical anginal symptoms. In the NHLBI registry, 56% of patients with definite or probable angina had angiographic restenosis.5 In general, it is observed that two-thirds of patients who present with angiographic restenosis complain of anginal symptoms. It is also important to realize that
CLINICAL PRESENTATION
14% of patients in the registry who were asymptomatic also had evidence of angiographic restenosis (Fig. 3.2).5 Thus, the ability to utilize recurrent symptoms alone to detect restenosis is not reliable. Miller et al7 pooled data from several trials evaluating restenosis and found that symptoms alone had a positive predictive value of only 60% and a negative predictive value of 85%. Joelson et al19 evaluated the angiographic findings of 102 patients who underwent coronary angiography for recurrent angina. The mean interval from PTCA to recurrent chest pain was 5.3 months and the mean interval from PTCA to follow-up angiography was 6.9 months. Sixty-three percent of the patients were classified as having angiographic restenosis, 15% had new coronary narrowings, 9% had incomplete revascularization, and 15% had no significant angiographic stenosis. Univariate analysis revealed that chest pain prior to 1
month after angioplasty was associated with incomplete revascularization in six of 12 patients (50%). Restenosis was present in only one of 12 patients (8%). Restenosis was the most common finding for recurrent angina 1 to 6 months after PTCA, present in 60 of 69 patients (87%). In patients with recurrent angina more than 6 months after PTCA, new coronary disease was most often responsible and restenosis was found only in two of 21 patients (10%) (Fig. 3.3).19 Referencing recurrent symptoms with the timing of occurrence after angioplasty improves the utility of clinical symptoms to identify those patients with restenosis. In general, patients with typical symptom recurrence 1 to 6 months after angioplasty are more likely to have restenosis of the index lesion. These patients warrant further studies to define the presence of significant restenosis. Development of anginal symptoms prior to 1 month is more commonly associated with
100% 80%
44
60%
86
40% 56 20% 14
0% Symptomatic
Asymptomatic Restenosis
No restenosis
Figure 3.2 Correlation between angiographic restenosis and recurrence of anginal symptoms. Data from Holmes Jr DR, Vlietstra RE, Smith HC et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53:77C–81C.
25
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
100% 90% 80% 70%
New coronary disease
60%
Restenosis
50%
Incomplete revascularization
40%
Normal
30% 20% 10% 0% ⬍1
1 to 6
⬎6
Months after successful PTCA
Figure 3.3 Relationship of angiographic findings with the timing of recurrent angina. [⬍ 1 month n ⫽ 12, 1 re, 0 new, 6 ir, 5 nl; 1 to 6 months n ⫽ 69, 60 re, 2 new, 2 ir, 5 nl; ⬎ 6 months n ⫽ 21, 2 re, 13 new, 1 ir, 5 nl]. (re – restenosis, new – new significant coronary lesions, ir – incomplete revascularization, nl – no significant lesions at the time of follow-up). Data from Joelson JM, Most AS, Williams DO. Angiographic findings when chest pain recurs after successful percutaneous transluminal angioplasty. Am J Cardiol 1987; 60:792–795.
incomplete revascularization or abrupt vessel closure. Symptom occurrence beyond 6 months is likely a result of disease progression involving a different stenosis.19 Patients who present with symptoms atypical of those prior to angioplasty infrequently have restenosis.20
Asymptomatic or silent restenosis Even though the presence of angiographic restenosis is commonly associated with a return of pre-angioplasty symptoms, anywhere from 2% to 50% of these patients remain
26
asymptomatic.5,13,21–23 With such a wide range of reported rates for silent restenosis, several explanations have been proposed to explain the disparity. Amongst the landmark trials, factors influencing the rate of silent restenosis include variable definitions of angiographic restenosis, differing methods of analysing angiographic data, timing of follow-up angiography, rates of late angiographic examination, presence of collaterals, degree of antianginal therapy, and differing baseline patient characteristics including history of infarction and diabetes. Using pooled data
NON-INVASIVE EVALUATION OF RESTENOSIS
from several small and large trials, Moliterno and Topol6 calculated that silent restenosis occurs in approximately 12% of the post PTCA population. Asymptomatic or silent restenosis has been commonly defined as angiographically observed ⱖ 50% diameter stenosis in the absence of anginal symptoms up to 6 months after angioplasty. Several hypotheses have been proposed to explain the occurrence of silent restenosis. Popma et al21 and Hernandez et al22 found that up to 50% of patients with silent restenosis at 6 months went on to develop symptoms in later months. These patients may represent a subset who are characterized as silent restenosis early after angioplasty but eventually progress to develop restenosis later on. There also exists evidence that patients with asymptomatic restenosis may actually have less severe coronary obstruction. Other theories claim that the formation of collateral vessels may protect against ischemia despite a progressive reduction in index lesion diameter. It has also been suggested that if infarction is present in the vascular territory supplied by the index vessel, reduced metabolic requirements may accommodate the reduction in flow imposed by restenosis. These theories bring into question whether the angiographic definition of restenosis is adequate. As part of its imperfection, the definition does not reflect the physiologic significance of the lesion.21,22 The long-term significance of silent restenosis has yet to be determined. However, data exist to suggest that the clinical outcome of these patients is favorable.6,7,24 In evaluating thallium for detecting restenosis, Pfisterer et al24 found that 60% of 405 patients with nuclear evidence of ischemia were asymptomatic. Compared to those with symptomatic ischemia, the asymptomatic population was less likely to undergo repeat
revascularization.24 Other studies followed similar patients for a mean period of three years and discovered that the majority of patients (about 80%) remained symptom free.6,7,25,26 Of the 20% who experienced a cardiac event, three-quarters suffered from recurrent angina and one-quarter suffered a non-fatal myocardial infarction.26 Weintraub et al13 followed 1 500 patients with restenosis for 6 years; the symptomatic group had a higher incidence of MI, CABG, and PTCA when compared to the asymptomatic group. There are no prospective trials looking at the need for intervention in patients with silent restenosis. Adding to the difficulty in defining the long-term significance of silent restenosis is the fact that any long term study would be confounded by the natural progression of coronary artery disease (CAD). With the available data, it appears that this patient population possesses a good prognosis. Any repeat interventions in these patients should be guided by the emergence of symptoms or significant ischemia.
Non-invasive evaluation of restenosis The use of non-invasive testing for evaluating restenosis has become increasingly popular. Although very attractive as a mode of evaluation in this setting, it is still important to note that the American College of Cardiology/American Heart Association (ACC/AHA) do not recommend the universal use of noninvasive testing in every post PTCA patient.27 If widespread testing was implemented, analysis estimates that it would cost around $10 000 to $20 000 to identify an asymptomatic patient with restenosis.28 The wide availability and safety of non-invasive testing is no substitute for an educated approach towards
27
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
risk stratification and management of these patients.
Exercise electrocardiography Exercise testing can be a valuable tool in evaluating patients with coronary heart disease. Duration of exercise, increase in heart rate, blood pressure response, and reproduction of symptoms represent complementary functional data that can be incorporated in the evaluation and management of these patients. Additionally, exercise has the unique advantage of providing a powerful physiologic stress by which to evaluate endothelial vasodilatory capacity, a major contributor to myocardial ischemia. Pharmacologic stress suffers from the disadvantage of not producing a physiologic stress on the cardiovascular system. It is therefore recommended that exercise stress should be performed whenever possible.29 Since the presence of chest pain after PTCA does not signify restenosis with certainty, there exists a need for a noninvasive technique that can accurately predict and identify restenosis, reducing the need for unnecessary coronary angiography. The use of exercise electrocardiographic testing in this setting has been widely studied. Some of the limitations encountered with exercise testing after PTCA include the presence of multivessel disease, previous myocardial infarction, baseline electrocardiographic abnormalities, and the significant number of uninterpretable tests. Exercise testing soon after successful angioplasty for predicting restenosis Early exercise testing after PTCA is reliably utilized to establish a new functional baseline, increase patient confidence in resuming early activity or return to work, and aid in establishing guidelines for cardiac rehabilitation counseling.30,31 Evaluation of early exercise
28
treadmill testing (ETT) in the prediction of restenosis has alternatively produced variable results and has significant limitations. Exercise testing in this setting has been evaluated by a number of groups; Deligonul et al32 performed testing a mean of 9 days after successful PTCA, Balady et al32 at 1–3 days, and Korzick et al31 at 1–4 days. None of these authors could support any prognostic value of early exercise in predicting future cardiac events or restenosis. For example, the values observed by Korzick et al31 were as poor as 35.3% sensitivity, 52.5% specificity, 39.6% positive predictive value, and 48% negative predictive value. Thus, a positive ETT early after successful angioplasty is of no value to the clinician. It is postulated that early after angioplasty the presence of vasoconstriction, smooth muscle cell migration and proliferation, and platelet adhesion and aggregation may play a role in producing a misleading early positive exercise test despite the absence of true anatomic restenosis. Furthermore, several reports have questioned the safety of high workload and symptom limited exercise testing soon after angioplasty.30,33 Incidence of acute ischemic complications associated with post PTCA exercise testing range from 0.8% to 1.4%.30,31 Subgroup analysis by Sionis et al found that patients with an angioplasty complicated by intimal dissection had early exercise complication rates as high as 5%.30 Early exercise testing after successful angioplasty for predicting restenosis not only is limited in its prognostic value but also is not without risk. The ACC/AHA have concluded that exercise testing following PTCA may be performed on patients after discharge for activity counseling and/or exercise training as part of cardiac rehabilitation in patients who have undergone coronary revascularization. Based on the above data, early exercise testing after revas-
NON-INVASIVE EVALUATION OF RESTENOSIS
cularization for the purpose of predicting restenosis is not recommended.27 Exercise testing 1–12 months after successful angioplasty for the assessment of restenosis Considerable efforts have also focused on analysing the utility of ETT to detect restenosis. One to 8 months after successful PTCA, Wijns et al34 and Ernst et al35 performed exercise tests on patients prior to repeat angiography. The positive predictive value of exercise induced angina or horizontal ST segment depression ⱖ 1 mm to detect restenosis was only 50%.34,35 In a larger study involving 854 patients, Hillegass et al36 found the sensitivity and specificity of ETT for detecting restenosis to be a disappointing 58% and 62–64% respectively. Additionally important was the fact that 29% of the studies were uninterpretable. Miller et al7 pooled data from 15 studies that examined the predictive value of ETT in the post PTCA setting. This included 2249 patients with angiographic follow-up. Statistical analysis revealed a 55% positive predictive value and a 76% negative predictive value, results that are no better than those of recurrent angina in predicting restenosis.7 The ACC/AHA concur that a Class I indication for performing ETT is for the evaluation of restenosis in patients with recurrent symptoms 1–6 months after catheter-based revascularization.33 For the detection of silent restenosis, some have advocated the use of routine exercise testing in all patients after PTCA. The ACC/AHA favors an alternative approach. Routine exercise testing should be reserved for a select group of asymptomatic patients considered to be higher risk. This includes those with decreased left ventricular function, multivessel CAD, proximal left anterior descending disease, family history of sudden death, diabetes mellitus, hazardous occupations, and suboptimal PTCA results.33
Regardless of the strategy used, clinicians should realize that exercise ECG is an insensitive detector of restenosis. Use of adjunctive data obtained from exercise testing for the assessment of restenosis Adjunctive data obtained from exercise testing has been looked at to possibly improve the predictive value of ETT in detecting restenosis. Michaelides et al37 compared ST segment changes in exercise testing before and after angioplasty and asked whether changes observed in the same leads or different leads were more closely related to restenosis. They found that restenosis was more commonly associated with ST segment depression in the same leads (48%) and that ST segment depression observed in different leads was only associated with restenosis 12% of the time.37 Investigations using other measurable values such as Delta ST, Sigma ST, Delta ST/Delta heart rate index, or QT dispersion measurements, resulted in only modest improvements of the predictive values of treadmill testing to detect restenosis and have not found their way into regular clinical use.38–43 A more hopeful finding came from a study evaluating exercise capacity measurements to detect restenosis. A group of 395 patients underwent bicycle exercise testing 2 weeks before and 2 and 20 weeks after PTCA, as well as repeat angiography 20 weeks after angioplasty. Exercise capacity was defined as work performed by body weight ((watts ⫻ minutes)/kg). Both exercise capacity and MLD increased after PTCA and then decreased at 20-week follow-up, correlating with a statistical significance of p ⱕ 0.0001. Multivariate logistic regression analysis revealed that a late decrease in exercise capacity was independently predictive of both angiographic restenosis (⫺5.3 vs 0.4 W ⫻ minutes/kg, p ⬍ 0.0001) and clinical
29
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
restenosis (⫺6.3 vs 0.09 W ⫻ minutes/kg, p ⬍ 0.0001).44 Although exercise electrocardiographic stress testing is an insensitive predictor of restenosis, utilizing adjunctive data produced by stress testing shows promise in complementing clinical and non-invasive efforts to detect restenosis.
Nuclear imaging Combining stress testing with nuclear imaging has become one of the most popular and reliable non-invasive techniques for identifying and excluding restenosis.6,7,34,35,45–50 Additionally, SPECT imaging has exhibited an added ability to localize ischemic coronary vascular territories when evaluating restenosis. Limitations of nuclear imaging to detect restenosis have included multivessel disease, previous myocardial infarction, incomplete revascularization, and the presence of collaterals.48,51–53 Nuclear testing early after successful angioplasty for predicting restenosis Studies of stress nuclear imaging early after successful PTCA have evaluated the potential for predicting restenosis, assessing adequacy of revascularization, and detecting complications of angioplasty.34,45,51,54,55 Observations noted an improvement in regional myocardial perfusion in the distribution of the dilated coronary artery and that the degree of improvement tended to correlate with the change in luminal diameter achieved. However, when nuclear measurements of perfusion were compared with invasive measurements of coronary perfusion early after PTCA a discrepancy was observed. A similar discrepancy was also seen by Johnson et al who measured coronary vasodilator reserve early after PTCA and found that it correlated poorly with angiographically measured lumen patency.56 Powelson et al57 sought to evaluate this
30
prospectively in 46 patients by performing thallium SPECT and repeat angiography 1–2 days after successful angioplasty. Thallium perfusion defects were present in 13 vascular territories of which only four had evidence of early restenosis. Investigators observed an increased rate of false positive thallium scans soon after successful coronary intervention and found that the presence of perfusion abnormalities soon after PTCA was not a strong predictor for restenosis.48,57 This discordance is thought to be related to a temporary impairment of regional blood flow related to local trauma or sustained abnormalities in myocardial cell uptake (stunned or hibernating myocardium).57 In an effort to characterize the changes of myocardial perfusion observed in patients after complete revascularization, Manyari et al58 evaluated 43 patients who underwent successful PTCA for single vessel CAD, had no previous MI, and no evidence of restenosis on follow-up. Serial exercise thallium scintigraphy was performed before PTCA and at 9 days, 3 months, and 6 months after PTCA. Abnormal scans were observed in 28% of patients after PTCA with a significant increase in myocardial perfusion at 9 days and 3 months. No significant changes were seen at 6 months. Thus, abnormalities of myocardial perfusion observed with nuclear imaging early after PTCA progressively improve and usually normalize by 3 months. Based on the available data, performing exercise nuclear imaging for the prediction or detection of restenosis early after PTCA is not recommended. 48 Nuclear testing 1–12 months after successful angioplasty for the assessment of restenosis Stress nuclear imaging 1–12 months after successful angioplasty is clinically useful in detecting and localizing ischemia related to
NON-INVASIVE EVALUATION OF RESTENOSIS
restenosis. Hecht et al performed thallium SPECT imaging in 116 patients before undergoing repeat angiography for suspected restenosis.51 SPECT imaging accurately identified restenosis in 86% of sites with similar results for patients with partial or complete revascularization.6,51 The negative predictive value of thallium SPECT has also proven to be of significant clinical importance. Breisblatt et al56 performed three sequential follow-up thallium SPECT studies in each of 121 patients after successful PTCA. Of the 104 patients who remained asymptomatic at the time of imaging 4–6 weeks after PTCA, regional perfusion abnormalities in the target vessel were demonstrated in 25%. Of these patients, restenosis was demonstrated in 85% at 6 months and 96% at 1 year. Patients with normal scans at 3–6 months had a very low likelihood of developing recurrent symptoms or angiographic restenosis.48,56 Pooling data amongst four benchmark studies of thallium SPECT to detect restenosis revealed a sensitivity of 91%, specificity of 87%, positive predictive value of 83%, and negative predictive value of 93%.6,7,51,56,57,59 Comparable results have also been observed with the use of sestamibi SPECT.60,61 In those patients who are unable to exercise, the use of pharmacological stress with dipyridamole or dobutamine has yielded similar results also.59,62 The improved positive predictive value, as well as the significant negative predictive value, makes thallium SPECT a valuable noninvasive tool in evaluating patients for restenosis.6,7,48 Detection of silent restenosis by nuclear testing The value of SPECT imaging to detect silent restenosis has also been looked at. Hecht et al63 performed thallium SPECT imaging and repeat coronary angiography on 116 patients
after PTCA, 41 of which were asymptomatic. SPECT imaging had a sensitivity of 96% and specificity of 75% for detecting restenosis in the asymptomatic group. The ischemia associated with restenotic lesions among symptomatic and asymptomatic patients was equal in amount and degree of severity.63 A similar study by Marie et al confirmed that thallium SPECT efficiently detected patients with asymptomatic restenosis.57 Regardless of its ability to detect silent restenosis, routine use of SPECT imaging in all patients who have undergone successful PTCA is not recommended. The prognosis of this subset of patients without intervention appears to be favorable and with no prospective trials looking at the need for repeat intervention in patients with silent restenosis routine SPECT after PTCA should be reserved for a select group of asymptomatic patients who are considered to be higher risk.
Stress echocardiography Performing supine bicycle exercise echocardiography early after angioplasty to predict restenosis was recently re-evaluated by Dagianti et al.64 Seventy-six patients with exercise-induced wallmotion abnormalities underwent elective PTCA and repeat exercise echocardiography 2–3 days after successful angioplasty. Congruent with prior studies, wall motion abnormalities and exercise performance improved after successful PTCA. However, 29% of the patients continued to exhibit exercise-induced wall motion abnormalities despite successful angioplasty. In their analysis, this was a predictor of restenosis with an odds ratio of 3.08.64 For predicting restenosis, stress echo initially appears to be promising. However, owing to its low sensitivity, early exercise echocardiography after successful angioplasty to predict restenosis is not universally recommended.
31
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
Stress echocardiography for non-invasive detection of restenosis 1–12 months after successful angioplasty has been found to be an equivalent alternative to nuclear testing. Stress echo can detect and locate transient stressinduced regional LV wall motion abnormalities and correlate them to perfusion territories of individual coronary arteries, similar to SPECT.28 An advantage of stress echo is the ability to evaluate exercise effects on LV systolic function, which is a strong indicator of true myocardial ischemia. Limitations of stress echocardiography include the incidence of technically difficult imaging that is unsuitable for interpretation, as well as the subjectivity involved with the interpretation of studies. Crouse et al65 and Hecht et al66 looked at using exercise echo in patients with suspected restenosis as much as a year after successful angioplasty. Results for detecting restenosis were as impressive as a sensitivity of 87–95% and specificity of 82–95%.65,66 Using pharmacologic stress with echocardiographic imaging to detect restenosis has also been studied. Heinle et al67 looked at dobutamine stress echocardiography (DSE) and Takeuchi et al68 compared DSE with thallium stress. DSE was comparable in diagnostic accuracy to SPECT for detecting restenosis in patients after PTCA.67,68 A similar comparison by Pirelli et al using dipyridamole echocardiography and exercise thallium yielded similar findings.69 In experienced hands, stress echo has a diagnostic accuracy equal to that of nuclear imaging. Thus, preferential use of either noninvasive modality to detect restenosis would be largely institutionally dependant.
Positron emission tomography (PET) Using different isotopes, PET studies can quantitate regional myocardial metabolism
32
and perfusion as well as evaluate wall motion with diagnostic accuracy equal to or possibly better than sestamibi. The potential for use of PET in evaluating restenosis exists but has not been specifically evaluated at this time.70,71
Effect of stenting on non-invasive evaluation of restenosis Delay of restoration of coronary flow reserve has been documented in vascular territories that have undergone coronary angioplasty. This phenomenon has been postulated to be directly related to the high incidence of false positive noninvasive tests observed early after angioplasty. Mechanisms of this phenomenon are unclear. Release of vasoactive agents at the site of intervention related to mechanical trauma as well as local spasm or dynamic recoil might play an integral role. Those who hypothesize that the mechanical instability of the coronary wall after PTCA is a major determining factor believe that implantation of stents should stabilize the artery wall and may reduce the observed phenomenon. Early investigations with invasive and noninvasive measurements of coronary flow suggest that early normalization does occur in arteries dilated by stents compared to those dilated by balloon angioplasty.72–74 At this time, it is unknown how stenting has influenced the non-invasive evaluation of restenosis.
A practical approach After a successful percutaneous intervention the clinician should have thorough knowledge and documentation of the clinical, angiographic, and procedural risk factors for restenosis. The clinician should follow the patient closely during the ‘vulnerable period’ (day 1 to 3 months). For patients in whom typical symptoms recur or those with atypical
A PRACTICAL APPROACH
symptoms and abnormal non-invasive testing after complete revascularization at the index procedure, it is our practice to go directly to the cardiac catheterization laboratory for confirmation of restenosis. We tend to avoid exercise imaging for the first 3–4 weeks because a substantial percentage (28%) of patients with single vessel disease and a successful procedure will have abnormal scans with no clinical or angiographic evidence of restenosis (i.e. false positive). Possible explanations for this phenomenon include impaired vasodilator reserve distal to the intervention site, stunned myocardium, or hibernating myocardium. One to 12 months after successful intervention, our choice is to use stress nuclear or echo to stratify patients with atypical symptoms. Patients with normal studies are likely to remain free of significant restenosis and can be followed clinically. Substantial clinical judgment is required on how to handle asymptomatic patients with positive exercise imaging at 2–3 months. The clinical setting, angiographic factors, the
degree of ischemia, and the patient’s desires should all be carefully weighed. At the time of repeat study for suspected restenosis, it is our custom to discuss the potential solutions with the patient and family as is appropriate. Just as the oncologist has the difficult task of approaching the cancer patient with the various approaches of chemotherapy, radiation, and surgery; the cardiologist needs to have an eclectic, multi-pronged, ‘cancer-like’ approach while we await more discoveries. It is reasonable to use debulking and stenting as our ‘first surgical’ approach and the advent of radiation therapy appears extremely promising. It is likely that some ongoing chemotherapy will involve antiplatelet, antiproliferative, or genetically directed agents. One can speculate that this intensive multi-tiered approach will markedly reduce the incidence of restenosis, but there are probably a certain percentage of cases that will be refractory to treatment until new concepts and research find the missing pieces of the puzzle.
33
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
References
1.
Block PC. Percutaneous transluminal coronary angioplasty: role in the treatment of coronary artery disease. Circulation 1985; 72:161. 2. Surruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 1988; 77:361–371. 3. Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12:616–623. 4. Rodriguez A, Santaera O, Larribeau M et al. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. Am J Cardiol 1993; 71:1391–1395. 5. Holmes Jr DR, Vlietstra RE, Smith HC et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53:77C–81C. 6. Moliterno DJ, Topol EJ. Restenosis: epidemiology and treatment. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven Publishers, 1998, 2065–2100. 7. Miller JM, Ohman EM, Moliterno DJ, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology 3rd ed., Philadelphia: WB Saunders Company, 1999, 379–415. 8. Roubin GS, Douglas JS Jr, King SB et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty: a prospective randomized study. Circulation 1988; 78:557–565. 9. Piessens JH, Stammen F, Desmet W et al. Immediate and 6-month follow-up results of coronary angioplasty for restenosis: analysis of factors predicting recurrent clinical restenosis. Am Heart J 1993; 126:565–570. 10. Nobuyoshi M, Kimura T, Ohishi H et al.
34
11.
12.
13.
14.
15.
16.
17. 18.
19.
20.
Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991; 17:433–439. Pocock SJ, Henderson RA, Rickards AF et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346:1184–1189. Grüntzig AR, King SB III, Schlumpf M et al. Long-term follow-up after percutaneous transluminal coronary angioplasty. N Engl J Med 1987; 316:1127–1132. Weintraub WS, Ghazzal ZM, Douglas Jr JS et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation 1993; 87:831–840. Ormiston JA, Stewart FM, Roche AHG et al. Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Circulation 1997; 96:468–474. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting, and directional atherectomy. J Am Coll Cardiol 1993; 21:15–25. Jeremias A, Kutscher S, Haude M et al. Chest pain after coronary interventional procedures: incidence and pathophysiology. Herz 1999; 24:126–131. Schwartz RS. The vessel wall reaction in restenosis. Semin Interv Cardiol 1997; 2:83–88. Forrester JS, Fishbein M, Helfant R et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17:758–769. Joelson JM, Most AS, Williams DO. Angiographic findings when chest pain recurs after successful percutaneous transluminal angioplasty. Am J Cardiol 1987; 60:792–795. Bengtson JR, Mark DB, Honan MB et al. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using
REFERENCES
21.
22.
23.
24.
25.
26.
27.
28.
29.
the exercise treadmill test. Am J Cardiol 1990; 65:28–34. Popma JJ, van den Berg EK, Dehmer GJ. Longterm outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 62:1298–1299. Hernandez RA, Macaya C, Iniguez A et al. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1992; 19:1402–1409. Levine S, Ewels CJ, Rosing DR, Kent KM. Coronary angioplasty: clinical and angiographic follow-up. Am J Cardiol 1985; 55:673–676. Pfisterer M, Rickenbacher P, Kiowski W et al. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. J Am Coll Cardiol 1993; 22:1446–1454. Kovac JD, Brack MF, Harley A et al. Longerterm clinical outcome in patients presenting with asymptomatic restenosis at 4 month trial angiography (abstract). Circulation 1995; 92:I-347. Laarman G, Luijten HE, Van Zeyl LG et al. Assessment of ‘silent’ restenosis and long-term follow-up after successful angioplasty in singlevessel coronary artery disease: the value of quantitative exercise electrocardiography and quantitative coronary angiography. J Am Coll Cardiol 1990; 16:578–585. Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260–315. Mak KH, Eisenberg MJ, Shaw J. Cost-efficacy modeling of functional testing with perfusion imaging to detect asymptomatic restenosis following percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv 1999; 48:352–356. Runge MS, Stouffer GA, Sheahan RG et al. Use of stress testing to evaluate patients with recurrent chest pain after percutaneous coronary revascularization. Am J Med Sci 1998; 316:46–52.
30. Sionis D, Vrolix MC, Glazier JJ et al. Early exercise testing after successful percutaneous transluminal coronary angioplasty: a word of caution. Am Heart J 1992; 123:530–532. 31. Korzick DH, Underwood DA, Simpfendorfer CC. Early exercise testing following percutaneous transluminal coronary angioplasty. Cleve Clin J Med 1990; 57:53–56. 32. Deligonul U, Vandormael MG, Shah Y et al. Prognostic value of early exercise stress testing after successful coronary angioplasty: importance of the degree of revascularization. Am Heart J 1989; 117:509–514. 33. Balady GJ, Ceitschhuh ML, Jacobs AK et al. Safety and clinical use of exercise testing one to three days after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69:1259–1264. 34. Wijns W, Surruys PW, Reiber JHC et al. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am J Cardiol 1985; 55:357–361. 35. Ernst SMPG, Hillebrand FA, Klein B et al. The value of exercise tests in the follow-up of patients who underwent transluminal coronary angioplasty. Int J Cardiol 1985; 7:267–279. 36. Hillegass WB, Ancukiewicz M, Bengtson JR et al. Does follow-up exercise testing predict restenosis after successful angioplasty? Circulation 1992; 86(Suppl I):I-137. 37. Michaelides AP, Dilaveris PE, Psomadaki ZD et al. Reliability of the exercise-induced STsegment changes to detect restenosis three months after coronary angioplasty: significance of the appearance in other leads. Am Heart J 1998; 135:449–456. 38. Malekianpour M, Rodes J, Cote G et al. Value of exercise electrocardiography in the detection of restenosis after coronary angioplasty in patients with one vessel disease. Am J Cardiol 1999; 84:258–263. 39. Koide Y, Yotsukura M, Ando H et al. Accuracy of treadmill exercise electrocardiography in detecting restenosis following single vessel percutaneous transluminal coronary angioplasty. Am J Cardiol 1997; 80:1282–1286. 40. Koide Y, Yotsukura M, Tajino K et al. Use of QT dispersion measure on treadmill exercise electrocardiograms for detecting restenosis
35
CLINICAL PRESENTATIONS AND NONINVASIVE ASSESSMENT OF RESTENOSIS
41.
42.
43.
44.
45.
46.
47.
48.
49.
36
after percutaneous transluminal angioplasty. Clin Cardiol 1999; 22:639–648. Hamasaki S, Arima S, Tahara M et al. Increase in the delta ST/delta heart rate index: a new predictor of restenosis after successful percutaneous transluminal angioplasty. Am J Cardiol 1996; 78:990–995. Hamasaki S, Abematsu H, Arima S et al. A new predictor of restenosis after successful percutaneous transluminal coronary angioplasty in patients with multivessel coronary artery disease. Am J Cardiol 1997; 80:411–415. Aytemir K, Ozer N, Aksoyek S et al. QT dispersion plus ST-segment depression: a new predictor of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Cardiol 1999; 22:409–412. Jorgensen B, Simonsen S, Endresen K et al. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity. Am Heart J 2000; 139:482–490. O’Keefe JH, Lapeyre AC, Holmes DR et al. Usefulness of early radionuclide angiography for identifying low-risk patients for late restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61:51–54. DePuey EG, Boskovic D, Krajcer Z et al. Exercise radionuclide ventriculography in evaluating successful transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1983; 9:153–166. DePuey EG, Leatherman RD, Dear WE et al. Restenosis after transluminal coronary angioplasty detected with exercise-gated radionuclide ventriculography. J Am Coll Cardiol 1984; 3:1103–1113. DePuey, Gordon E. Radionuclide methods to evaluate percutaneous transluminal coronary angioplasty. In: Seminars in Nuclear Medicine, vol XXI, no 2. WB Saunders Company, 1991; 102–115. Hardoff R, Shefer A, Gips S et al. Predicting late restenosis after coronary angioplasty by very early (12 to 24 h) thallium-201 scintigraphy: implications with regard to mechanisms of late coronary restenosis. J Am Coll Cardiol 1990; 15:1486–1492.
50. Scholl JM, Chaitman BR, David PR et al. Exercise electrocardiography and myocardial scintigraphy in the serial evaluation of the results of percutaneous transluminal coronary angioplasty. Circulation 1982; 66:380–390. 51. Hecht HS, Shaw RE, Bruce TR et al. Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1993; 126:571–577. 52. Breisblatt WM, Barnes JV, Weiland F et al. Incomplete revascularization in multivessel percutaneous transluminal coronary angioplasty: the role for stress thallium-201 imaging. J Am Coll Cardiol 1988; 11:1183–1190. 53. Marie PY, Canchin N, Karcher G et al. Usefulness of exercise SPECT-thallium to detect asymptomatic restenosis in patients who had angina before coronary angioplasty. Am Heart J 1993; 126:571–577. 54. Lewis BS, Hardoff R, Merdler A et al. Importance of immediate and very early post procedural angiographic and thallium-201 single photon emission computed tomographic perfusion measurements in predicting late results after coronary intervention. Am Heart J 1995; 130:425–432. 55. Miller DD, Liu P, Strauss W et al. Prognostic value of computer-quantitated exercise thallium imaging early after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987; 10:275–283. 56. Johnson MR, Wilson RF, Skorton DJ et al. Coronary lumen area immediately after angioplasty does not correlate with coronary vasodilator reserve: a videodensitometric study. Circulation 1986; 74(Suppl II):II-193 (abst). 57. Powelson SW, DePuey EG, Roubin GS et al. Discordance of coronary angiography and thallium tomography early after transluminal coronary angioplasty. J Nucl Med 1986; 27:6. (abst) 58. Manyari DE, Knudtson M, Kloiber R et al. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. Circulation 1988; 77:86–95. 59. Jain SP, Jain A, Collins TJ et al. Predictors of
REFERENCES
60.
61.
62.
63.
64.
65.
66.
restenosis: a morphometric and quantitative evaluation by intravascular ultrasound. Am Heart J 1994; 128:664–673. Georgaoulias P, Demakopoulos N, Kontos A et al. Tc-99 tetrofosmin myocardial perfusion imaging before and six months after percutaneous transluminal coronary angioplasty. Clin Nucl Med 1998; 23:678–682. Milan E, Zoccarato O, Terzi A et al. Technetium-99m-sestamibi SPECT to detect restenosis after successful percutaneous coronary angioplasty. J Nucl Med 1996; 37:1300–1305. Elhendy A, Geleijnse ML, Roelandt JR et al. Dobutamine TC-99m-mibi SPET myocardial perfusion scintigraphy in the prediction of restenosis after percutaneous transluminal coronary angioplasty in patients unable to perform an exercise test. Nucl Med Comm 1996; 18:122–128. Hecht HS, Shaw RE, Chin HL et al. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991; 17:670–677. Dagianti A, Rosanio S, Penco M et al. Clinical and prognostic usefulness of supine bicycle exercise echocardiography in the functional evaluation of patients undergoing elective percutaneous transluminal coronary angioplasty. Circulation 1997; 95:1176–1184. Crouse L, Vacek J, Beauchamp G et al. Use of exercise echocardiography to evaluate patients after coronary angioplasty. Am J Cardiol 1996; 78:1163–1166. Hecht H, DeBord L, Shaw R et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71:293–296.
67. Heinle S, Lieberman E, Ancukiewicz M et al. Usefulness of dobutamine echocardiography for detecting restenosis after percutaneous transluminal angioplasty. Am J Cardiol 1993; 72:1220–1225. 68. Takeuchi M, Miura Y, Toyokawa T et al. The comparative diagnostic value of dobutamine stress echocardiography and thallium stress tomography for detecting restenosis after coronary angioplasty. J Am Soc Echocardiography 1995; 8:696–702. 69. Pirelli S, Danzi G, Massa D et al. Exercise thallium scintigraphy versus high-dose dipyridamole echocardiography testing for detection of asymptomatic restenosis in patients with positive exercise tests after coronary angioplasty. Am J Cardiol 1993; 71:1052–1056. 70. Bergman SR, Cardiac Positron Emission Tomography. Seminars in Nuclear Medicine 1998; vol XXVIII: 320–340. 71. Ronnow Sand NP, Bottcher M, Madsen MM et al. Evaluation of regional myocardial perfusion in patients with severe left ventricular dysfunction: comparison of 13N-ammonia PET and 99mTC sestamibi SPECT. J Nucl Cardiol 1998; 5:4–13. 72. Kern MJ, Aguirre FV, Donohue TJ et al. Impact of residual lumen narrowing on coronary flow after angioplasty and stent: intravascular ultrasound Doppler and imaging data in support of physiologically-guided coronary angioplasty. Circulation 1995; 92 (Suppl I): I-263 (abst). 73. Bowers TR, Safian RD, Stewart RE et al. Normalization of coronary flow reserve immediately after stenting but not after PTCA. J Am Coll Cardiol 1996; 27:19A (abst). 74. Kosa I, Blasini R, Schneider-Eicke J et al. Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol 1999; 34:1036–1041.
37
4 Clinical, biochemical, angiographic and intravascular ultrasound predictors of restenosis Stefan Verheye and Glenn Van Langenhove
Introduction Restenosis after percutaneous intervention has plagued interventional cardiology since its inception. Multiple techniques have been tried without success to eliminate this problem. One of the main reasons for this failure is the lack of knowledge regarding the mechanism of restenosis. It is crucial, therefore, that other factors, which may help in assessing the risk of restenosis, be determined. Indeed, the assessment of clinical risk factors for coronary heart disease is now commonplace in clinical cardiology; the prevention and treatment of these risks have been a major step forward in cardiology, and many patients have benefited from it. In a similar way, knowledge of a variety of factors with a predictive value may help in the selection and treatment of patients who are at increased risk of restenosis and therefore reduce the rate of restenosis. The focus of this chapter is to give an overview of predictors of restenosis after any percutaneous intervention – clinically, biochemically, angiographically as well as by using intravascular ultrasound (IVUS) – that have been proposed in the recent literature.
Clinical predictors Clinical parameters of restenosis with varying predictive value after conventional balloon
angioplasty have been considered for more than two decades. Other interventional techniques have been introduced and along with that, clinical predictors have changed and others have been added. However, a clinical predictor is defined as a clinical marker with a (low or high) value in predicting restenosis, regardless of interventional technique. The determination of predictors is based on statistical analyses of uni- and multivariate regression models that rely on groups of patients with different characteristics. Published reports usually differ from each other with regard to patient characteristics and in addition, differences between prospective studies and retrospective database analyses may account for differences in predictive markers. Furthermore, one has to bear in mind that many reports are related to a specific indication for percutaneous revascularization and therefore predictors must be judged in relation to the situation the cardiologist is dealing with, i.e. restenosis after balloon angioplasty differs from in-stent restenosis. As a consequence, contradictory findings in the literature are not uncommon. The importance of defining the problem is illustrated by the following two observations. Analyses of earlier studies evaluating the effect of an angiotensin-converting enzyme (ACE)inhibitor after conventional balloon angioplasty on restenosis at 6 months showed that
39
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
the restenosis phenomenon could not be predicted accurately by any patient variables.1 On the other hand, Gershlick et al2 found positive clinical parameters in patients undergoing balloon angioplasty with 6-month follow-up and reported that early recurrent symptoms were the best predictors of angiographic restenosis, whereas history of recurrent angina or positive exercise testing alone at follow-up were poor predictors. The predictive value even increased when exercise testing was positive in patients complaining of angina.2 The first study tried to predict restenosis based on clinical variables prior to the procedure, whereas the second study tried to determine predictors that are partially post procedural. ‘Classical’ clinical factors such as age and male gender have been proposed as independent predictors for restenosis after angioplasty.3,4 Although a significantly increased risk of acute complications could be documented only in women undergoing percutaneous transluminal coronary angioplasty (PTCA) for stable angina pectoris and not in acute coronary syndrome, Heidland et al reported that gender was not a predictor since the long-term outcome was similar between the two sexes.5 The same group also concluded that age and cardiovascular risk factors were not predictors for restenosis. Gurlek et al also showed that age and sex were not associated with risk of restenosis.6 However in another study reporting long-term results of patients who underwent a first stent implantation, multivariable analysis showed that female sex was an independent predictor of increased mortality after stenting.7 Many reports concluded that the restenosis risk could not be predicted from clinical variables known at the time of the procedure (directional atherectomy or stent implantation).8–11 However, a history of unstable angina12 as well as duration of angina less
40
than 6 months13 were both found to be independent predictors for restenosis although Mittal et al found that rather the presence of angina at the time of follow-up was significantly associated with restenosis.8 On the other hand, in the EPIC trial, absence of rest angina was also independently associated with an increased rate of clinical events.14 Traditional risk factors for atherosclerosis are generally not related to increased restenosis and are therefore poor predictors.13 However, several authors have reported on some well known risk factors for atherosclerosis that may function as good predictors for restenosis. Smoking is an important risk factor and is found to be an independent predictor not only for in-stent restenosis, but also for target vessel revascularization.15–18 However, Gurlek et al reported that smoking was not a predictor for restenosis,6,19 which was confirmed by another group.20 Similarly, diabetes mellitus is a traditional risk factor that has been associated with restenosis as an independent predictor more than any other risk factor.21–27 According to Kastrati et al, diabetes increased the risk of binary restenosis with an odds ratio (OR) (95% confidence interval [CI]) of 1.86 and the risk of target lesion revascularization with an OR of 1.45.22 Furthermore, in a report published by Lee et al, diabetes was associated with diffuse in-stent restenosis after coronary stent placement that may reflect an enhanced rate of neointimal formation within the stent in diabetic patients.24 Van Belle et al go further and report that treatment with insulin is an independent predictor for vessel occlusion in the same patient population.27 Again, conflicting results have been reported regarding the predictive value of the presence of diabetes mellitus after angioplasty6,28 and stent implantation29 being negative in both situations. Other clinical predictors have been
BIOCHEMICAL AND GENETIC PREDICTORS
Clinical predictors
Relative importance
Age Male gender Smoking Diabetes mellitus Hypertension Previous myocardial infarction Peripheral vascular disease Prior restenosis Presence of organ failure Hypercholesterolemia Statin therapy
+ – ± +++ + + + + + ± ±
Table 4.1. Clinical predictors of restenosis (relative importance graded from – to +++ with ± meaning that conflicting results were reported).
described and include the presence of a previous myocardial infarction, a history of peripheral vascular disease, prior restenosis, and the presence of organ failure.13,14,26,27,30 In a recent report, multivariate analysis identified statin therapy as an independent predictor for reduced subsequent restenosis development. Statin therapy may be associated with reduced recurrence rates and improved clinical outcome after coronary stent implantation,31 although randomized trials of statins have failed to show benefit. Finally, hypertension has also been associated with increased risk of restenosis after percutaneous intervention.6 An overview of clinical predictors is presented in Table 4.1.
Biochemical and genetic predictors A whole variety of serum markers have been proposed as possible predictors for restenosis. However, the mechanism of restenosis between the two types of intervention (balloon
angioplasty and stenting) differs, resulting in up- or down-regulation of several proteins and genes that can be detected and, therefore, the prediction of restenosis in both situations may require separate screening methods.32 An analysis of the available literature discussing these predictors is presented below.
Serum lipid concentration Serum cholesterol is a well known risk factor for atherosclerosis, however, its role in the prediction of restenosis after percutaneous intervention is unknown. In a mega-analysis based on four major restenosis trials in patients undergoing coronary balloon angioplasty, Violaris et al found that there was no association between cholesterol and 33 restenosis. Even subgroup analysis based on HDL and LDL cholesterol levels revealed no differences in the categorical restenosis rate, suggesting no influence of these cholesterol subfractions on restenosis. It was suggested, therefore, that reduction of total cholesterol
41
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
would not result in reduction of restenosis. This suggestion was evaluated in the PREDICT trial in which it was shown that cholesterol lowering had no effect on angiographic outcome at the target site 6 months after coronary angioplasty.34 This finding is in contrast with other reports demonstrating that high levels of serum cholesterol are associated with a higher restenosis rate.6,30,35
C-reactive protein The preprocedural C-reactive protein (CRP) level, a marker of acute phase response that can be easily measured, is a powerful predictor of both early and late outcome in patients undergoing single vessel balloon angioplasty, suggesting that early complications and clinical restenosis are markedly influenced by the preprocedural degree of inflammatory cell activation.36 Using multivariate analysis, Heeschen et al found that both CRP and troponin T emerged as independent predictors of mortality and myocardial infarction at 6-month follow-up. On the other hand, the incidence of coronary restenosis during 6-month follow-up was not related to Troponin T status (3% vs 4.5%; p=0.49) but was significantly related to CRP status (7% vs 2.3%; p=0.03). These authors concluded that CRP was an independent predictor of both cardiac risk and repeated coronary revascularization (coronary artery bypass graft surgery and PCTA) during 6-month follow-up.36 Other markers of inflammation, such as IL6, have also been shown to be related to restenosis.38 Conflicting results were provided by Zhou et al, who demonstrated that although both Chlamydia infection and elevated CRP levels are associated with coronary artery disease and coronary artery disease events, neither appears to play a role in the development of restenosis in human subjects.39
42
Fibrinogen Tschopl et al40 showed comprehensively that baseline plasma fibrinogen, CRP concentration, and the severity of the arterial disease were significantly predictive of coronary restenosis. Their results indicate that high procoagulant factors and persistent thrombin generation of the haemostatic system might promote restenosis, particularly in patients with extended atherosclerosis.40 A high plasma fibrinogen level also seems to play a role in the development of restenosis after renal artery intervention.41 Schoebel et al found that the high rate of angiographic restenosis in patients with end stage renal disease seems to be related to the size of the vessel dilated and to an increased prothrombotic risk, as indicated by higher fibrinogen concentrations.42 Others, however, have contradicted the importance of fibrinogen as a predictor for restenosis.43
Lipoprotein (a) Serum lipoprotein (a) [Lp(a)] level is a known risk factor for arteriosclerotic coronary artery disease, but its association with restenosis after balloon angioplasty in coronary arteries is controversial. It was hypothesized that through a pathophysiological mechanism leading to excess thrombin generation or inhibition of fibrinolysis, the risk for restenosis would be increased. However, several groups found no correlation between restenosis after balloon angioplasty and levels of Lp(a),28,44,45 while others have found conflicting results. Balloon angioplasty and Japanese origin in combination with an increased Lp(a) level seems to constitute a risk factor for restenosis.46–49 In a study analysing the predictive role of plasma Lp(a) for restenosis after elective coro-
ANGIOGRAPHIC PREDICTORS
nary stenting, Ribichini et al50 found that multiple stents were associated with a higher incidence of restenosis (p = 0.006), but biochemical data in these patients were similar to those treated with single stents. They concluded that the basal plasma level of Lp(a) measured before the procedure is not a predictor for restenosis after elective high-pressure coronary stenting.50 Wehinger et al confirmed these results at 1-year follow-up.51
Serum amyloid A A somewhat unusual predictive factor was described by Blum et al.52 Patients who had an increase in their serum amyloid type A level of > 100% in the first 24 hours after balloon angioplasty and also developed a positive antibody result (antinuclear factor or anticardiolipin), had a relative risk of 10.6 for developing restenosis in the first year after the initial revascularization.
after conventional balloon angioplasty.53–55 Hamon et al took it a step further and concluded that genotyping of ACE and angiotensin I-receptor polymorphisms before conventional balloon angioplasty is not clinically useful.56 More encouraging results between restenosis and ACE I/D polymorphism were found in patients undergoing coronary artery stent implantation.57,58 Analysis of these studies showed that the I/D polymorphism was significantly associated with the occurrence of in-stent restenosis, suggesting that ACE may indeed play an important part in the formation of neointimal tissue after stent implantation. However, another group looking at a similar patient population recently could not confirm these results.59
Other Several other parameters have been described and are referred to in Table 4.2.
Angiotensin-converting enzyme
Angiographic Predictors
The angiotensin-converting enzyme (ACE) is an important molecule that is involved in the conversion of angiotensin I to angiotensin II and the inhibition of bradykinin. The plasma and cellular levels of ACE in humans are associated with an I (insertion)/D (deletion) genetic polymorphism in the ACE gene. Patients with DD have higher levels of ACE. It has been suggested that polymorphisms of this system are involved in neointimal formation after arterial injury. Since neointimal formation plays an important role in renarrowing after balloon angioplasty and a predominant role after coronary artery stenting, the ACE I/D polymorphism has been thoroughly evaluated as a predictive marker for restenosis. Several groups agreed on the lack of correlation between ACE polymorphism and restenosis
Numerous angiographic studies have evaluated the effects of balloon angioplasty, stent implantation, directional coronary atherectomy, rotational atherectomy, laser angioplasty, intracoronary brachytherapy, systemic pharmacological treatment, local drug delivery, and stent coating on angiographic restenosis. The majority of them have tried to determine specific variables after different and complex analyses that would help in predicting the risk of restenosis after a given percutaneous coronary intervention. It is apparent from several studies that these so-called predictive factors differ, depending on the technique, the number of patients, the nature of the trial, the selection bias, the angiographic endpoints, the percentage follow-up and last, but not least, the definition of restenosis itself.
43
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
Factor
Correlation
Reference
CD64 CD66 IL-1 beta Plasma uPA antigen levels PAI-1 antigen levels high plasma activity of ACE intracoronary SMMHC Serum levels of soluble Fas ligand Mac-1 (CD11b/CD18) on the surface of the neutrophils increased sICAM-1 levels homozygosity for apolipoprotein epsilon 4 high endothelin levels von Willebrand factor
– – + + + + + + + + + + +
18 18 18 Strauss 99 Strauss 99 Ribichini 97 Tsuchio 2000 Hara 2000 Inoue 98 Inoue 98 Van Bokxmeer 94 20 Montalescot 95
IL, interleukin; ACE, angiotensin-converting enzyme; PAI, plasminogen activator inhibitor; SMMHC, serum smooth muscle; PA, plasminogen activator Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999; 100:1616–1622. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998; 97:147–154. Tsuchio Y, Naito S, Nogami A, et al. Intracoronary serum smooth muscle myosin heavy chain levels following PTCA may predict restenosis. Japanese Heart Journal 2000; 41:131–140. Hara H, Sato R, Katagiri T, Hasegawa M. Evaluation of restenosis by serum levels of soluble Fas, Fas ligand and nuclear matrix protein before and after coronary intervention. Journal of Cardiology 2000; 35:89–93. Inoue T, Sakai Y, Hoshi K, Yaguchi I, Fujito T, Morooka S. Lower expression of neutrophil adhesion molecule indicates less vessel wall injury and might explain lower restenosis rate after cutting balloon angioplasty. Circulation 1998; 97:2511–2518. van Bockxmeer FM, Mamotte CD, Gibbons FR, Taylor RR. Apolipoprotein epsilon 4 homozygosity–a determinant of restenosis after coronary angioplasty. Atherosclerosis 1994; 110, 195, 202. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995; 92:91–98.
Table 4.2. Other biochemical and genetic predictors for restenosis. Correlation is + when predictive of restenosis, and – if protective.
Defining restenosis is of the utmost importance, as it must correlate well with clinical end points and it determines the success of a treatment modality. Several definitions have been proposed and each of them must be seen in relation to the purpose of each individual study. The traditional definition is a dichotomous definition in which restenosis is defined as a > 50% renarrowing at follow-up. This definition relates to a late failure of an initial successful intervention. However, since restenosis is a continuous phenomenon and
44
parametric statistical tests are more powerful, it might be preferable to use late percentage diameter stenosis or absolute late minimal lumen diameter (MLD) rather than any binary restenosis definition.60 The absolute late loss itself is an even better measure, however, since late loss is highly related to the acute gain produced by the intervention, it is common to define restenosis as the ratio of late loss to acute gain or “loss index.” Based on several analyses, this index has also been found to be relatively insensitive to the device used. It has
ULTRASOUND PREDICTORS
correctly identified a number of biological variables (left anterior descending LAD artery, location, diabetes) that increase restenosis. These considerations should be taken into account when analysing the predictive angiographic parameters for restenosis. A common finding in nearly all of the angiographic studies evaluating predictive factors for restenosis is the MLD after the intervention.3,13,21–24,30,31,61–64 The magnitude of the predictive value of the post intervention MLD varies among several reports and is often related to the technique used to treat the lesion. In a multivariable modeling for restenosis after balloon angioplasty, Carozza et al showed that a post procedure lumen diameter < 2.80 mm was one of the only independent predictors of restenosis among diabetes mellitus, and prior restenosis.61 Using univariate analysis, Moscucci et al demonstrated that a post procedure luminal diameter < 3.1 mm was a strong predictor for binary restenosis.26 In relation to directional coronary atherectomy, Fishman et al found that a post procedure lumen diameter > 3 mm was a predictor of a lower restenosis rate.30 Using rotational atherectomy, the burr-to-artery ratio (< 0.6) was found to be a univariate predictor of repeat restenosis.65 In another study by Rau et al, a post stenting MLD of ≤ 2.54 mm was also found to adversely influence the angiographic outcome.66 Kastrati et al reported that a MLD < 3 mm at the end of the procedure augmented the risk of binary restenosis with an OR of 1.81.22 A second well known predictor for restenosis is the reference vessel diameter. Small vessels are invariably found to be associated with an increased risk of restenosis.13,21,24,62,63,67,68 The length of the lesion or the stented vessel segment length is another common and good predictor for restenosis.15,23,62,69,70 Popma et al
found that a lesion length of more than 10 mm was associated with an increased risk of restenosis after directional coronary atherectomy.3 According to Rau et al, a stent length > 16 mm has a high chance of restenosis.66 Increasing the number of stents also negatively influences the long-term angiographic outcome,7,22,25 as does multivessel stenting.7,24 The location of the lesion is another important predictor. Very often, the risk for restenosis is increased when the LAD artery is involved,13,26 the lesion is ostial or at the proximal segment of an artery,13,65,71 the stenosis is within a saphenous vein graft,3,17,20,21,26,27 or it involves a bifurcation.27 Other factors with a predictive value for restenosis after balloon angioplasty and/or stent implantation have been reported and include percentage diameter stenosis after the procedure63 and at follow-up,71 a balloon/ vessel diameter ratio for final stent expansion ≤ 1.00,65 the presence of a dissection after balloon angioplasty,65 lesion symmetry,15,67 the angiographic pattern of in-stent restenosis,25,64 bailout stenting,7 acute neointimal recoil,72 stenting without debulking,70 high-pressure balloon inflation (>16 atm),70 prestenting vessel angulation,73 and the changes in vessel angulation after stent implantation.73 Very recently, the placement of a new stent in conjunction with intravascular brachytherapy has been found to be associated with a high predictive value of late total occlusion in patients with in-stent restenosis.74
Ultrasound predictors The abundance of trials on angiographic prediction of restenosis stands in sharp contrast to the paucity of strong data concerning the ultrasound predictors of restenosis. To our knowledge, no well-conducted trial has investigated the possibility of IVUS as a predictor
45
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
of restenosis in a non-biased way. Later in this chapter we will describe two trials that used ultrasound guidance; although the pharmacological agents used in these trials did not show any benefit in reducing in-stent restenosis, the data that arose from these trials were very useful in constructing an IVUS-guided prediction model for in-stent restenosis. 75 In a small study of IVUS-guided balloon angioplasty, Jain et al76 found that of the various parameters analysed, the absence of plaque fracture, the existence of a major dissection, and greater plaque burden were associated with increased incidence of restenosis 6 months after the index balloon angioplasty. They indicated that IVUS can identify a subset of patients in whom restenosis is likely to develop, and that the information about the morphological features of the atheroma and its composition may be used to modify the interventional strategy and thus optimize lumen size and possibly reduce the chance of restenosis. Mintz et al found that reference vessel size, the preintervention quantitative coronary angiographic (QCA) assessment of lesion severity and the postintervention IVUS crosssectional measurements predicted the late angiographic results in a study of 350 patients following balloon angioplasty.77 In particular, the IVUS postintervention cross-sectional narrowing (plaque plus media cross-sectional area (CSA) divided by external elastic membrane CSA) predicted the primary end point (restenosis) as well as two of the three secondary end points (follow-up diameter stenosis and late lumen loss) and was therefore the most consistent predictor of restenosis. In a study of 70 patients where 40 were treated by balloon angioplasty alone, and 30 by combination of rotational atherectomy plus balloon angioplasty, Schiele et al found that the only independent predictor of late clinical
46
outcome after percutaneous re-intervention for in-stent restenosis was final lumen size, no matter which means were used to achieve it.78 In a study of 164 patients, Peters et al stated that qualitative IVUS parameters after balloon angioplasty did not predict restenosis.79 A larger lumen and vessel area and a smaller plaque area by IVUS were associated with a larger angiographic MLD at follow-up, but these parameters were not significantly related to categorical restenosis. Moreover, plaque morphology data did not seem to correlate to restenosis rate. This study may have been biased by its retrospective design. In two landmark studies, Albiero et al80 and de Jaegere et al81 both demonstrated the added benefit of performing IVUS during stent implantation to reduce the 6-month restenosis rate. Albiero et al showed that the dichotomous restenosis rate was lower in the IVUS group than in the angiographic group (9.2% vs 22.3%; p = 0.04).80 The authors concluded that in matched lesions treated with high-pressure stenting, IVUS guidance achieved a larger MLD than angiographic guidance. In the MUSIC trial, which was originally set up to validate the safety and feasibility of IVUSguided stenting without subsequent anticoagulation, and its impact on the 6-month restenosis rate, de Jaegere et al found that in selected patients, stents can be implanted safely without the use of systemic anticoagulation, provided optimal stent expansion is achieved.81 Based on these initial findings, de Feyter et al created a reference chart to predict the expected in-stent restenosis rate based on operator-dependent IVUS parameters.75 IVUSdetermined post-stent-implantation predictors of 6-month in-stent restenosis on QCA were identified by logistic regression analysis. These predictors were used to construct a reference chart that predicts the expected 6-month QCA restenosis rate. IVUS and QCA data were
ULTRASOUND PREDICTORS
obtained from three registries (MUSIC [Multicenter Ultrasound Stenting in Coronaries study], WEST-II [West European Stent Trial II], and ESSEX [European Scimed Stent EXperience]) and two randomized in-stent restenosis trials (ERASER [Evaluation of ReoPro And Stenting to Eliminate Restenosis] and TRAPIST [TRApidil vs placebo to Prevent In-STent intimal hyperplasia]), as neither abciximab nor trapidil resulted in a reduction of instent restenosis. IVUS predictors were minimum and mean in-stent area, stent length, and instent diameter. Multiple models were constructed with multivariate logistic regression analysis. The model containing minimum instent area and stent length best fit the Hosmer–Lemeshow goodness-of-fit test. Thus, the expected 6-month in-stent restenosis rate after stent implantation for short lesions in relatively large vessels can be predicted by considering the in-stent minimal area (which is inversely related to restenosis) and stent length (which is directly related to restenosis; Fig. 4.1). Hong et al confirmed the findings of the MUSIC trial.82 In 285 consecutive patients
Restenosis
1.00
0.67
0.33 60
0.00 3.0
35
7.5 Minimum in-stent area
12.0 10
Stent length
Figure 4.1 Three-dimensional representation of restenosis rate (y-axis) in relation to minimum in-stent area (x-axis) and stent length (z-axis).
with 304 native coronary lesions, the investigators evaluated the predictors of angiographic restenosis and compared them with stent lumen CSA and stent length between short stent length (< 20 mm) and long (≥ 20 mm) coronary stenting. The overall angiographic restenosis rate in this group was 22.8% (56 of 246 lesions) (short stent 17.6% vs long stent 32.2%, p = 0.009). Using multivariate logistic regression analysis, the independent predictors of angiographic restenosis were the IVUS stent lumen CSA (OR 1.51, 95% CI 1.18–1.92, p = 0.001 for overall comparison among groups) and stent length (OR 0.95, 95% CI 0.91–1.00, p = 0.039). The angiographic restenosis rate was 54.8% for stent lumen CSA of < 5.0 mm2 (short stent 37.5% vs long stent 73.3%, p = 0.049), 27.4% for CSA between 5.0 and 7.0 mm2 (short stent 24.1% vs long stent 31.7%, p = 0.409), 10.5% for CSA between 7.0 and 9.0 mm2 (short stent 10.0% vs long stent 12.5%, p = 0.772), and 11.4% for stent lumen CSA of ≥ 9.0 mm2 (short stent 10.4% vs long stent 13.3%, p = 0.767) (p = 0.001). Interestingly, long coronary stenting, as opposed to short coronary stenting, is an effective treatment modality to cover long lesions resulting in comparable long-term clinical outcomes providing that a stent lumen CSA of ≥ 7.0 mm2 is achieved. Therefore, the most important factor determining angiographic restenosis, regardless of the stent length, is the IVUS stent lumen CSA in relatively large coronary artery lesions. Hofmann et al found that ostial lesion location and IVUS preinterventional plaque burden (plaque/total arterial area) and postinterventional lumen dimensions were the most consistent predictors of angiographic in-stent restenosis in a study of 382 lesions in 291 patients treated with 476 Palmaz–Schatz stents.71
47
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
In a large retrospective study of 1,706 patients with 2,343 lesions treated with intracoronary stenting, Kasaoka et al found instent restenosis was angiographically documented in 282 patients with 409 lesions (25%).62 The restenosis group had a significantly longer total stent length, smaller reference lumen diameter, smaller final MLD by angiography and smaller stent lumen CSA by IVUS. In lesions where IVUS guidance was used, the restenosis rate was 24% compared with 29% if IVUS was not used (p < 0.05). By multivariate logistic regression analysis, longer total stent length, smaller reference lumen diameter and smaller final MLD were strong predictors of in-stent restenosis. In lesions with IVUS guidance, IVUS stent lumen CSA was a better independent predictor than the angiographic measurements. The conclusions of the investigators were somewhat predictive of what was later to be found in randomized trials, namely that achieving an optimal stent lumen CSA by using IVUS guidance during the procedure and minimizing the total stent length may reduce in-stent restenosis.
Practical implications It is not an easy task to provide a straightforward list with actions to be undertaken to minimize the risk for restenosis. As has been mentioned previously, many conflicting results are provided in the literature. In Figure 4.2 we have tried to capture the most important risk factors. We have divided them into three categories: those that have arisen from non-confirmed circumstantial evidence (small circles), those that have provided conflicting results but provided positive evidence in most cases (medium-sized circles) and those that are based on solid evidence (large circles). The colour code further splits them into treatable (green) and non-treatable (red).
48
Fibrinogen
Smoking
Organ failure Lipoprotein (a)
Male
Cholesterol Unstable Old age
CRP
Hypertension
S Amyloid A
ACE I/D polym
Diabetes
Previous MI
Restenosis
Proximal segm
Ref vessel size IVUS Periph vasc dis Ostial lesion LAD involved
Small vessels
MLD post interv Radioact stent
Lesion length
High press PTCA
Diss PostPTCA Prior restenosis
Figure 4.2 Qualitative overview of the most important risk factors for restenosis. We divided them into three categories: those that have arisen from nonconfirmed circumstantial evidence (small circles), those that have provided conflicting results but provided positive evidence in most cases (medium-sized circles), and those that are based on solid evidence (large circles). The color code further splits them into treatable (green) and nontreatable (red). Unstable = Unstable angina at presentation; Previous MI = previous myocardial infarction; CRP = C-reactive protein; S Amyloid A = Serum Amyloid A; ACE I/D polym = Angiotensine-converting enzyme insertion deletion polymorphism; Proximal segm = Proximal segment; LAD = Left anterior descending artery; Radioact stent = Radioactive stent; Periph Vasc Dis = Peripheral vascular disease; High press percutaneous transluminal coronary angioplasty = High pressure PTCA; Diss PostPTCA = Dissection post PTCA; MLD post interv = Minimal luminal diameter post intervention; Ref vessel size IVUS = Reference vessel size using intravascular ultrasound.
CONCLUSIONS
Looking at this figure, it becomes obvious that restenosis is a complex, multi-tiered process that is not easy to tackle. It is probably safe to say that an old, smoking, hypertensive diabetic with hypercholesterolemia with a history of restenosis in a previously treated vessel, who is now treated with a radioactive stent after high-pressure PTCA for a 40 mm lesion in a 2.5 mm caliber LAD lesion is likely to develop restenosis. Caution should be exercised therefore, when patients with a ‘high-risk profile’ present with coronary lesions. Treatable risks should be taken care
of, and angiographic and ultrasound parameters should be optimized.
Conclusions Restenosis represents the last hurdle for the interventional cardiologist in overcoming their restraint in treating all coronary lesions percutaneously. In this chapter we represent an overview of how optimization of the patient’s clinical characteristics and of the periprocedural parameters can be modified so as to minimize this hazardous event.
49
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
References
1.
2.
3.
4.
5.
6.
7.
8.
50
Hermans WR, Rensing BJ, Foley DP et al. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. J Cardiovasc Pharmacol 1993; 22 Suppl 4:S45–S57. Gershlick A, Brack MJ, More RS et al. Angiographic restenosis after angioplasty: comparison of definitions and correlation with clinical outcome. Cor Art Dis 1993; 4:73–81. Popma JJ, De Cesare NB, Pinkerton CA et al. Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. Am J Cardiol 1993; 71:552–557. van’t Hof AW, de Boer MJ, Suryapranata H et al. Incidence and predictors of restenosis after successful primary coronary angioplasty for acute myocardial infarction: the importance of age and procedural result. Am Heart J 1998; 136:518–527. Heidland UE, Heintzen MP, Klimek WJ et al. Acute complications and restenosis in women undergoing percutaneous transluminal coronary angioplasty. Is it possible to define sex differences and to determine risk factors? J Cardiovasc Risk 1998; 5:297–302. Gurlek A, Dagalp Z, Oral D et al. Restenosis after transluminal coronary angioplasty: a risk factor analysis. J Cardiovasc Risk 1995; 2:51–55. van Domburg RT, Foley DP, de Jaegere PP et al. Long term outcome after coronary stent implantation: a 10-year single-centre experience of 1000 patients. Heart 1999; 82 Suppl 2:II27–II34. Mittal S, Weiss DL, Hirshfeld JW Jr et al. Comparison of outcome after stenting for de novo versus restenotic narrowings in native coronary arteries. Am J Cardiol 1997; 80:711–715.
9.
10. 11.
12.
13.
14.
15.
16.
17.
18.
Petkar S, Gambhir DS, Trehan V et al. Clinical, angiographic and histopathological predictors of restenosis after directional coronary atherectomy. Ind Heart J 1995; 47:227–231. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31:1291–1298. Marti V, Salas E, Aymat RM et al. Influence of residual stenosis in determining restenosis after cutting balloon angioplasty. Catheter Cardiovasc Intervent 2000; 49:410–414. Sirnes PA, Molstad P, Myreng Y, Golf S. Predictors for restenosis after angioplasty of chronic coronary occlusions. Int J Cardiol 1998; 67:111–118. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25:362–369. Thel MC, Califf RM, Tcheng JE et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137:264–273. Kereiakes DJ, Midei M, Hermiller J et al. Procedural and late outcomes following MULTILINK DUET coronary stent deployment. Am J Cardiol 1999; 84:1385–1390. Kereiakes D, Linnemeier TJ, Baim DS et al. Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials). Am J Cardiol 2000; 86:336–341. Jolly N, Ellis SG, Franco I et al. Coronary artery stent restenosis responds favorably to repeat interventions. Am J Cardiol 1999; 83: 1565–1568. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating
REFERENCES
19.
20.
21.
22. 23.
24.
25.
26.
27.
28.
29.
phagocytes before treatment. Circulation 1995; 91:1320–1325. Taira DA, Seto TB, Ho KK et al. Impact of smoking on health-related quality of use after percutaneous coronary revascularization. Circulation 2000; 102:1369–1374. Kotamaki M, Laustiola K, Syvanne M, Heikkila J. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. J Intern Medicine 1996; 240:293–301. Wong SC, Baim DS, Schatz RA et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter US Palmaz–Schatz stent experience. The Palmaz–Schatz Stent Study Group. J Am Coll Cardiol 1995; 26:704–712. Kastrati A, Schomig A, Elezi S et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30:1428–1436. Dauerman HL, Baim DS, Cutlip DE et al. Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998; 82:277–284. Lee SG, Lee CW, Hong MK et al. Predictors of diffuse-type in-stent restenosis after coronary stent implantation. Catheter Cardiovasc Intervent 1999; 47:406–409. Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872–1878. Moscucci M, Piana RN, Kuntz RE et al. Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy. Am J Cardiol 1994; 73:1147–1153. Van Belle E, Abolmaali K, Bauters C et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999; 34:476–485. Alaigh P, Hoffman CJ, Korlipara G et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscl Thromb Vascul Biol 1998; 18:1281–1286. Van Belle E, Bauters C, Hubert E et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angio-
30.
31.
32. 33.
34.
35.
36.
37.
38.
39.
plasty in native coronary vessels. Circulation 1997; 96:1454–1460. Fishman RF, Kuntz RE, Carrozza JP Jr et al. Long-term results of directional coronary atherectomy: predictors of restenosis. J Am Coll Cardiol 1992; 20:1101–1110. Walter DH, Schachinger V, Elsner M et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000; 85:962–968. Lafont A, Guerot C, Lemarchand P. Which gene for which restenosis? Lancet 1995; 346:1442–1443. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994; 90:2267–2279. Bertrand ME, McFadden EP, Fruchart JC et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol 1997; 30:863–869. Kishi K, Hiasa Y, Tanaka H et al. The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina. J Cardiol 1996; 28:79–84. Buffon A, Liuzzo G, Biasucci LM et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34:1512–1521. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535–1542. Hojo Y, Ikeda U, Katsuki T et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84:83–87. Zhou YF, Csako G, Grayston JT et al. Lack of association of restenosis following coronary
51
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
52
angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999; 84:595–598. Tschopl M, Tsakiris DA, Marbet GA. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscl Thromb Vascul Biol 1997; 17:3208–3214. Symonides B, Januszewicz A, Rowinski O et al. Plasma fibrinogen as a risk factor for restenosis after percutaneous transluminal renal angioplasty in patients with atherosclerotic renal artery stenosis. J Cardiovasc Risk 1999; 6:269–272. Schoebel FC, Gradaus F, Ivens K et al. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case–control study using quantitative coronary angiography. Heart 1997; 78:337–342. Schumacher M, Eber B, Tiran A et al. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angiography. Cardiology 1992; 80:345–348. Cooke T, Sheahan R, Foley D et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994; 89:1593–1598. Jorgensen B, Simonsen S, Endresen K et al. Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids. Eur Heart J 1999; 20:1407–1414. Miyata M, Biro S, Arima S et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996; 132:269–273. Horie H, Takahashi M, Izumi M et al. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation 1997; 96:166–173. Desmarais RL, Sarembock IJ, Ayers CR et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91:1403–1409. Yamamoto H, Imazu M, Yamabe T et al. Risk
50.
51.
52. 53.
54.
55.
56.
57.
58.
59.
factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J 1995; 130:1168–1173. Ribichini F, Steffenino G, Dellavalle A et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98:1172–1177. Wehinger A, Kastrati A, Elezi S et al. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999; 33:1005–1012. Blum A, Kaplan G, Vardinon N et al. Serum amyloid type A may be a predictor of restenosis. Clinic Cardiol 1998; 21:655–658. Hamon M, Bauters C, Amant C et al. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995; 92:296–299. Samani NJ, Martin DS, Brack M et al. Insertion/deletion polymorphism in the angiotensinconverting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 1995; 345:1013–1016. Kasi JC, Zhang Y, Calvino R et al. Angiotensin-converting enzyme insertion/deletion polymorphism and restenosis after coronary angioplasty in unstable angina pectoris. Am J Cardiol 1996; 77:875–877. Hamon M, Amant C, Bauters C, et al. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty. Am J Cardiol 1998; 81:79–81. Amant C, Bauters C, Bodart JC et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96:56–60. Ribichini F, Steffenino G, Dellavalle A et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998; 97:147–154. Kelbaeck H. Angiotensin-converting enzyme genotype and restenosis trial: six months angiographic follow-up study in 350 patients with stent implantation examining the influence of D/I ACE genotype on the occurrence of
REFERENCES
60. 61.
62.
63.
64.
65.
66.
67.
68.
69.
restenosis. European Society of Cardiology 2000. Amsterdam. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation 1993; 88:1310–1323. Carrozza JP Jr, Kuntz RK, Schatz RA et al. Inter-series differences in the restenosis rate of Palmaz–Schatz coronary stent placement: differences in demographics and post-procedure lumen diameter. Catheter Cardiovasc Diagn 1994; 31:173–178. Kasaoka S, Tobis JM, Akiyama T et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32:1630–1635. Serruys PW, Kay IP, Disco C et al. Periprocedural quantitative coronary angiography after Palmaz–Schatz stent implantation predicts the restenosis rate at six months: results of a metaanalysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999; 34:1067–1074. Bossi I, Klersy C, Black AJ et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35:1569–1576. Sharma SK, Duvvuri S, Dangas G et al. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. J Am Coll Cardiol 1998; 32:1358–1365. Rau T, Schofer J, Schluter M et al. Stenting of nonacute total coronary occlusions: predictors of late angiographic outcome. J Am Coll Cardiol 1998; 31:275–280. Strauss BH, Natarajan MK, Batchelor WB et al. Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty. Circulation 1995; 92:348–356. Hernandez-Antolin RA, Alfonso F, Goicolea J et al. Results (> 6 months) of stenting of > 1 major coronary artery in multivessel coronary artery disease. Am J Cardiol 1999; 84:147–151. Kobayashi Y, De Gregorio J, Kobayashi N et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651–659.
70. Kini A, Marmur JD, Dangas G et al. Angiographic patterns of in-stent restenosis and implications on subsequent revascularization. Catheter Cardiovasc Intervent 2000; 49:23–29. 71. Hoffmann R, Mintz GS, Mehran R et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz–Schatz stents. J Am Coll Cardiol 1998; 31:43–49. 72. Radke PW, Klues HG, Haager PK et al. Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study. J Am Coll Cardiol 1999; 34:33–39. 73. Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35:1580–1589. 74. Waksman R, Bhargava B, Mintz GS, et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000; 36:65–68. 75. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999; 100:1777–1783. 76. Jain SP, Jain A, Collins TJ et al. Predictors of restenosis: a morphometric and quantitative evaluation by intravascular ultrasound. Am Heart J 1994; 128:664–673. 77. Mintz GS, Popma JJ, Pichard AD et al. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol 1996; 27:1678–1687. 78. Schiele F, Meneveau N, Seronde MF et al. Predictors of event-free survival after repeat intracoronary procedure for in-stent restenosis; study with angiographic and intravascular ultrasound imaging. Eur Heart J 2000; 21:754–762. 79. Peters RJ, Kok WE, Di Mario C et al. Prediction of restenosis after coronary balloon angioplasty. Results of PICTURE (Post- IntraCoronary Treatment Ultrasound Result Evalu-
53
CLINICAL, BIOCHEMICAL, ANGIOGRAPHIC AND INTRAVASCULAR ULTRASOUND
ation), a prospective multicenter intracoronary ultrasound imaging study. Circulation 1997; 95:2254–2261. 80. Albiero R, Rau T, Schluter M et al. Comparison of immediate and intermediate-term results of intravascular ultrasound versus angiography-guided Palmaz–Schatz stent implantation in matched lesions. Circulation 1997; 96:2997–3005. 81. de Jaegere P, Mudra H, Figulla H et al.
54
Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998; 19:1214–1223. 82. Hong MK, Park SW, Mintz GS, et al. Intravascular ultrasonic predictors of angiographic restenosis after long coronary stenting. Am J Cardiol 2000; 85:441–445.
5 Importance of physiologic assessment pre- and post intervention* Michael D Eisenhauer and Morton J Kern
Introduction Coronary angiography is the principle tool for the evaluation of coronary stenoses, including those lesions recurring after percutaneous coronary intervention. In clinical terms, however, the use of angiography has significant limitations when assessing lesions of intermediate severity, and becomes even more problematic when evaluating the results following coronary interventions with the inherent and inconsistent luminal disruption. Because of the limitations of lumenography, the physiologic assessment of coronary stenoses, both before and after intervention, has emerged with an increasingly important role. It is generally appreciated that an assessment of coronary blood flow is important for decision-making in patients with coronary artery disease. Objective evidence of abnormal coronary blood flow by noninvasive stress testing is relied upon in every cardiology center worldwide. The American College of Cardiology/American Heart Association (AHA/ACC) guidelines for percutaneous transluminal coronary angioplasty (PTCA)
*The opinions or assertions contained herein reflect the views of the authors, and are not to be construed as official, or as representing the position of United States Army Medical Department, the Department of Defense, or the United States Federal Government.
recommend acquiring ‘. . . assurance that . . . symptoms are indeed due to the coronary lesion proposed for dilatation’, and discuss the importance of objective evidence of regional myocardial ischemia before proceeding with an intervention.1 Widely accepted indirect methods to detect regional abnormalities in coronary blood flow include inducible left ventricular contractile abnormalities during stress echocardiography, ischemic electrocardiographic changes on exercise or ambulatory monitoring, and abnormal stress radionuclide perfusion scintigraphy (Table 5.1). However, these indirect methods of coronary blood flow evaluation often require additional time and expense either before or after diagnostic catheterization. The direct influence of a coronary stenosis on physiology, evaluating the distal arterial pressure–flow relationship, can now be easily and safely measured with sensor-tipped angioplasty guidewires at the time of coronary angiography. The measurements of post stenotic absolute coronary flow velocity reserve (CVR), the relative CVR (rCVR), and the pressure-derived fractional flow reserve (FFR) of the myocardium have been identified, refined, simplified, and validated. Assessing coronary blood flow provides unique information that complements anatomic data obtained during diagnostic angiography and following an intervention.2–5 This chapter will review the
55
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
Indirect methods Electrocardiographic stress or ambulatory ischemia monitoring Radionuclide scintigraphy/perfusion stress imaging Exercise stress Pharmacologic stress: adenosine, dipyridamole, dobutamine Two-dimensional echocardiographic left ventricular imaging Exercise stress Pharmacologic stress: dobutamine, dipyridamole Echocardiographic myocardial perfusion Contrast echocardiography Harmonic processing/tissue Doppler velocities Positron emission tomography Magnetic resonance imaging/angiography Direct methods Anatomic Coronary angiography Intravascular ultrasound Physiologic Intracoronary Doppler flow velocity and reserve (CVR) Intracoronary pressure gradients during hyperemia (FFR) Coronary sinus thermodilution
Table 5.1 Methods of coronary artery assessment.
fundamental assumptions, methodology, validation, and clinical applications for lesion assessment before and after coronary interventions.
Basic coronary physiology An epicardial stenosis produces an increased resistance to antegrade blood flow. In response to decreased epicardial flow, the distant microvascular resistance vessels dilate to maintain regional basal flow at a level appropriate for concurrent myocardial oxygen demand. Increasing the capacitance of the vascular bed reduces the potential maximal flow reserve available. The resting post stenotic epicardial blood flow is generally unchanged from its normal level until the stenosis becomes very
56
severe (usually ⬎ 90% narrowed), and usually is satisfactory to maintain myocardial systolic function, oxidative metabolism, and cellular viability. In the presence of a significant stenosis, any further increase in myocardial oxygen demand or other hyperemic stimuli will result in a reduced post stenotic hyperemia relative to the coronary flow increase that would occur in the same or another myocardial region without a stenosis. A blunted post stenotic hyperemia (reserve) can be easily identified in the catheterization laboratory using a pharmacologic hyperemic stimuli, such as intracoronary adenosine or papaverine, and measuring coronary flow velocity. As a companion to diminished flow, a significant stenosis also produces a loss of post stenotic arterial pressure because of a loss of
BASIC CORONARY PHYSIOLOGY
kinetic energy due to viscous friction, turbulence, and flow separation. The reduction of the distal distending arterial pressure results in a pressure differential (gradient) between the aortic and distal coronary pressure. The absolute distal pressure is directly related to the flow rate as described by the curvilinear pressure–flow relationship of stenosis resistance (Fig. 5.1).6
A
B ⌬P
Flow
Pd B
A
Figure 5.1 Coronary pressure–flow relationship for two stenoses of same angiographic severity (A and B), demonstrating a physiologic difference between lesions. Top: pressure gradient (⌬P) vs coronary flow. Bottom: absolute distal coronary pressure (Pd) versus flow. Increasing coronary flow produces a marked loss of Pd and an increase in ⌬P. Loss of Pd in absolute terms determines myocardial perfusion pressure (Pd – venous pressure) and potential for inducible ischemia. (Adapted from reference 3, with permission).
Until recently, the hemodynamic significance of a given stenosis as determined by the pressure–flow relationship has not been routinely incorporated into clinical practice. Earlier cumbersome techniques and conflicting results from validating studies7,8 raised adverse theoretical concerns regarding the translation of basic physiology from experimental animal models to patient care.9 Most, if not all objections have been overcome by employing sensor guidewires and validating a more thorough understanding of coronary physiology using distal flow and pressure measurements.
Coronary flow velocity reserve Intracoronary Doppler flow velocity can be measured using a Doppler-tipped angioplasty guidewire. This guidewire is a 175 cm long, 0.014–0.018 inch (0.035–0.046 cm) diameter, flexible, steerable wire with a piezoelectric ultrasound transducer integrated into the tip (FloWire; Endosonics, Inc., Rancho Cordova, CA, USA). The cross-sectional area of the wire itself is 0.164 mm2, only 21% of the crosssectional area of a 1 mm catheter. As a result, the guidewire induces very little flow disturbance, and like standard angioplasty guide wires, can be used as a primary angioplasty crossing wire with ⬎ 90% success for most coronary stenoses. The velocity signals are processed through a real-time spectrum analyser, continuously displayed on a video monitor, and recorded on videocassette or a thermal page printer. Reproducibility of the velocity signals is generally excellent with low interobserver (⬍ 12%) and intraobserver (9%) variability.10 Coronary flow velocity is calculated from the Doppler frequency shift defined as the difference between the transmitted and returning frequency: V ⫽ [(F1–F0)*C]/[(2F0)*(Cos )]
57
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
where: V ⫽ velocity of blood flow F0 ⫽ transmitting (transducer) frequency F1 ⫽ returning frequency C ⫽ constant: speed of sound in blood ⫽ angle of incidence Volumetric blood flow is calculated as the product of vessel cross-sectional area (cm2) and flow velocity (cm/sec), yielding a value in cm3/sec. Doppler coronary flow velocities represent changes in absolute coronary flow only when the vessel cross-sectional area remains unchanged during measurements. The maximum velocity is most accurately recorded when the transducer beam is parallel to blood flow and is zero (Cos ⫽ 1).11 Assuming a constant vessel diameter and an interrogating Doppler angle of ⬍ 20°, the flow rate can be calculated from the velocity measurements within 5% of absolute values. The influence of a stenosis on coronary flow velocity produces characteristic alterations of phasic flow patterns, hyperemic capacity, and, relative distal flow compared to other unobstructed arterial branches. For normal coronary vessels with diameters ⬎ 2.0 mm, arterial flow velocity is nominally maintained within 15% from proximal to distal regions along the course of the artery.10,12 Normally, there is no significant decline in distal blood flow velocity, since the blood flow volume and epicardial conduit cross-sectional area are proportionately reduced over the course of the vessel. A proximal to distal velocity ratio of nearly 1 can then be assumed.12 A marked decrement in distal flow relative to proximal flow is seen with hemodynamically significant lesions and is predicated on a branched tube model, wherein flow is diverted away from the branch with a higher resistance (stenosis) to branches with lower resistance (normal, open segments). A proximal to distal
58
blood flow velocity ratio (P/D) ⬎ 1.7 (i.e. distal velocity reduced) is associated with a resting translesional pressure gradient ⬎ 30 mmHg, usually warranting intervention.12 In a branching system, coronary flow or velocity measured proximal to a stenosis will differ from post stenotic flow or velocity, because of the lower prelesional branch resistance directing flow away or around the coronary stenosis.13 The proximal/distal flow ratio does not apply in conduits without branches, wherein the continuity equation mandates equality of flow at all points along the circuit. A proximal/distal flow velocity ratio is therefore not useful for left main stenosis, very proximal or ostial lesions, LIMA or saphenous vein graft conduits, diffusely diseased vessels, or those vessels with multiple sequential stenoses. Coronary flow velocity reserve (CVR) is computed as the ratio of maximal hyperemic/basal mean coronary flow velocities distal to the stenosis (Fig. 5.2). Coronary hyperemia is induced by intracoronary papaverine (10 mg) or adenosine (18–24 g in the right coronary artery or 24–30 g in the left coronary artery), or intravenous adenosine infusion 140 g/kg/min.14,15 Although early studies suggested a CVR ratio of 3.5–5 in normal patients,16 lower values are more commonly observed in patients with chest pain undergoing cardiac catheterization with angiographically normal vessels, suggesting a degree of patient–patient variability and distal microvascular disease that is beyond the threshold of angiographic detection.17 A post stenotic CVR ⬎ 2.0 has a high correlation with normal myocardial perfusion stress imaging.18–21 High sensitivity, specificity, and predictive accuracy are reported in CVR correlation studies with both perfusion sestamibi and 201thallium imaging and contrast stress echocardiography.22 Most investigators
BASIC CORONARY PHYSIOLOGY
Figure 5.2 Coronary flow velocity signals obtained in a normal circumflex coronary artery (N.L., CFX). Left panel: The display screen is divided into top and bottom panels, and the bottom half is divided into left and right panels. The top half represents continuous flow velocity signals in real-time. The electrocardiogram, heart rate, aortic pressure, and spectral flow signals are provided in each window. The scale is 0–120 cm/s. S and D ⫽ systolic and diastolic flow periods demarcated by the electrocardiogram, respectively. The lower left panel demonstrates basal flow velocity, and the lower right panel demonstrates the peak hyperemic velocity after intracoronary adenosine administration. Right panel: The trend plot of the continuous flow velocity measurement (average peak velocity (APV)) is shown in the lower window. After intracoronary adenosine administration, APV increased from 11 to 29 cm/s, producing a coronary flow reserve (CFR) ratio of 2.6. The duration of hyperemia shown is 45 seconds in a 90-second display window. The scale is 0–40 cm/s. (Adapted from reference 2, with permission).
consider the post stenotic CVR ⬍ 2.0 to be abnormal.
Relative coronary flow velocity Because CVR is the summed response of a two-component system, there is some uncertainty in accepting an abnormal CVR as the sole indicator of lesion significance. Post stenotic coronary flow reserve is determined not only by epicardial stenosis severity but also by the structural and functional status of the microvasculature, as well as variations in heart rate, blood pressure, and myocardial contractile function.23,24 Factors such as hyper-
tension, diabetes, hypercholesterolemia, and smoking will affect both the microcirculation and macrocirculation, presumably in a uniform distribution. It may be impossible to differentiate which of these factors, if any, is responsible for a reduced CVR. Gould et al first introduced the concept of relative coronary flow (volume) reserve (rCVR), defined as maximal flow in the coronary with stenosis/maximal flow in a coronary without stenosis.25 His team demonstrated that rCVR is independent of the aortic pressure and rate–pressure product, and is particularly well suited to assess the physiologic significance of coronary stenoses when an
59
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
stenosis in the target vessel. Because of the necessity of instrumenting a normal reference vessel, the rCVR cannot be determined in patients with 3-vessel disease. FFR
rCVR
CVRTARGET
CVRREFERENCE
Figure 5.3 Anatomic representation comparing FFR, CVR, and rCVR. The fractional flow reserve (FFR) evaluates only the pressure gradient across the target stenosis, while the coronary flow velocity reserve (CVR) incorporates the resistance effect of the myocardium and distal microvascular disease (as well as the effect of the target stenosis) in the measurement of hyperemic coronary flow velocity. The relative CVR (rCVR) allows for comparison between target and reference vessels, thereby canceling the effect of distal microvascular and myocardial resistance.
adjacent non-diseased coronary artery is available. In the catheterization lab, it is believed that the ratio between measured CVR in a target and reference vessel reflects a similar physiology (Fig. 5.3). CVR measurements in normal vessels generally are similar (i.e. ⬍ 10% variance) among the perfusion territories of the three major coronary arteries.17,26 Baumgart et al,27 demonstrated that the relative difference in CVR between a target artery compared with a normal reference artery segment in another distribution does, indeed, correlate more strongly than CVR alone with the degree of
60
Coronary pressure: basics of fractional flow reserve The concept of a pressure-derived index of coronary perfusion, the myocardial fractional flow reserve (FFR), has been developed as an invasively determined index of the functional severity of a stenosis.4,5,28 FFR, simply defined, is the ratio of maximal blood flow through the stenotic artery to the myocardium to the theoretical normal maximal flow through the artery in the absence of the stenosis. This index represents the fraction of the normal
s
n
FFR ⫽
Max Hyperemic Pressures Max Hyperemic Pressuren
Since n ⫽ aortic pressure if the proximal coronary is unobstructed, then FFR ⫽
Max Hyperemic Pressures Aortic Pressure
Figure 5.4 Fractional flow reserve (FFR) is the ratio between maximal hyperemic pressure beyond a target stenosis (s) and the maximal hyperemic pressure in the same vessel in the theoretical absence of the stenosis (n). Because pressure transmission along the course of the coronary artery is preserved, aortic pressure can be used for the pressure of the theoretical normal vessel.
BASIC CORONARY PHYSIOLOGY
FFR⫽ 105/133⫽0.78
adenosine
aortic
Pa
coronary Pd
CVR ⫽ 2.2 Coronary velocity
Figure 5.5 Case example of simultaneous aortic and coronary pressures following the hyperemic response after intracoronary adenosine administration. The pressure gradient (Pa–Pd) is greatest approximately 15–20 sec after the adenosine is given. Note that the resting gradient is small, but is exaggerated during the hyperemic state. FFR ⫽ Pa/Pd, or 0.78, a non-ischemia related value. Simultaneous coronary velocity as measured by Doppler, demonstrates a coronary flow velocity reserve (CVR) of 2.2, also a normal value. Pa ⫽ pressure, aortic; Pd ⫽ pressure, distal coronary.
maximal flow that can be achieved despite the coronary stenosis. It is derived from formulas equating pressure changes to measured flow when resistance is at an absolute minimum (Fig. 5.4). FFR is calculated as the ratio of the mean absolute distal coronary artery pressure to the mean aortic pressure measured during maximal vasodilatation as shown in Fig. 5.5.28 This index is independent of changes in systemic blood pressure and heart rate, and is unaffected by conditions known to increase the baseline myocardial flow.29 Unlike CVR or
rCVR, FFR takes into account the contribution of the collateral blood supply to maximal myocardial perfusion.28,30 The normal FFR is 1.0, regardless of the patient or the specific vessel studied.5 A threshold value of FFR ⬍ 0.75 has been identified, indicating a functionally significant epicardial stenosis that correlates with induced ischemia by stress testing in ⬎ 90% of patients.4 The correlation between rCVR and FFR appears to be strong (r ⫽ 0.91) when simultaneously compared in the same artery (Fig. 5.6).27 However, like CVR, FFR has potential
61
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
4
1.0 0.9
rCVR
CVR
3
2
0.8 0.7
y⫽ 0.01⫻ ⫹1.16 r⫽0.33 p⫽ 0.12
1
0 0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
FFR
y ⫽0.79⫻ ⫹17.7 r ⫽ 0.91 p ⬍ 0.0001
0.6 0.5 0.4
0.5
0.6
0.7
0.8
0.9
1.0
FFR
Figure 5.6 Left panel: Correlation between FFR and CVR. The correlation indicates no significant relation between the two variables. Right panel: Linear correlation between FFR and rCVR. The correlation is highly significant (r ⫽ ⫺0.91). (Adapted from reference 27, with permission).
limitations. Small-vessel disease, diffuse coronary artery disease, and left ventricular (LV) hypertrophy are conditions which restrict the increase in blood flow after pharmacologic vasodilatation, and potentially blunt the corresponding decrease in distal coronary artery pressure.4,5,28,30 Under these conditions, FFR may underestimate the severity of a stenosis because of a limited increase in flow. However, FFR still addresses the degree to which luminal enlargement may improve flow. Under conditions of microcirculatory abnormality, a normal FFR indicates that angioplasty alone would not likely augment coronary flow perfusion at the microvascular level. Intracoronary pressure measurements can be made with either of two commercially available devices, the Pressure Guide (Radi Medical Systems, Uppsala, Sweden) or the WaveWire (Endosonics, Inc., Rancho Cordova, CA, USA). Both sensor wires
62
produce a high fidelity signal with phasic pressure waveforms equivalent to larger highfidelity catheters.
Preintervention physiologic assessment Validation with noninvasive testing Several single center studies18–20,22 and one multicenter trial,21 report strong correlations between post stenotic CVR and FFR with noninvasive stress echocardiography, electrocardiography, or perfusion scintigraphy. An abnormal distal hyperemic flow velocity reserve (CVR ⬍ 2.0) corresponds to abnormal myocardial perfusion scintigraphy defects with high sensitivity (86–92%), specificity (89–100%), predictive accuracy (89–96%), and positive and negative predictive values (94–100%, and 77–95%, respectively).
PREINTERVENTION PHYSIOLOGIC ASSESSMENT
Pijls et al4 documented a very strong correlation between FFR and four commonly used noninvasive tests to detect myocardial ischemia in patients with moderate coronary stenoses. In patients with an FFR of ⱖ 0.75, all tests for myocardial ischemia were negative (NPV ⫽ 88%). An FFR of ⬍ 0.75 identified physiologically significant stenoses associated with inducible myocardial scintigraphic ischemia, with high sensitivity (88%), specificity (100%), positive predicted value (100%), and overall accuracy (93%).4,31
Preintervention assessment: comparison to QCA and IVUS In a comparative preintervention study between intravascular ultrasound (IVUS), quantitative coronary analysis (QCA), and CVR in 73 patients, Abizaid et al32 reported that a minimum lumen cross-sectional area (CSA) of ⱖ 4.0 mm2 or mean lumen diameter (MLDIVUS) of ⱖ 2.0 mm has a diagnostic accuracy of 92% for identification of diseased vessels with a measured hyperemic CVR of ⱖ 2.0. QCA determinations of lesion length, but not lumen diameter, were also independent predictors of hyperemic CVR. A similar preintervention study comparing IVUS, QCA and FFR in 42 patients with 51 stenoses, also demonstrated that QCA alone was not effective in determining physiologic lesion significance assessed by either IVUS or FFR.33 There was, however, a strong correlation between MLDIVUS ⱕ 3.0 mm2 and CSAIVUS stenosis ⬎ 60% with a measured FFR ⬍ 0.75 (IVUS sensitivity 83%, specificity 92%), indicating abnormal flow physiology.
Deferring interventions Based on the results of several studies, a strategy of deferring interventions for intermediate
lesions with normal physiologic measurements can be strongly supported. The clinical outcomes of deferring coronary intervention for intermediate stenoses with normal physiology are remarkably consistent, with clinical event rates of ⬍ 10% over a 2-year follow-up period.4,34–37 Owing to clinical and ethical requirements, in these studies it was not feasible to defer treatment in symptomatic patients with abnormal translesional physiology. It is highly likely that those individuals would, at the least, continue to be as symptomatic or have even higher event rates. However, there remain some patients with deferred procedures who may still have recurrent angina, requiring continued medical therapy.35 Nonetheless, when physiologically normal, the functional and clinical impact of angiographically intermediate stenoses is associated with an excellent clinical outcome. In-laboratory translesional hemodynamics may not reflect the episodic ischemia-producing conditions of daily life; particularly those related to vasomotor changes during exercise or emotional stress.38 Fortunately, most dynamic conditions are often highly responsive to medical therapy. Criteria validated with ischemic stress testing appear to support decisions to defer intervention in such situations while continuing medical therapy for endothelial dysfunction, hypertension, hyperlipidemia, and episodic coronary vasoconstriction. Direct measurements of coronary blood flow prior to intervening may also prove helpful in selecting the hemodynamically significant lesions in patients with multivessel coronary disease. Because of the uncertainty regarding the physiologic impact of angiographically intermediate stenoses, the simple identification of restenosis by angiography should not drive the strategy towards repeat intervention with the attendant increased recurrence rates. This response, sometimes known as the ‘oculo-
63
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
stenotic reflex’, can be overcome by measuring the physiologic significance of the stenosis when objective evidence of ischemia is lacking.
Predicting restenosis? Unfortunately, there is no data currently available to suggest that a preintervention physiologic measurement of coronary flow with CVR, rCVR, or FFR can predict which lesions will restenose following coronary intervention. From large percutaneous transluminal coronary angioplasty (PTCA) registries, clinical and anatomic variables such as vessel size and anatomy (i.e. branch points), lesion length and location (LAD), and the degree of calcification appear more predictive than current physiologic data.
Physiologic assessment post intervention Provisional stenting using physiologic guidance Angiography is an insufficient tool to determine a satisfactory PTCA result. QCA is limited in its ability to assess short and long term outcomes, because dissections induced by balloon inflation may fill with contrast medium, resulting in near-normal angiographic luminography. IVUS studies have shown that an almost normal angiographic luminogram after PTCA can still be accompanied by considerable residual stenosis.39 Moreover, during the initial years, first-generation stents were difficult to place, and limited by an uncertain future regarding acute thrombotic occlusion and/or delayed restenosis. In this setting, a concept of provisional stenting using balloon angioplasty, augmenting the angiographic endpoint with physiology to obviate
64
obligatory stenting, was tested and validated. In the contemporary era of third generation stents and potent anti-platelet pharmacotherapy, the concept of provisional stenting is rarely practiced although, as studies show, it remains valid.40 A multicenter prospective trial (DEBATE: Doppler End Point Balloon Angioplasty Trial Europe) demonstrated that the combination of optimal angiographic and functional results by coronary flow velocity measurements could identify a subset of patients in whom a clinical event rate was low at 6 months and comparable to results after coronary stenting. The Debate I study revealed that a combined endpoint of QCA residual stenosis ⬍ 35% and CVR ⬎ 2.5 immediately after PTCA is associated with reduced incidence of recurrent angina, need for repeat target lesion revascularization (TLR), and provided for angiographic restenosis rates of ⬍ 16%.40 These data support a physiologically guided intervention to facilitate achieving an optimal lumen and perhaps reduce unnecessary stent placement. Indeed, preliminary data from several other multicenter trials in progress (DEBATE II, Destini-CVR, and FROST) also demonstrate that a direct assessment of coronary flow (CVR) following angioplasty is predictive for recurrent ischemia, TLR, and restenosis.
Mechanisms of abnormal CVR after PTCA and stenting Because balloon angioplasty usually converts an angiographically severe stenosis into an angiographically acceptable but physiologically intermediate stenosis, intracoronary flow measurements can help determine the adequacy of restoration and stabilization of flow following PTCA. Early studies of impaired post angioplasty CVR were likely to be
PHYSIOLOGIC ASSESSMENT POST INTERVENTION
associated with residual lumen impairment undetected by satisfactory angiographic results. Sequential flow velocity data have confirmed that the normalization of CVR occurring in only 50% of patients after PTCA alone may be increased to 80% of patients after stenting (Fig. 5.7).41,42 The relationship between lumen area and coronary blood flow, examined by serial measurements of CVR, rCVR, QCA, and IVUS in a 55-patient study after PTCA alone and again after stent placement, emphasizes the physiologic importance of lumen enlargement.41 The percentage diameter stenosis decreased from 75 ⫾ 13% to 40 ⫾ 18% after PTCA, and to 10 ⫾ 9% after stent placement. CVR increased from 1.6 ⫾ 0.7 to 1.9 ⫾ 0.6 after PTCA, and to 2.5 ⫾ 0.8 after stenting, with normalization of rCVR (0.64 ⫾ 0.26 to 1.00 ⫾ 0.34). In a 15patient subset, IVUS cross-sectional area was significantly larger after stenting compared with PTCA alone (7.6 mm2 vs 4.5 mm2, p ⬍ 0.01), again demonstrating the relationship between lumen size and coronary flow.
CVR and rCVR post intervention Although a majority of patients after stenting have a normalized CVRTARGET, some patients may still have an abnormal CVRTARGET (⬍ 2.0). It has been suggested that in patients with a CVRTARGET ⬍ 2.0 after stenting, a normal calculated rCVR (CVRTARGET/CVRREFERENCE) supports the diagnosis of global microvascular disease.43 Theoretically, rCVR should normalize the abnormal absolute CVRTARGET for regional differences. The improvement in CVR in the myocardial region supplied by a stented coronary artery compared to an adjacent territory with no intervention has also been demonstrated indirectly by positron emission tomography (PET).44 Several studies also demonstrate a late
improvement of impaired CVR following PTCA without stenting, most likely owing to remodeling of the epicardial lesion44 and/or delayed recovery of autoregulation.45 Van Liebergen et al42 reported long-term changes in coronary blood flow in 54 patients with single-vessel disease and normal left ventricular function after PTCA alone (n ⫽ 34) compared with stenting (n ⫽ 20). Both CVR and rCVR were measured immediately after the intervention and again 6 months later. An improvement in CVR and rCVR towards normal values occurred immediately after PTCA alone (CVR, 1.6 ⫾ 0.7 to 3.1 ⫾ 1.0; rCVR, 0.50 ⫾ 0.22 to 0.96 ⫾ 0.32). Despite the additional lumen enlargement (determined angiographically) after stent implantation, there was no further improvement in either CVR (2.8 ⫾ 1.1) or rCVR (0.87 ⫾ 0.24) compared to PTCA alone (CVR 2.6 ⫾ 0.7, rCVR 0.84 ⫾ 0.22). Approximately 40% of patients had a persistently abnormal CVR (ⱕ 2.5) immediately post-PTCA or stenting, which was related to an increase in baseline blood flow velocity rather than blunted hyperemia. In both the PTCA-treated and stent-treated groups, the impaired CVR values following the intervention improved at 6-month followup, increasing toward the values of the reference vessel CVR in patients without restenosis (PTCA rCVR, 0.65 ⫾ 0.16 to 0.84 ⫾ 0.21; stent rCVR, 0.71 ⫾ 0.19 to 1.05 ⫾ 0.12). Post PTCA and post stent CVR and FFR measurements have revealed several mechanisms that may limit the immediate normalization of coronary blood flow. One major mechanism of persistently impaired coronary blood flow after PTCA is suboptimal lumen expansion that may not be identified by conventional angiography.43 In distinction from quantitative angiography or IVUS alone, an increased CVR after PTCA to normal ranges coupled with satisfactory anatomic results is
65
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
Figure 5.7 Angiographic and coronary flow velocity data before and after transluminal percutaneous coronary angioplasty (PTCA) and again after stent placement. Cineangiographic frames and coronary basal and hyperemic flow velocity are shown after each stage in the procedure. CVR is 1.0 before PTCA (top row), increasing to 2.0 after PTCA (middle row), and 2.7 after stenting (bottom row). Velocity scale is 0–120 cm/s. APV ⫽ average peak velocity; DSVR ⫽ diastolic/systolic velocity ratio; MPV ⫽ maximal peak velocity; ACC ⫽ acceleration index; S and D ⫽ systolic/diastolic phase markers based on electrocardiogram. (Adapted from reference 41, with permission).
66
PHYSIOLOGIC ASSESSMENT POST INTERVENTION
associated with a reduced 30-day and 6-month ischemic event rate.
Predictors of acute occlusion Cyclical flow variations during PTCA are easily detected by the Doppler flow wire, and often precede angiographic signs of impending vessel failure such as no/slow reflow, thrombus embolization, progressive dissection, or vasospasm.46 Because of the early detection and improved ability to continuously monitor coronary flow, early precautionary actions can be initiated. If used for monitoring PTCA procedures, the Doppler wire assists by guiding therapy, and may reduce the volume of injected contrast needed for serial angiograms over a 15–30 minute monitoring period.
FFR after angioplasty or stenting Compared to CVR, FFR has emerged as a relatively easy and straightforward method to assess stenoses both pre- and post intervention. FFR measurements prior to interventional procedures can determine whether a particular stenosis is associated with inducible ischemia. After intervention, FFR provides important prognostic benefit as well. A hyperemic FFRSTENT ⬎ 0.90 is better than simple resting transstenotic gradients to predict the percent diameter restenosis at 6-month followup angiography.47 Bech et al47 reported 2-year clinical followup data for 60 patients after single vessel angioplasty compared with post-intervention FFR. In the 43% (26 of 60) of patients with optimal PTCA angiographic (QCA residual ⱕ 35%) and functional (FFR ⱖ 0.90) results, event-free survival rates were significantly better at 6 months (92% vs 72%, p ⫽ 0.047), 12 months (92% vs 69%, p ⫽ 0.028), and 24 months (88% vs 59%, p ⫽ 0.014) months
compared to those patients with at FFR ⬍ 0.90. No improvement in clinical outcome was gained by additional stenting. These data suggest that with an optimal functional and angiographic result after PTCA, the incidence of clinically significant restenosis is equal to that after stenting. Conversely, given the high event rate in study patients with a suboptimal functional PTCA reflected by an FFR ⬍ 0.90, further intervention to improve the result with stenting seems appropriate.
Relationship between IVUSSTENT and FFRSTENT Although IVUS is the present standard for the evaluation of optimum stent deployment, it is expensive and not routinely practiced in most catheterization laboratories. In an elegant study of 30 patients with staged stent deployment to increasing pressures, Hanekamp et al48 demonstrated that the coronary pressurederived FFR is a potentially inexpensive and rapid alternative to IVUS for that purpose. During serial increases in balloon implantation pressures within a Wiktor-i stent, a total of 81 paired IVUS and FFR measurements reaching the optimum threshold were obtained, with a 91% concordance in the ability to predict suboptimum stent deployment with either technique (p ⬍ 0.00001). On the contrary, QCA alone showed a low concordance rate with both IVUS and FFR (48% and 46%, respectively). The utility of FFR to identify the physiologic endpoint after coronary stenting is currently under evaluation in a US multicenter trial (FUSION study).
Alternative noninvasive methods post intervention Many catheterization laboratories do not have the hardware required to perform either FFR
67
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
or CFR determinations following PTCA. A subjective TIMI (thrombolysis in myocardial infarction) flow-grading system may be used as a qualitative measure of coronary flow,49 and may be standardized by using the corrected TIMI frame count (CTFC) as a semiquantitative approach.50,51 Recently, Stankovic et al52 demonstrated that a new index comparing the corrected TIMI frame count against the mean luminal diameter (MLD, using electronic calipers) after PTCA, was predictive of both angiographic and clinical restenosis. The measured CTFC correlated well with post stenotic average peak velocity (APV) values (as measured with a Doppler guidewire) and volumetric flow both before and after PTCA (r ⫽ 0.82 and r ⫽ 0.80, respectively). The investigators demonstrated that the CTFC/MLD ratio, containing information on coronary flow normalized by the residual MLD was strongly predictive for both angiographic and clinical restenosis, with an odds ratio of 1.42 (1.13–1.79, p ⫽ 0.003). Although the number of patients evaluated in this retrospective study was relatively small, CTFC/MLD ratio cutoff values of ⬎ 7.88 and ⬎ 7.94 predicted angiographic and clinical restenosis with a sensitivity of 72–77%, specificity 64–68%, and negative predictive value of 81%, respectively. In the population studied, the ratio was more predictive than either measurement alone and better than measured CVR.53 Although not yet convincingly demonstrated in a post PTCA group, Doppler echocardiographic techniques appear to be of some value in determining CVR in the left anterior descending (LAD) coronary artery. Both transthoracic contrast-enhanced secondand transharmonic echo-Doppler,54 esophageal (TEE) pulsed-wave Doppler mapping55,56 correlate with intracoronary Doppler-guidewire measured flow velocity.
68
Paraskevaidis et al57 demonstrated that TEEderived CVR (but not resting coronary velocity) could identify a residual proximal LAD stenosis 72 hours after PTCA. Other investigators report that an increase in diastolic flow measured by TEE may serve as an index of successful LAD PTCA.58 Although cumbersome and limited to the LAD, these evolving techniques may predict restenosis following a coronary intervention.
Coronary lesion assessment for patients with myocardial infarction The assessment of stenoses associated with acute myocardial infarction (AMI) represents the next frontier for coronary physiologic evaluation. AMI results in regional heterogeneity of the microcirculation, invalidating the use of both CVR and rCVR for lesion assessment. A large transmural infarction may alter the measured CVR in the infarcted vessel as well as in adjacent noninfarct related arteries, thus invalidating a primary assumption upon which rCVR is based. The applicability of FFR in this setting remains promising and is under investigation. Nonetheless, some studies suggest that physiologic measurements may be useful for viability assessments, and therefore, carry with it some prognostic information. Experimental animal reperfusion studies and recent clinical studies with perfusion imaging techniques have shown that the CVR is severely impaired after an infarct induced by transient occlusion of the target vessel.59 As might be anticipated, Claeys et al60 demonstrated that CVR was significantly lower in patients with a recent MI (13 ⫾ 7 days) than in those without prior MI, and that CVR remained impaired even after angiographically successful PTCA. Pre- and post PTCA CVR
CORONARY LESION ASSESSMENT FOR PATIENTS WITH MYOCARDIAL INFARCTION
values were lower in infarct-related vessels compared with noninfarct-related vessels over a wide range of stenosis severity: 1.22 ⫾ 0.26 vs 1.50 ⫾ 0.45 before PTCA (p ⬍ 0.05), and 1.72 ⫾ 0.43 vs 2.21 ⫾ 0.74 after PTCA, respectively (p ⬍ 0.01).
Coronary physiologic responses of no-reflow and viability Animal experiments61 and clinical studies62 suggest that the no-reflow phenomenon (reperfusion injury) following MI is the major reason that LV function cannot be salvaged, even after adequate recanalization. Prolonged ischemia resulting in cellular injury initiates a local inflammatory response, accumulation of neutrophils and production of leukotrienes, thereby increasing vascular permeability.63 Increasing vascular permeability completes a deleterious cycle exacerbating interstitial edema and extravascular resistance to blood flow. Beyond the microvascular injury, patients with a recent MI may also show an abnormal vasomotor response with inappropriate constriction of the small resistance vessels as a result of the platelet release and activation of vasoactive substances (thromboxane A2, serotonin, thrombin).63 Restoration of flow after stenting has been identified by both positron emission tomography (PET) and video densitometry, reflecting an impaired myocardial vasodilating response owing to reperfusion-related microvascular injury.59,64 Although some studies report a CVR ⬎ 1.3 to be associated with post infarction viability, Claeys et al60 found no relationship between CVR and residual viability (assessed scintigraphically), and CVR did not differentiate those patients with extensive versus small infarction. This suggests that the coronary vasodilating capacity is not totally affected by the gross amount of microvascular necrosis,
and further suggests that an impaired CVR is related to the degree of microcirculatory injury in the region adjacent to the infarct, and is mediated by a process of microvascular stunning that is partially reversible over time.65 Unlike CVR after PTCA, the lower CVR in patients with recent MI appears to be related to lower hyperemic APV values, suggesting an impaired flow resistance in the reperfused myocardium rather than a resetting of basal flow. Kawamoto et al65 measured APV as well as diastolic flow velocity deceleration time (DDT) in 23 patients with acute anterior MI, demonstrating that if the APV was ⬎ 6.5 cm/s or the DDT ⬎ 600 ms, the more myocardium within the infarcted region would recover with an improved regional wall motion assessed by echocardiography. Tsunoda et al66 evaluated 19 patients with acute anterior MI with continuous flow velocity measurements for 18 ⫾ 4 hours after successful PTCA. Two divergent groups were identified. Regional wall motion and overall LV systolic function were shown to improve in those patients in whom APV increased after only a transient decline (EF increased 17 ⫾ 9%), whereas LV systolic function did not improve if the APV progressively decreased throughout the next day (EF increased only 4 ⫾ 9%, p ⫽ 0.007). Evidence such as this indicates that a short course of hemodynamic support with an intraaortic balloon pump (IABP) might augment myocardial perfusion and result in improved myocardial salvage,67 or that vasodilators such as verapamil68 or adenosine69 might modulate reperfusion injury.
Recovery of LV function and microcirculatory regulation post infarction Neumann et al70 measured coronary flow, CVR, and regional LV function immediately
69
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
after stenting and again 14 days later in two groups of acute infarction patients; a control group treated with standard heparin, and another group treated with glycoprotein (GP) IIb/IIIa inhibition with abciximab (ReoPro™). Improved recovery of coronary vascular function as well as regional systolic wall motion was observed in the abciximab group compared with heparin alone after intracoronary stenting (Fig. 5.8).70 The authors concluded that not only large-vessel patency but also improved microvascular perfusion is an achievable and rewarding goal for the treatment of AMI patients. GP IIb/IIIa antithrombotic therapy may limit the degree of
microvascular damage, and lead to improved LV function and long term outcomes.
The economics of lesion assessment In view of the clinical validation of physiologic assessments in the catheterization laboratory to accurately guide therapy, questions regarding economic feasibility should be addressed. Doppler and pressure guidewires in use today cost $350–450, with capital equipment expenses of $45 000 and $15 000 for Doppler and pressure signal analysers, respectively.
GP IIb/IIIa receptor blockade in AMI 40
0.8 heparin
abciximab p⫽ 0.024
30
20 p⫽ 0.15 10
0
⌬Wall motion index (SD/chord)
⌬Coronary flow velocity (cm/s)
abciximab
heparin
p⫽ 0.007
0.6
0.4
0.2
0 Basal
Peak
Figure 5.8 Left panel: Chart of differences between 14-day follow-up and initial post-interventional study in basal flow velocity and in papaverine-induced peak flow velocity at the treated lesion. Right panel: Chart of differences between 14-day follow-up and initial post-interventional study in wall motion index. Both panels: Columns represent mean difference; error bars indicate 95% CI. The p-values above each pair of columns refer to statistical differences between the two treatment groups (abciximab vs heparin). (Adapted from reference 70, with permission).
70
SUMMARY
These expenses are offset by the costs of noninvasive stress testing and associated additional hospital time. To compare potential cost savings using inlaboratory physiologic assessment versus a strategy of out-of-laboratory thallium scintigraphy, the PEACH trial randomized 53 patients with intermediate coronary stenoses to CVR measurements in the lab or thallium stress testing in the days following angiography.71 A definitive diagnosis was made in 28 of 29 patients randomized to in-lab testing, with an average associated cost of $1914 ⫾ 55. Patients randomized to stress thallium testing required an additional 2.1 ⫾ 0.8 hospital days, with an average calculated cost of $2718 ⫾ 242. The investigators concluded that in-lab coronary lesion assessment is a cost-effective and clinically useful means for managing CAD patients with intermediate coronary stenoses. The current status of reimbursement does provide for a partial recovery of the expenses of ancillary device (IVUS, pressure, flow) use in the catheterization laboratory. Although HCFA reimburses for physician interpretation of results ($93 for first vessel, $72 for each additional vessel), the disposable and fixed
equipment expenses of non-angiographic methods for evaluating stenoses must be covered by the institution. The clinical benefit is provided to the patient, but the cost of the information translates into an operational expense for the laboratory budget, albeit at an overall savings to the health care delivery system.
Summary The direct physiologic influence of a coronary stenosis, prior to an intervention for either de novo or restenotic lesions, can be easily and safely determined with sensor-tipped angioplasty guidewires, employing post stenotic absolute coronary flow velocity reserve (CVR), relative CVR (rCVR), and the pressure-derived fractional flow reserve (FFR). This information supports decisions regarding planned interventions on restenotic or de novo lesions of intermediate angiographic severity. Following percutaneous interventions, these measurements provide prognostic information that may not only direct the need for repeat balloon dilatation, stent implantation or highpressure expansion, but also predict long term clinical outcome.
71
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
References
1.
2.
3. 4.
5.
6.
7.
8.
9.
72
Ryan TJ, Bauman WB, Kennedy JW et al. Guidelines for percutaneous transluminal angioplasty; ACC/AHA Task Force Report. J Am Coll Cardiol 1993; 22:2033–2054. Kern MJ, deBruyne B, Pijls NHJ. From research to clinical practice: current role of intracoronary physiologically based decision making in the cardiac catheterization laboratory. J Am Coll Cardiol 1997; 30:613–620. Kern MJ. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. Circulation 2000; 101:1344–1351. Pijls NHJ, deBruyne B, Peels K et al. Measurement of myocardial fractional flow reserve to assess the functional severity of coronary artery stenosis. N Engl J Med 1996; 334:1703–1708. Pijls NHJ, VanGelder B, VanDerVoort P et al. Fractional flow reserve: a useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. Circulation 1995; 92:3183–3193. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis: instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974; 33:87–94. Peterson RJ, King SB III, Fajman WA et al. Relation of coronary artery stenosis and pressure gradient to exercise-induced ischemia before and after coronary angioplasty. J Am Coll Cardiol 1987; 10:253–260. Zilstra F, Fioretti P, Reiber J, Serruys PW. Which cineangiographically assessed anatomic variable correlates best with functional measurements of stenosis severity? A comparison of quantitative analysis of the coronary cineangiogram with measure coronary flow reserve and exercise/redistribution thallium-201 scintigraphy. J Am Coll Cardiol 1988; 12:686–691. Klocke FJ. Measurement of coronary flow reserve: defining pathophysiology versus
10.
11.
12.
13.
14. 15.
16.
17.
18.
making decisions about patient care. Circulation 1987; 76:1183–1189. Ofili EO, Kern MJ, Labovitz AJ et al. Analysis of coronary blood flow velocity dynamics in angiographically normal and stenosed arteries before and after endoluminal enlargement by angioplasty. J Am Coll Cardiol 1993; 21:308–316. Hatle L, Angelsen B. Flow velocity and volumetric principle. In: Doppler Ultrasound in Cardiology. Philadelphia, PA: Lea & Feibeger, 1985, 15–25. Donohue TJ, Kern MJ, Aquirre FV et al. Assessing the hemodynamic significance of coronary artery stenoses: analysis of translesional pressure-flow velocity relationships in patients. J Am Coll Cardiol 1993; 22:449–458. Geschwind HJ, Dupouy P, Dubois-Rande JL et al. Restoration of coronary blood flow in severely narrowed and chronically occluded coronary arteries before and after angioplasty: implications regarding restenosis. Am Heart J 1994; 127:252–262. Wilson RF, Wyche K, Christensen BV et al. Effects of adenosine on human arterial circulation. Circulation 1990; 82:1595–1606. Kern MJ, Deligonul U, Tatineni S et al. Intravenous adenosine: continuous infusion and low dose bolus administration for determination of coronary vasodilatory reserve in patients with and without coronary artery disease. J Am Coll Cardiol 1991; 18:718–729. Wilson RF, White CW. Intracoronary papaverine: an ideal coronary vasodilator for studies of the coronary circulation in conscious humans. Circulation 1986; 73:444–451. Kern MJ, Bach RG, Mechem CJ et al. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation, and coronary artery disease. J Am Coll Cardiol 1996; 28:1154–1160. Miller DD, Donohue TJ, Younis LT et al. Correlation of pharmacologic 99mTc-sestamibi myocardial perfusion imaging with post-
REFERENCES
19.
20.
21.
22.
23.
24. 25.
26.
27.
28.
stenotic coronary flow reserve in patients with angiographically intermediate coronary stenoses. Circulation 1994; 89:2150–2160. Joye JE, Schulman DS, Lasorda D et al. Intracoronary Doppler guide wire versus stress single-photon emission computed tomographic thallium-201 imaging in assessment of intermediate coronary stenoses. J Am Coll Cardiol 1994; 24:940–947. Deychak YA, Segal J, Reiner JS et al. Doppler guide wire flow-velocity indexes measured distal to coronary stenoses associated with reversible thallium perfusion defects. Am Heart J 1995; 129:219–227. Heller LI, Cates C, Popma J et al, for the FACTS study group. Intracoronary Doppler assessment of moderate coronary artery disease: comparison with 201thallium imaging and coronary angiography. Circulation 1997; 96:484–490. Danzi GB, Pirelli S, Mauri L et al. Which variable of stenosis severity best describes the significance of an isolated left anterior descending coronary artery lesion? Correlation between quantitative coronary angiography, intracoronary Doppler measurements and high dose dipyridamole echocardiography. J Am Coll Cardiol 1998; 31:526–533. McGinn AL, White CW, Wilson RF. Interstudy variability of coronary flow reserve: influence of heart rate, arterial pressure, and ventricular preload. Circulation 1990; 81:1319–1330. Czernin J, Muller P, Chan S et al. Influence of age and hemodynamics on myocardial blood flow and reserve. Circulation 1993; 88:62–69. Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 1990; 15:459–474. Wolford TL, Donohue TJ, Bach RG et al. Heterogeneity of coronary flow reserve in the examination of multiple individual allograft coronary arteries. Circulation 1999; 99:626–632. Baumgart D, Haude M, Goerge G et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. Circulation 1998; 98:40–46. Pijls NHJ, van Son JAM, Kirkeeide RL et al.
29.
30.
31.
32.
33.
34.
35.
36.
Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993; 87:1354–1367. deBruyne B, Bartunek J, Sys SU et al. Simultaneous coronary pressure and flow velocity measurements in humans: feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. Circulation 1996; 94:1842–1849. Pijls NHJ, Bech GJW, el Gamal MIH et al. Quantification of recruitable coronary collateral blood flow in conscious humans and its potential to predict future ischemic events. J Am Coll Cardiol 1995; 25:1522–1528. de Bruyne B, Bartunek K, Sys SU, Heyndrickx GR. Relation between myocardial fractional flow reserve calculated from coronary pressure measurements and exercise-induced myocardial ischemia. Circulation 1995; 92:39–46. Abizaid A, Mintz GS, Pichard AD et al. Clinical, intravascular ultrasound, and quantitative angiographic determinants of the coronary flow reserve before and after percutaneous transluminal angioplasty. Am J Cardiol 1998; 82:423–428. Takagi A, Tsurumi Y, Ishii Y et al. Clinical potential of intravascular ultrasound for physiological assessment of coronary stenosis: relationship between quantitative ultrasound tomography and pressure-derived fractional flow reserve. Circulation 1999; 100:250–255. Kern MJ, Donohue TJ, Aguirre FV et al. Clinical outcome of deferring angioplasty in patients with normal translesional pressureflow velocity measurements. J Am Coll Cardiol 1995; 25:178–187. Ferrari M, Schnell B, Werner GS, Figulla HR. Safety of deferring angioplasty in patients with normal coronary flow velocity reserve. J Am Coll Cardiol 1999; 33:83–87. Bech GJ, deBruyne B, Bonnier HJRM et al. Long-term follow-up after deferral of percutaneous transluminal coronary angioplasty of intermediate stenosis on the basis of coronary pressure measurement. J Am Coll Cardiol 1998; 31:841–847.
73
IMPORTANCE OF PHYSIOLOGIC ASSESSMENT PRE- AND POST INTERVENTION
37. Lesser JL, Wilson RF, White CW. Physiologic assessment of coronary stenoses of intermediate severity: can facilitate patient selection for coronary angioplasty? J Cor Art Dis ????; 1:697–705. 38. Gould KL. Dynamic coronary stenosis. Am J Cardiol 1980; 45:286–292. 39. Hodgson JM, Reddy KG, Suneja R et al. Intracoronary ultrasound imaging: correlation of plaque morphology with angiography, clinical syndrome and procedural results in patients undergoing coronary angioplasty. J Am Coll Cardiol 1993; 21:35–44. 40. Serruys PW, DiMario C, Piek J et al, for the DEBATE Study Group. Prognostic value of intracoronary flow velocity and diameter stenosis in assessing the short- and long-term outcomes of coronary balloon angioplasty: the DEBATE study (Doppler Endpoints Balloon Angioplasty Trial Europe). Circulation 1997; 96:3369–3377. 41. Kern MJ, Dupouy P, Drury JH et al. Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: a combined intravascular ultrasound Doppler flow and imaging study. J Am Coll Cardiol 1997; 29:1520–1527. 42. van Liebergen RAM, Piek JJ, Kock KT et al. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary blood flow velocity reserve. Circulation 1998; 98:2133–2140. 43. Kern MJ, Puri S, Bach RG et al. Abnormal coronary flow velocity reserve after coronary artery stenting in patients: role of relative coronary reserve to assess potential mechanisms. Circulation 1999; 100:2491–2498. 44. Kosa I, Blasini R, Schneider-Eicke J et al. Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol 1999; 34:1036–1041. 45. Nanto S, Kodama K, Hori M et al. Temporal increase in resting coronary blood flow causes an impairment of coronary flow reserve after coronary angioplasty. Am Heart J 1992; 123:28–36. 46. Eichhorn EJ, Grayburn PA, Willard JE et al. Spontaneous alterations in coronary blood
74
47.
48.
49. 50.
51.
52.
53. 54.
55.
56.
57.
flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991; 17:43–52. Bech GJW, Pijls NHJ, deBruyne B et al. Usefulness of fractional flow reserve to predict clinical outcome after balloon angioplasty. Circulation 1999; 99:883–888. Hanekamp CEE, Koolen JJ, Pijls NHJ et al. Comparison of quantitative coronary angiography, intravascular ultrasound, and coronary pressure measurement to assess optimum stent deployment. Circulation 1999; 99:1015–1021. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med 1985; 31:932–936. Gibson CM, Cannon CP, Daley WL et al. The TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879–888. Al-Mousa EN, Dodge JT, Rizzo M et al. Thrombolysis in myocardial infarction frame count in saphenous vein grafts. Am Heart J 1998; 135:323–328. Stankovic G, Manginas A, Voudris V et al. Prediction of restenosis after coronary angioplasty by use of a new index: TIMI frame count/minimal luminal diameter ratio. Circulation 2000; 101:962–968. Faxon DP. Predicting restenosis: bigger is better but not best (editorial). Circulation 2000; 101:946–947. Caiati C, Montaldo C, Zedda N et al. New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 1999; 99:771–778. Coletta C, Galati A, Ricci R et al. Coronary flow reserve of normal left anterior descending artery in patients with ischemic heart disease: a transesophageal Doppler study. J Am Soc Echocardiogr 1999; 12:720–728. Gadallah S, Taker KB, Kawanishi D et al. Comparison of intracoronary Doppler guide wire and transesophageal echocardiography in measurement of flow velocity and coronary flow reserve in the left anterior descending coronary artery. Am Heart J 1998; 135:38–42. Paraskevaidis IA, Tsiapras DP, Kyriakides ZS, Kremastinos DT. Transesophageal Doppler evaluation of left anterior descending coronary
REFERENCES
58.
59.
60.
61. 62.
63.
64.
65.
artery angioplasty. Am J Cardiol 1997; 80:947–951. Isaaz K, Bruntz FJ, Ethevenot G et al. Noninvasive assessment of coronary flow dynamics before and after coronary angioplasty using transesophageal Doppler. Am J Cardiol 1993; 72:1238–1242. Uren N, Crake T, Lefroy D, DeSilva R et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1994; 331:222–227. Claeys MJ, Vrints CJ, Bosmans J et al. Coronary flow reserve during coronary angioplasty in patients with a recent myocardial infarction: relation to stenosis and myocardial viability. J Am Coll Cardiol 1996; 28:1712–1719. Cobb F, McHale P, Remert J. Effects of acute cellular injury on coronary vascular reactivity in awake dogs. Circulation 1978; 57:962–968. Ito H, Tomooka T, Sakai N et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in acute myocardial infarction. Circulation 1992; 85:1699–1705. Willerson J, Golino P, Eidt J et al. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80:198–205. Suryapranata H, Zijlstra F, MacLeod D et al. Predictive value of reactive hyperemic response on reperfusion on recovery of regional myocardial function after coronary angioplasty in acute myocardial infarction. Circulation 1994; 89:1109–1117. Kawamoto T, Yoshida K, Akasaka T et al.
66.
67.
68.
69.
70.
71.
Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angiography predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 1999; 100:339–345. Tsunoda T, Nakamura M, Wakatsuki T et al. The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct balloon angioplasty. J Am Coll Cardiol 1998; 32:338–344. Ishihara M, Sato H, Tateishi H et al. Intraaortic balloon pumping as the postangioplasty strategy in acute myocardial infarction. Am Heart J 1992; 122:385–389. Piana RJ, Paik GY, Moscucci M et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 1994; 89:2514–2518. Olafsson B, Forman MB, Puett DW et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the noreflow phenomenon. Circulation 1987; 76:1135–1145. Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695–2701. Joye JD, Cates CU, Farah T et al. Cost analysis of intracoronary Doppler determination of lesion significance: preliminary results of the P.E.A.C.H. study. J Invasive Cardiol 1995; 3:27.
75
6 The role of intravascular ultrasound in the prevention and treatment of restenosis Shinichi Shimodozono, Yasuhiro Honda, Heidi N Bonneau and Peter J Fitzgerald
Introduction Intravascular ultrasound (IVUS) represents a major development for the assessment of arterial disease. In addition to providing accurate on-line quantitative information regarding lumen size and residual plaque burden, IVUS has contributed to our understanding of plaque behavior and morphology. Although cineangiography remains an indispensable part of diagnosis and treatment for coronary artery disease, angiography provides only a two dimensional silhouette of the lumen. Furthermore, angiography cannot evaluate the mechanisms of various interventional procedures over time, with respect to disease progression/ regression and vessel morphology. IVUS can look beyond the lumen and assess plaque mass, thereby influencing clinical decision-making, initial device selection as well as optimizing the endpoint of various interventional strategies. This chapter will examine the role of IVUS in the prevention and treatment of restenosis. In particular, the importance of accurate knowledge regarding vessel architecture for diagnosis, device selection, endpoint analysis, and as a direct therapy will be addressed.
Practical catheterization lab uses Modalities for coronary endoluminal intervention have increased significantly since the birth of interventional cardiology, first performed by Andreas Grüntzig in September, 1977.1 Today the use of IVUS in the cardiac catheterization laboratory provides direct tomographic visualization of the extent of coronary artery disease. With the improved image quality and signal penetration of currently available systems, IVUS enables a view beyond the vessel surface and a spatial orientation based on veins, pericardium and often adventitial landmarks. In addition, recent advances in reduced IVUS catheter profiles permit the examination of serial changes during a particular intervention in vivo as well as the critical vessel morphologic parameters, including vessel size, length and plaque type. These IVUS-derived parameters contribute to the ‘road map’ of angiography in providing a unique lesion assessment of atherosclerotic coronary disease.
Vessel size Numerous studies have examined the accuracy and reproducibility of angiography. The
77
THE ROLE OF INTRAVASCULAR ULTRASOUND
limitations of angiography include: 1. Planner silhouette imaging – Necropsy and IVUS studies have reported that coronary cross-sectional anatomy is frequently eccentric and complex. Angiographic images depict complex coronary lesions from a planner silhouette of the contrast-filled lumen. These complex coronary lesions often appear as unclear images, either slitlike or hazy. Thus, angiography is sometimes unable to reveal the exact degree of lesion complexity and severity. Coronary interventions such as balloon angioplasty often produce acute lumen gain by creating plaque fracture or dissection.2 Con-
sequently, the newly created lumen often seems extensively enlarged, often hazy in angiographic appearance. As a result, the angiographic silhouette may overestimate the actual gain in cross-sectional area (Fig. 6.1). 2. Indirect estimation of luminal narrowing (compared to reference) – To assess lesion severity, angiographic estimates are based on the comparison of minimum lumen dimensions at the lesion site with an adjacent, ‘normal looking’ reference. However, necropsy studies report that lesion characteristics emerge as diffuse in most circumstances rather than focal in nature.3,4 Diffuse atherosclerosis often appears as a
Post PTCA complex lesion
View B
True stenosis
View A
Figure 6.1 Limitation of angiography. Schematic demonstration of overestimation of newly created cross sectional lumen vs true luminal stenosis on the basis of viewing silhouette with multiple direction.
78
VESSEL SIZE
small ‘normal looking’ vessel. Additionally, a positively remodeled lesion with large plaque burden can be seen angiographically as a ‘mild’ luminal irregularity. On the other hand, IVUS provides several advantages for the accurate assessment of luminal dimensions; first, IVUS produces a complete 360° tomographic view, allowing for the immediate on-line measurement of lumen, plaque, and vessel from a cross-sectional area. These IVUS indices have been validated in vivo and in vitro.5–7 Vessel features seen by IVUS are of great value for the interventional cardiologist in selecting treatment, whether or not to intervene at all, and device sizing. Although angiographers often encounter lesions of uncertain severity in the catheterization laboratory, especially as multiple vessel
disease is approached percutaneously, it is often difficult to decide whether to intervene without ‘on-line’ functional assessment. For intermediate lesions, direct tomographic visualization permits not only the morphologic assessment of atherosclerotic plaque but also an accurate quantitative measurement, independent of the radiographic projection, confirming its significance, thus providing the clue to avoiding unnecessary treatment (Fig. 6.2). A recent report comparing preinterventional IVUS measurements and stress myocardial perfusion SPECT in 70 de novo coronary lesions, in which a lesion lumen area ⱕ 4.0 mm2 visualized by IVUS was defined as significant coronary stenosis, demonstrated a sensitivity of 88% and a specificity of 90%.8 Regarding physiologic assessment by IVUS,
MLA : 3.2 mm2
Figure 6.2 Angiographic hazy appearance. Intravascular ultrasound (IVUS) revealed ambiguous degree of stenosis in complex calcified lesion which appeared to be hazy by angiographic silhouette. IVUS shows critical lumen compromise with minimum lumen area (MLA) ⫽ 3.2 mm2.
79
THE ROLE OF INTRAVASCULAR ULTRASOUND
other investigators have demonstrated a high diagnostic accuracy with the same criteria (lesion lumen area ⱕ 4.0 mm2) in comparison with an abnormal coronary flow reserve of 2.0 by Doppler technique.9 Abizaid et al9 reported long term results after deferred intervention on the basis of this IVUS criteria in 300 patients with 357 intermediate de novo native coronary lesions. At 12 months follow-up, clinical event rates were 4.4% with a target lesion revascularization (TLR) rate of 2.8% in 248 lesions with a lesion lumen area ⱖ 4.0 mm2. The long term follow-up after IVUS-guided deferred intervention was comparable to those after physiological assessment such as coronary flow reserve or FFRMYO in previous reports.10 The unique capability of IVUS to yield tomographic images also has a direct impact on device selection and sizing when used prior to or during coronary intervention. Numerous studies have documented that the major determinant of the late loss is the percentage diameter stenosis or minimum lumen diameter (MLD) achieved after intervention, leading to a ‘bigger is better’ approach. However, the use of balloons larger than the angiographic reference lumen diameter failed to improve the result of percutaneous transluminal coronary angioplasty (PTCA) and was associated with an unacceptably high rate of acute complications.11,12 With IVUS, the balloon size selection can be based on measurements of the total diameter of the vessel wall. The CLOUT (CLinical Outcome with Ultrasound Trial) investigators13 proposed increasing the diameter of the balloon based on the mean diameter of the lumen and vessel at the reference site. This IVUS-guided strategy produced favorable target lesion dimensions without increased rates of dissection or in-hospital ischemia. A single-center, nonrandomized study of 252 patients has demonstrated that
80
long term outcome utilizing vessel size adapted PTCA, according to the external elastic membrane (EEM) diameter as measured by IVUS, resulted in a low restenosis rate (19%) after 1 year.14 This aggressive strategy of using a larger balloon has become an alternative in treating coronary artery stenosis in de novo lesions. In a subgroup analysis from the BENESTENT-1 trial, which revealed good long term results for stand alone balloon angioplasty when stent-like results (residual diameter stenosis ⱕ 30%) were obtained, this was especially true for the non-left anterior descending lesion group.15 The OCBAS (Optimal Coronary Balloon Angioplasty with provisional stenting vs primary Stent) trial provides support for provisional stenting with similar restenosis rates (19.2% vs 16.4%, p ⫽ NS) and TLR rates (17.5% vs 13.5%, p ⫽ NS) in agreement with the BENESTENT-1 trial.16 Appropriate sizing of the balloon to the arterial segment using IVUS may be a strategy for improving PTCA by creating a larger post procedural MLD, in particular, for angiographically appearing small vessels that actually might be larger vessels with diffuse atherosclerosis.17
Vessel length For appropriate device selection, vessel length is another important element to be determined. Actual lesion length is often underestimated following angiography because of a ‘normal looking’ reference vessel. Mintz et al systematically demonstrated that only 60 (6.8%) of 884 angiographically normal reference segments were normal by IVUS.18 In addition, angiographic lesion length measurements are limited by the difficulty in visualizing a foreshortened, tortuous, threedimensional vascular conduit in two dimensions.
VESSEL SIZE
IVUS utilizing the motorized pullback device throughout the length of distal to proximal reference sites enables axial length measurement, which has been validated in vivo.19 Rapid processing with IVUS machines capable of presenting longitudinal views facilitates spatial orientation of the vasculature, and allows lesion length quantitation with the ability to ‘truly’ match a single stent length to extent of disease.
Plaque type Another important feature which IVUS can provide for device selection is the detection and quantification of calcific patterns as well as the presence of remodeling. These IVUS findings prior to intervention appear to have an impact on both acute and long-term outcomes. Calcified plaque The presence of calcium within the vessel wall may have a critical impact on the diagnostic evaluation, treatment strategy and long term outcome. Calcium is commonly seen by IVUS as a bright echo reflection without ultrasound signal penetration through plaque substance (shadowing) and with reverberation within the distal shadowing. Heavily calcified lesions can often be misinterpreted as more severe stenotic lesions owing to an angiographic hazy appearance, produced by distortion of luminal geometry and shadow contrast filling. This misinterpretation, in fact, may have an influence on the decision to intervene on intermediate lesions based on angiography. Ultrasound is more sensitive than angiography in the detection of calcification, permitting identification of calcified atheroma without any apparent calcification on fluoroscopy. In comparison with ultrasound, fluoroscopy
detects calcium deposits which involve more than 180° of the vessel circumference with sensitivity (63%) but is less reliable with smaller calcium deposits.20,21 Mintz et al20 reported that in 1155 coronary lesions, IVUS detected calcium in 73% of the lesions (38% by angiography). In this study, overall sensitivity of angiography was 48% with specificity of 89% compared to IVUS.20 In the clinical setting, the presence of calcium was found to limit the vessel expansion, resulting in failure to achieve sufficient luminal gain after intervention,22,23 which has been considered the most critical factor in preserving luminal patency. Additionally, IVUS can clarify the location and extent of calcification; deep at the medial border, at the luminal surface, and/or within the plaque itself. Thus, lesion-specific treatment regarding the location and extent of calcium can be done when IVUS is used to interrogate the target lesion within the coronary artery. For heavily calcified lesions, highspeed rotational atherectomy (HSRA) has been found to be an alternative catheter-based treatment modality, owing to its ability to selectively ablate calcific plaque. Kovach et al reported the mechanism of HSRA and adjunct balloon angioplasty using IVUS in 48 lesions.24 Sequential IVUS images have revealed that HSRA produces lumen enlargement by selective ablation of calcified plaque with little tissue disruption and rare arterial expansion. Further increases in lumen cross-sectional area produced by adjunctive balloon angioplasty are a result of combined dissection and expansion of more compliant plaque elements. Although several studies have shown favorable acute results with HSRA, high restenosis rates of 37–51% remained after rotational atherectomy.25–27 To challenge heavily calcified lesions, stenting following HSRA has been shown to be a promising strategy for such lesions. Moussa et al28 found
81
THE ROLE OF INTRAVASCULAR ULTRASOUND
procedural success and angiographic restenosis rates at 4.6 ⫾ 1.9 months to be 93% and 23%, respectively. Recently, a nonrandomized, single-center analysis of 306 patients,29 comparing calcified lesions in large (ⱖ 3.0 mm) vessels treated with HSRA and stenting to those treated with either HSRA or stenting alone, demonstrated favorable acute and long term results among those patients treated with HSRA prior to stenting. Larger final MLDs were obtained after HSRA prior to stenting (3.21 ⫾ 0.49 mm) compared to stent alone (2.88 ⫾ 0.51 mm) or HSRA plus balloon angioplasty (2.29 ⫾ 0.55 mm). Ninemonth follow-up revealed higher event-free survival sustained in the HSRA prior to stent cohort vs either stent alone or HSRA cohorts. Remodeling As first described by Glagov et al,30 adaptive arterial remodeling early in coronary artery arteriosclerosis delays focal stenosis despite significant plaque accumulation. Lumen reduction may be induced either by tissue growth that has exceeded the vessel’s ability to remodel, or by failure to remodel in the presence of a small or moderate plaque burden. Pathological remodeling rather than intimal growth has been considered to be the predominant mechanism of the restenotic process following angioplasty.31–33 In recent studies, positive remodeling has been associated with unstable clinical syndromes, implying that this process may be indicative of biologically active or vulnerable plaques.34,35 The direction and extent of arterial remodeling and clinical presentations of patients with coronary artery disease were investigated extensively by Shoenhagen et al,34 showing that positive remodeling occurred in 52% of the unstable syndrome group and in only 20% of the stable angina group. In addition, other studies examining the extent and
82
direction of remodeling in patients with stable coronary syndromes reported a high proportion of negative remodeling.36 Furthermore, in an analysis of 777 lesions treated with nonstent coronary intervention, Dangas et al showed that positive lesion-site remodeling was associated with a higher longterm TLR after the nonstent intervention.37 Pasterkamp et al reported in a necropsy study of femoral arteries that positive remodeling is associated with histologic markers for vulnerable plaque in both the cap and shoulder of the plaque, suggesting the enhancement of the risk of plaque rupture.38 Currently, only IVUS can detect these remodeling conditions in vivo (Figs 6.3, 6.4). Thus, with improved image quality in the future, IVUS may have potential as a diagnostic modality for predicting vulnerable plaque. With regard to device selection, stenoses due to negative (or pathologic) remodeling may require expansion of the total vessel area, possibly using a stent to prevent acute or chronic vessel recoil. For stenoses with larger plaque burden in positively remodeled vessels, atherectomy or other plaque removal catheters might be preferable as a suitable therapeutic device. Directional coronary atherectomy (DCA) is primarily used for debulking eccentric, noncalcified lesions in proximal, nontortuous vessels that are large enough to accommodate the DCA device. Without IVUS guidance, more than 50% of the DCA cuts collected the media and 30% reached the adventitia.39,40 Thus, the use of IVUS during DCA to appropriately direct debulking toward the maximal zone of plaque accumulation may minimize trauma and complications following DCA. The presence of a large plaque burden may limit complete stent expansions, in part accounting for suboptimal results in complex lesions. Accordingly, debulking the plaque prior to stent
VESSEL SIZE
Figure 6.3 Positive remodeling. Intravascular ultrasound can reveal localized vessel enlargement with plaque accumulation (vessel area: proximal 17.1 mm2, lesion 19.7 mm2, distal 16.9 mm2, respectively).
deployment appears to provide the best anatomical conditions for optimal stent expansion. The Stenting after Optimal Lesion Debulking (SOLD) registry, which tested plaque removal using DCA prior to stent placement with 71 consecutive patients, showed a remarkably low angiographic restenosis rate of 11% at 6-month follow-up.41 Preliminary IVUS analysis from DESIRE (the DEbulking and Stenting In Restenosis Elimination), which is a randomized multicenter trial
comparing DCA prior to stent implantation to conventional stenting, demonstrated larger acute gain in patients who underwent DCA/stent compared to those who underwent stent alone (7.2 ⫾ 2.1 vs 5.7 ⫾ 1.5 mm2), resulting in a larger minimal lumen area after the procedure (8.6 ⫾ 2.3 vs 7.2 ⫾ 2.6 mm2, p ⫽ 0.03).42 This improved acute gain with DCA prior to stent implantation may translate into better long term results. Ongoing prospective multicenter trials of DESIRE and
83
THE ROLE OF INTRAVASCULAR ULTRASOUND
Figure 6.4 Negative remodeling. Vessel shrinkage with less plaque accumulation contributed to luminal stenosis (vessel area: proximal 17.6 mm2, lesion 8.5 mm2, distal 12.5 mm2, respectively).
AMIGO (Atherectomy before Multilink Improves lumen Gain and clinical Outcomes) may address the superiority of debulking plus stenting to stenting alone in a randomized manner.
Stent optimization Intracoronary stenting was initially limited to the treatment of acute closure complicating coronary angioplasty. At present it has been widely used for elective catheter treatment of obstructive coronary artery disease, reducing
84
the incidence of clinical restenosis with mechanical scaffolding. Stents have reduced restenosis in both de novo and restenotic lesions, especially in vessels ⬎ 3.0 mm in size, and the left anterior descending (LAD) location.43–45 IVUS can detect vessel stent subtleties not apparent by angiographic features. Apart from assisting with selection of stent size, length, and post dilation balloon diameter, IVUS can be used to accomplish complete apposition and sufficient geometric expansion within the stented segment. IVUS had an essential role in the develop-
STENT OPTIMIZATION
ment of an optimal strategy for stent deployment. Early stent implantation utilized inflation pressures of 6–8 atm, with resultant unacceptable subacute stent thrombosis rates of 18–24%.46,47 IVUS observations demonstrated that incomplete apposition of the stent struts to the vessel wall, residual lumen narrowing or irregular eccentric lumen in the stented segment were still present in 88% of the cases despite having an optimal angiographic result.48 IVUS-guided high-pressure stent deployment coupled with specific antiplatelet regimens were shown to dramatically decrease subacute stent thrombosis rates.48,49 IVUS can detect morphologic and morphometric issues which are often silent by angiography, including incomplete apposition (struts separated from the vessel wall), incomplete expansion (MLD not achieving desired size), and edge dissections; these IVUS findings are illustrated in Fig. 6.5.
A. Incomplete apposition
Long term Because the vast majority of coronary interventions include stenting, rigid assessment of stent geometry following deployment is crucial. In the era of stent optimization, IVUS can be used as a reliable modality to evaluate the minimal stent area (MSA) immediately after stent deployment. Several single center studies have demonstrated significant negative correlation between MSA and subsequent restenosis.50–53 In addition, these studies have also reported an inverse relationship between clinical outcome and the IVUS-derived final MSA. Lessons from multicenter clinical trials In the MUSIC (Multicenter Ultrasound guidance of Stents In Coronaries) study, strict IVUS optimization criteria led to a very low restenosis rate (9.7%), and TLR rate during
B. Incomplete expansion
C. Edge dissection
Figure 6.5 Ultrasound findings after stenting. Incomplete apposition (A), incomplete expansion (B), and edge tear (C). Panel A shows a gap between the stent strut and the vessel wall. Panel B shows incomplete expansion of the stent relative to the vessel size. Panel C shows the edge tear at the stent margin (see arrow).
85
THE ROLE OF INTRAVASCULAR ULTRASOUND
follow-up was 4.5%.54 The RESIST (REStenosis after Ivus guide STenting) study group showed a 6.3% absolute reduction in the angiographic restenosis rate (22.5% vs 28.8%) and a 20% increase in late lumen cross-sectional area in the IVUS guidance group compared to angiography guidance alone.55 The recent report of the multicenter randomized CRUISE (Can Routine intravascular Ultrasound Influence Stent Expansion) study, an IVUS substudy of STARS (STent Antithrombotic Regimen Study), demonstrated the positive impact of IVUS on stent deployment in the high pressure era. A total of 525 patients were enrolled in this study, comparing IVUS-guided vs angiographic-guided stenting, which showed that ultrasound guidance resulted in a larger stent lumen area compared to angiographic guidance alone (7.78 ⫾ 1.72 vs 7.06 ⫾ 2.13 mm2, p ⬍ 0.001). Consequently, the IVUS-guided stenting cohort reported a decreased TLR rate (8.5% vs 15.3%, p ⬍ 0.05) with relative reduction of 44% at 9 months compared to angiographic guidance alone.56 The investigators suggest that ultrasound guidance of stent implantation may result in more effective stent expansion compared with angiographic guidance alone. Whether IVUS-guided stent deployment would offset initial catheter costs by a reduction in restenosis remains to be seen.
IVUS observations following brachytherapy Catheter-based intracoronary radiation therapy has been shown to favorably affect restenosis following angioplasty or stenting. IVUS plays a substantial role in elucidating responses, both favorable and unfavorable, following brachytherapy. In this section, the
86
current knowledge of brachytherapy from the imaging viewpoint will be reviewed, focusing on radiation dosimetry, specific findings after brachytherapy, and the role of IVUS in the field of catheter based brachytherapy.
Dosing (centered vs non-centered) In the animal model, follow-up results of irradiation were vascular positive remodeling and inhibition of neointimal formation.57,58 Similar results were obtained from IVUS analyses of human beta source studies.59,60 To optimize treatment, care must be given to insure accurate dose prescription via dosimetry. To date, beta and gamma emitters are the major classes of radioisotopes used for catheter-based brachytherapy. Beta source is characterized to attenuate much stronger than gamma source. Consequently, distance from the source to the target appears to be much more critical for beta than for gamma with respect to the actual dose on target vessel, particularly the adventitia. In this regard, IVUS can contribute to appropriate dose prescription with detailed quantitative dosimetric analysis. Two types of catheter-based brachytherapy devices, centering and non-centering, are presently in use in the clinical setting. One important question regarding local radiation delivery is whether centered delivery systems are needed for suitable dosing. Dose uniformity to the arterial wall depends on source positioning in the lumen and the cylindrical symmetry of the artery. Without centering, especially in a large artery, a non-centered position of the radiation source might cause overdosing on one side of the vessel wall and underdosing on the other side. In this regard, the use of a centering device would seem to have an advantage over the non-centering device. In earlier dosimetric reports, using
IVUS OBSERVATIONS FOLLOWING BRACHYTHERAPY
analytical calculations of dose distributions and dose rate,61 or measuring surface dose of different size balloons,62 centering devices produced good surface dose homogeneity. In most target lesions consisting of eccentric plaque, the centering device was limited in the delivery of a uniform dose to the vessel wall or adventitia, allowing centering only within the lumen but not within the vessel (Fig. 6.6). In light of this, one may question the effectiveness of the centering device in the clinical setting. Dose volume histogram (DVH) has been used to describe the cumulative distribution of dose over two specific volumes: at the level of the luminal surface, and the adventitia. Contours of the lumen and EEM that can be obtained from three-dimensional IVUS analy-
sis, are then entered into computer program to calculate DVH. DVH provides a tool for reporting the actual delivered dose at the site believed to be the target, the adventitia, and to detect excessive radiation which could lead to vascular complications. From a dosimetric study assessing the impact of centering on the distance from the source to the EEM and the longitudinal variations along the target vessel segment in the START (STents And Radiation Therapy) trial, Takagi et al63 demonstrated that the dose enhancement derived from centering at the EEM was only 11% (12.5–13.9 Gy) in the large vessel group, and 7% (11.1–11.9 Gy) in the small vessel group with 90Sr/Y source, despite the statistically significant decrease in the distance from source. They concluded that
Centering
Non-centering
Figure 6.6 Schematic demonstration of the position of centering and non-centering catheters within the vessel wall. Even the centering catheter is limited to the center of the lumen and not adventitia in eccentric plaque.
87
THE ROLE OF INTRAVASCULAR ULTRASOUND
centering did not impact on variation in dose as a function of distance along the longitudinal axis. Further investigation based on DVH using IVUS quantitative parameters will provide additional clues to better understand these issues.
Vascular remodeling after brachytherapy As mentioned above, vascular positive remodeling and inhibition of neointimal formation were considered to be an effect of irradiation at follow-up in animal models. Recently, serial three-dimensional IVUS observations in human studies have provided new insight regarding the mechanisms of brachytherapy. A three-dimensional IVUS study by Sabate et al,60 demonstrated that mean EEM volume and plaque volume in the beta-irradiated segment increased significantly, whereas luminal volume remained unchanged. The adaptive increase of EEM volume appears to be the major contributor to the luminal volume at follow-up. Furthermore, in another study with gamma irradiation (192Ir), even in the noninjured but irradiated reference segments, lumen area remains unchanged as a result of positive vessel remodeling despite the plaque growth.64
Delayed healing Intracoronary radiation may prevent normal healing processes after balloon injury, resulting in unhealed dissection (Fig. 6.7). According to reports by Kay et al, 16 of 22 nonstented patients from the BERT 1.5 cohort had dissection at initial procedure and dissection was still seen in six patients on angiography (38%) and eight patients (50%) on IVUS at 6 month follow-up.65 No relation was found between prescribed radiation dose and
88
healing outcomes. Additional quantitative investigation by Meerkin et al66 showed all residual dissections were partially healed at follow-up. No change in clinical outcomes was seen between completely healed dissection groups and partially healed ones. Whether dose and healing processes are closely related remains to be investigated in larger population studies with individual calculated dose prescription.
Therapeutic catheter-based ultrasound Beyond the phase of diagnostic use for cardiovascular disease, ultrasound technology has advanced into the therapeutic phase. The biomechanical effect of ultrasound has been reported to inhibit the proliferation of cancer cells as well as migration and adhesion of smooth muscle cells (SMCs),67–69 suggesting the therapeutic potential of ultrasound therapy in vivo to limit neointimal growth following stenting. A recent animal study70 demonstrated the favorable effect of therapeutic ultrasound, or sonotherapy, on neointimal hyperplasia in vivo, using a swine stent injury model. An 8F, over-the-wire catheter system (URX™, PharmaSonics Inc.) was developed for intracoronary sonotherapy treatment, which incorporates an ultrasonic transducer 8 mm in length, exposing an average peak ultrasonic intensity of 100 W/cm2 at a center frequency of 700 kHz (Fig. 6.8, left). Target segments were exposed to intracoronary sonotherapy for 300 seconds for both the cell proliferation study and intimal-growth study. At 7 days, SMC proliferation assessed by bromodeoxyuridine histology preparation was significantly reduced in the sonotherapy group compared to the control group (24.1 ⫾ 7.0 vs 31.2 ⫾ 3.0%). At 28 days, area stenosis was
CONCLUSION
Baseline
Follow up
Figure 6.7 Unhealed dissection at 8-month follow-up following brachytherapy. Tracking vessel morphology following brachytherapy shows unhealed dissection at follow-up (see arrows), which may be due to delay by radiation.
significantly less in the sonotherapy group than in the control group (36 ⫾ 24 vs 44 ⫾ 27%, p ⬍ 0.05) (Fig. 6.8, right). This first feasibility study indicated the efficacy of in vivo intracoronary sonotherapy on intimal hyperplasia in a swine stent model (Fig. 6.9). If intracoronary sonotherapy were also effective in human coronary arteries, it would be a novel method of inhibiting restenosis, offering some potential benefits compared to intracoronary brachytherapy. First, the delivery of ultrasound energy does not require shielding in the catheterization laboratory. Second, it may be able to be utilized during de novo stenting rather than for in-stent restenosis indications. Finally, ultrasound has been shown to enhance drug delivery as well as gene transfection, suggesting that sonotherapy
may be augmented further with a pharmacological approach.71,72 Apart from conventional IVUS use, therapeutic catheter-based sonotherapy is currently under human clinical investigation as a tool to prevent restenosis.
Conclusion Since its introduction to the cardiac catheterization laboratory, IVUS has been established as a new standard for the visualization of coronary atherosclerosis through its unique capability of acquiring direct tomographic images in humans. This feature is valuable not only for the accurate analysis of luminal stenosis but also for elucidating the composition of the atherosclerotic plaque, in aiding the decision of which interventional tool to use,
89
THE ROLE OF INTRAVASCULAR ULTRASOUND
40
p ⬍0.05
% BrdU
35
30
25
20 SHT
IST
Figure 6.8 Left panel: Angiographic appearance of catheter-based intracoronary sonotherapy catheter: Right panel: Smooth muscle cell proliferation after intracoronary sonotherapy. Smooth muscle cell proliferation assessed using bromodeoxyuridine (BrdU) histology preparation at 7 days in a swine injury model following intracoronary sonotherapy was significantly reduced compared to the control group.
Sham (control)
Sonotherapy
Figure 6.9 Histopathological samples demonstrating the effect of intracoronary catheter-based sonotherapy on neointimal growth.
90
CONCLUSION
sizing, and even for avoiding unnecessary intervention. As a guide to the interventional procedure, operators can improve suboptimal results to further reduce the risk of restenosis in the long term. In addition, IVUS plays an indispensable role in dosimetry analysis for
suitable brachytherapy, and in revealing the mechanisms and favorable/unfavorable effects after brachytherapy. Finally, beyond the diagnostic use of IVUS, therapeutic catheter-based ultrasound is being evaluated in clinical studies as an alternative treatment for restenosis.
91
THE ROLE OF INTRAVASCULAR ULTRASOUND
References
1.
Grüntzig A. Transluminal dilatation of coronary-artery stenosis [letter]. Lancet 1978; 1:263. 2. Waller BF. ‘Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters’ – the future treatment of atherosclerotic coronary artery disease? A clinicalmorphologic assessment. J Am Coll Cardiol 1989; 13:969–987. 3. Grondin CM, Dyrda I, Pasternac A et al. Discrepancies between cineangiographic and postmortem findings in patients with coronary artery disease and recent myocardial revascularization. Circulation 1974; 49:703–708. 4. Roberts WC, Jones AA. Quantitation of coronary arterial narrowing at necropsy in sudden coronary death: analysis of 31 patients and comparison with 25 control subjects. Am J Cardiol 1979; 44:39–45. 5. Tobis JM, Mallery JA, Gessert J et al. Intravascular ultrasound cross-sectional arterial imaging before and after balloon angioplasty in vitro. Circulation 1989; 80:873–882. 6. Potkin BN, Bartorelli AL, Gessert JM et al. Coronary artery imaging with intravascular high-frequency ultrasound. Circulation 1990; 81:1575–1585. 7. Nishimura RA, Edwards WD, Warnes CA et al. Intravascular ultrasound imaging: in vitro validation and pathologic correlation. J Am Coll Cardiol 1990; 16:145–154. 8. Nishioka T, Amanullah AM, Luo H et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol 1999; 33:1870–1878. 9. Abizaid AS, Mintz GS, Pichard AD et al. Clinical, intravascular ultrasound, and quantitative angiographic determinants of the coronary flow reserve before and after percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 82:423–428. 10. Abizaid AS, Mintz GS, Mehran R et al. Long-
92
11.
12. 13.
14.
15.
16.
17.
18.
term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation 1999; 100:256–261. Roubin GS, Douglas JS Jr, King SB 3rd et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty. A prospective randomized study. Circulation 1988; 78:557–565. Nichols AB, Smith R, Berke AD et al. Importance of balloon size in coronary angioplasty. J Am Coll Cardiol 1989; 13:1094–1100. Stone GW, Hodgson JM, St Goar FG et al. Improved procedural results of coronary angioplasty with intravascular ultrasoundguided balloon sizing: the CLOUT Pilot Trial. Clinical Outcomes With Ultrasound Trial (CLOUT) Investigators. Circulation 1997; 95:2044–2052. Schroeder S, Baumbach A, Haase KK et al. Reduction of restenosis by vessel size adapted percutaneous transluminal coronary angioplasty using intravascular ultrasound. Am J Cardiol 1999; 83:875–879. Serruys PW, Azar AJ, Sigwart U et al. Longterm follow-up of ‘stent-like’ (ⱕ 30% diameter stenosis post) angioplasty: a case for provisional stenting. J Am Coll Cardiol 1996; 27(2 Suppl A):15. Rodriguez A, Ayala F, Bernardi V et al. Optimal coronary balloon angioplasty with provisional stenting vs primary stent (OCBAS): immediate and long-term follow-up results. J Am Coll Cardiol 1998; 32:1351–1357. Haase KK, Athanasiadis A, Mahrholdt H et al. Acute and one year follow-up results after vessel size adapted PTCA using intracoronary ultrasound. Eur Heart J 1998; 19:263–272. Mintz GS, Painter JA, Pichard AD et al. Atherosclerosis in angiographically ‘normal’ coronary artery reference segments: an intravascular ultrasound study with clinical
REFERENCES
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
correlations. J Am Coll Cardiol 1995; 25:1479–1485. Fuessl RT, Mintz GS, Pichard AD et al. In vivo validation of intravascular ultrasound length measurements using a motorized transducer pullback system. Am J Cardiol 1996; 77:1115–1118. Mintz GS, Popma JJ, Pichard AD et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation 1995; 91:1959–1965. Tuzcu EM, Berkalp B, De Franco AC et al. The dilemma of diagnosing coronary calcification: angiography vs intravascular ultrasound. J Am Coll Cardiol 1996; 27:832–838. Albrecht D, Kaspers S, Fussl R et al. Coronary plaque morphology affects stent deployment: assessment by intracoronary ultrasound. Cathet Cardiovasc Diagn 1996; 38:229–235. Hoffmann R, Mintz GS, Popma JJ et al. Treatment of calcified coronary lesions with Palmaz–Schatz stents. An intravascular ultrasound study. Eur Heart J 1998; 19:1224–1231. Kovach JA, Mintz GS, Pichard AD et al. Sequential intravascular ultrasound characterization of the mechanisms of rotational atherectomy and adjunct balloon angioplasty. J Am Coll Cardiol 1993; 22:1024–1032. Stertzer SH, Rosenblum J, Shaw RE et al. Coronary rotational ablation: initial experience in 302 procedures. J Am Coll Cardiol 1993; 21:287–295. Safian RD, Niazi KA, Strzelecki M et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993; 88:961–968. Warth DC, Leon MB, O’Neill W et al. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24:641–648. Moussa I, Di Mario C, Moses J et al. Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results. Circulation 1997; 96:128–136. Hoffmann R, Mintz GS, Kent KM et al. Comparative early and nine-month results of rota-
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
tional atherectomy, stents, and the combination of both for calcified lesions in large coronary arteries. Am J Cardiol 1998; 81:552–557. Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371–1375. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994; 89:2816–2821. Kakuta T, Currier JW, Haudenschild CC et al. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994; 89:2809–2815. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94:35–43. Schoenhagen P, Ziada KM, Kapadia SR et al. Extent and direction of arterial remodeling in stable vs unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101:598–603. Smits PC, Pasterkamp G, Quarles van Ufford MA et al. Coronary artery disease: arterial remodelling and clinical presentation. Heart 1999; 82:461–464. Mintz GS, Kent KM, Pichard AD et al. Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation 1997; 95:1791–1798. Dangas G, Mintz GS, Mehran R et al. Preintervention arterial remodeling as an independent predictor of target-lesion revascularization after nonstent coronary intervention: an analysis of 777 lesions with intravascular ultrasound imaging. Circulation 1999; 99:3149–3154. Pasterkamp G, Schoneveld AH, van der Wal AC et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998; 32:655–662. Safian RD, Gelbfish JS, Erny RE et al. Coronary
93
THE ROLE OF INTRAVASCULAR ULTRASOUND
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
94
atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms. Circulation 1990; 82:69–79. Garratt KN, Edwards WD, Kaufmann UP et al. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: analysis of tissue obtained from 73 patients by directional atherectomy. J Am Coll Cardiol 1991; 17:442–448. Moussa I, Moses J, Di Mario C et al. Stenting after optimal lesion debulking (SOLD) registry. Angiographic and clinical outcome. Circulation 1998; 98:1604–1609. Hibi K, Aizawa T, Honda Y et al. Impact of coronary debulking prior to stenting vs conventional stenting on early outcome: initial IVUS findings. J Am Coll Cardiol 2000; 35(2 Suppl A):94. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489–495. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496–501. Erbel R, Haude M, Hopp HW et al. Coronaryartery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998; 339:1672–1678. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991; 324:13–17. Schatz RA, Goldberg S, Leon M et al. Clinical experience with the Palmaz–Schatz coronary stent. J Am Coll Cardiol 1991; 17(6 Suppl B):155B–159B. Nakamura S, Colombo A, Gaglione A et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89:2026–2034. Mudra H, Klauss V, Blasini R et al. Ultrasound
50.
51.
52.
53.
54.
55.
56.
57.
58.
guidance of Palmaz–Schatz intracoronary stenting with a combined intravascular ultrasound balloon catheter. Circulation 1994; 90:1252–1261. Hoffmann R, Mintz GS, Mehran R et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz–Schatz stents. J Am Coll Cardiol 1998; 31:43–49. Kasaoka S, Tobis JM, Akiyama T et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32:1630–1635. Moussa I, Di Mario C, Moses J et al. The predictive value of different intravascular ultrasound criteria for restenosis after coronary stenting. J Am Coll Cardiol 1997; 29. Ziada KM, Tuzcu EM, De Franco AC et al. Absolute, not relative, post-stent lumen area is better predictor of clinical outcome. Circulation 1996; 94:I-453. de Jaegere P, Mudra H, Figulla H et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998; 19:1214–1223. Schiele F, Meneveau N, Vuillemenot A et al. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies – with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. J Am Coll Cardiol 1998; 32:320–328. Fitzgerald PJ, Oshima A, Hayase M et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation 2000; 102:523–530. Waksman R, Robinson KA, Crocker IR et al. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995; 91:1533–1539. Waksman R, Rodriguez JC, Robinson KA et al. Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine
REFERENCES
59.
60.
61.
62.
63.
64.
coronary arteries. Circulation 1997; 96:1944–1952. Meerkin D, Tardif JC, Crocker IR et al. Effects of intracoronary beta-radiation therapy after coronary angioplasty: an intravascular ultrasound study. Circulation 1999; 99:1660–1665. Sabate M, Serruys PW, van der Giessen WJ et al. Geometric vascular remodeling after balloon angioplasty and beta-radiation therapy: A three-dimensional intravascular ultrasound study. Circulation 1999; 100:1182–1188. Amols HI, Zaider M, Weinberger J et al. Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys 1996; 36:913–921. Popowski Y, Verin V, Schwager M et al. A novel system for intracoronary beta-irradiation: description and dosimetric results. Int J Radiat Oncol Biol Phys 1996; 36:923–931. Takagi A, Honda Y, Morino Y et al. Vessel wall distance variation between centered and non-centered radiation: cross-sectional and longitudinal analysis by intravascular ultrasound. J Am Coll Cardiol 2000; 35(2 Suppl A):7. Ahmed JM, Mintz GS, Waksman R et al. Safety of intracoronary gamma-radiation on uninjured reference segments during the first 6 months after treatment of in-stent restenosis: a serial intravascular ultrasound study. Circulation 2000; 101:2227–2230.
65. Kay IP, Sabate M, Van Langenhove G et al. Outcome from balloon induced coronary artery dissection after intracoronary beta radiation. Heart 2000; 83:332–337. 66. Meerkin D, Tardif JC, Bertrand OF et al. The effects of intracoronary brachytherapy on the natural history of postangioplasty dissections. J Am Coll Cardiol 2000; 36:59–64. 67. Alter A, Rozenszajn LA, Miller HI, Rosenschein U. Ultrasound inhibits the adhesion and migration of smooth muscle cells in vitro. Ultrasound Med Biol 1998; 24:711–721. 68. Lejbkowicz F, Zwiran M, Salzberg S. The response of normal and malignant cells to ultrasound in vitro. Ultrasound Med Biol 1993; 19:75–82. 69. Lawrie A, Brisken AF, Francis SE et al. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation 1999; 99:2617–2620. 70. Fitzgerald PJ, Takagi A, Moore MP et al. Intravascular sonotherapy decreases neointimal hyperplasia following stent implantation in swine. Circulation 2001 (in press). 71. Tachibana K. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res 1992; 9:952–954. 72. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 1997; 23:953–959.
95
7 Pharmacological approaches to prevent restenosis Vatsal H Mody, Alex Durairaj and Anil O Mehra
Introduction Since the introduction of percutaneous transluminal coronary angioplasty (PTCA) by Andreas Grüntzig in 1977, tremendous progress has been made in the technique, in understanding its mechanisms, and in its applications. The use of angioplasty has been expanded to include patients with unstable angina, myocardial infarction (MI), multivessel coronary artery disease and complex lesions. Despite the high rate of initial procedural success and marked reduction in acute complications, such as hospital deaths, MIs and emergency bypass surgery, the major limitation of angioplasty remains the high incidence of restenosis. Although the introduction of stents has brought some reduction in the rate of restenosis, in-stent restenosis often occurs after the procedure. The pathophysiology of restenosis begins with vascular and plaque injury and is related to the process of wound healing. During angioplasty, immediately after balloon inflation, platelets adhere to the injured intimal surface and release thromboxane A2 (TXA2) which is a powerful vasoconstrictor and a strong stimulus for platelet aggregation. Through a complex interaction between platelets, coronary endothelium, inflammatory cells and vascular smooth muscle, a host of cytokines is released.1 These include plateletderived growth factor (PDGF), endothelial
and fibroblast growth factors, tumor necrosis factor alpha, transforming growth factor beta, insulin-like growth factor, several interleukins, adenosine diphosphate (ADP), thrombin, epinephrine, angiotensin II, serotonin, thrombospondin, and free oxygen radicals. These mitogens, particularly PDGF, stimulate migration and proliferation of smooth muscle cells from the media into the intima, followed by the formation of fibrocellular tissue with an abundant proteoglycan matrix. This results in an enlarging mass of neointimal hyperplasia causing coronary luminal stenosis and ischemia. Arterial remodeling plays an important role in balloon angioplasty and atherectomy that has been modified by the use of stents.2 Considering the widespread use of stents in the current management of the majority of patients with coronary artery disease, efforts to reduce restenosis have been redirected towards reducing neointimal hyperplasia. Keeping in mind the pathophysiology of restenosis, numerous animal studies and clinical trials have been conducted in an attempt to reduce restenosis by intervening at various steps.
Antiplatelet and antithrombotic agents (Table 7.1) Platelet adhesion and aggregation is a key initial event after percutaneous coronary
97
PHARMACOLOGICAL APPROACHES TO PREVENT RESTENOSIS
Aspirin Dipyridamole Thromboxane receptor antagonists – vapiprost, solutroban Prostacyclin analogs – epoprostanol, ciprostene Omega-3 fatty acids Ticlopidine Dextran Unfractionated heparin (UFH) Low molecular weight heparin (LMWH) Direct thrombin inhibitors – hirudin, hirulog Warfarin Glycoprotein IIb/IIIa inhibitors – abciximab, eptifibatide, tirofiban
Table 7.1 Antiplatelet and antithrombotic agents.
interventions, with subsequent thrombus formation and smooth muscle cell proliferation responsible for restenosis. TXA2, a product of arachidonic acid metabolism, is a powerful platelet aggregator and vasoconstrictor.3 Therefore, many investigators have directed the antiplatelet approaches toward various points in the arachidonic acid pathway (Fig. 7.1). Aspirin, one of the oldest antiplatelet agents, was initially studied in several restenosis trials. It irreversibly blocks the cyclooxygenase pathway in arachidonic acid metabolism and reduces the synthesis of TXA2 after vascular injury and reduces platelet activation and aggregation. However, a meta-analysis of four studies using aspirin for reducing restenosis showed a relative risk of restenosis of 0.932 with aspirin compared with placebo treatment.4 Aspirin, when compared to placebo did not significantly reduce restenosis, but was beneficial in reducing acute complications. Another meta-analysis of four dose finding
98
studies with aspirin showed that higher doses of aspirin might even exert a detrimental effect, with a relative risk of restenosis of 1.2 when a daily dose of ⬎ 1000 mg is used compared with a dose of ⬍ 350 mg.4 Thus, aspirin has not been shown to reduce restenosis effectively. Dipyridamole is thought to affect vasodilation and platelet-antagonism by mechanisms such as potentiation of prostacyclin’s inhibition of platelets by blocking platelet phosphodiesterase and increasing cyclic adenosine monophosphate (cAMP), the direct stimulation of prostacyclin release from the vascular endothelium, and the inhibition of cellular uptake and metabolism of adenosine. The Antiplatelet Trialists Collaboration, in an analysis of various trials involving about 800 patients after coronary angioplasty, found that allocation to 6 months of antiplatelet therapy, usually consisting of aspirin and dipyridamole, reduced the occurrence of coronary occlusion by only 4% in patients (p ⫽ 0.02).5 Other clinical trials in the literature have not shown that the addition of dipyridamole to aspirin achieves any benefit in preventing restenosis. As a result of the failure of aspirin and dipyridamole to reduce restenosis rates, attention was directed to other mechanisms, such as the selective blockade of TXA2 receptors, inhibition of thromboxane synthetase and supplementation of prostacyclin. Selective blockade of the TXA2 receptor blunts the effects of TXA2 and also blocks some intermediaries, including prostaglandins G2 and H2, which also activate the TXA2 receptor. In the Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism (CARPORT) trial, 697 postPTCA patients were randomized to receive vapiprost (a thromboxane receptor antagonist) or placebo, both in combination with aspirin.6 It was a well-designed, multicenter, randomized, double-blind, placebo-controlled trial
ANTIPLATELET AND ANTITHROMBOTIC AGENTS
Arachidonic acid Cyclooxygenase
Aspirin NSAIDs
Prostaglandin G2 Peroxidase Thromboxane synthase inhibitors
Prostaglandin H2
Prostacyclin synthase
Thromboxane synthase
Thromboxane A2
TXA2 receptor
Prostacyclin
Prostacyclin analogs
TXA2 receptor blocker
Figure 7.1 Formation of thromboxane A2 (TXA2) from arachidonic acid metabolism and mechanism of action of various antiplatelet agents. Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) inhibit cyclooxygenase. Thromboxane synthase inhibitors block conversion of prostaglandin H2 to TXA2, leading to increased formation of prostacyclin which prevents platelet aggregation and is a vasodilator. TXA2 receptor blockers reduce platelet aggregation and also block effects of prostaglandin H2 on platelets. Prostacyclin analogs are vasodilators and inhibit platelet aggregation induced by thrombin, collagen, and platelet activation factor. Adapted from Oates JA, Fitzgerald GA, Branch RA et al. Clinical implications of prostaglandins and thromboxane A2 formation. N Engl J Med 1988; 319:689–698.2
with a 6-month follow-up, including clinical evaluation, exercise test and quantitative angiography. However, it failed to show any difference in restenosis or clinical outcome between the treatment groups. The GRASP (Glaxo Restenosis and Symptoms Project) study, using long-term vapiprost therapy in 1192 patients after PTCA, showed a 21% reduction in ischemic clinical events at 6
months, especially MI and the need for repeat PTCA (p ⫽ 0.02), but did not provide information regarding angiographic restenosis.7 The Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) sought to determine the effect of solutroban, a TXA2 receptor inhibitor, relative to aspirin and to placebo. Seven hundred and fifty-two patients were randomized and followed-up
99
PHARMACOLOGICAL APPROACHES TO PREVENT RESTENOSIS
clinically and angiographically for 6 months. The results showed that neither aspirin nor solutroban differed from placebo in reducing the rate of angiographic restenosis.8 Thus, TXA2 receptor antagonists have not been conclusively shown to reduce angiographic restenosis. Prostacyclin is a vasodilator produced by endothelial cells. It has effects opposite to that of TXA2 and prevents platelet activation and aggregation. Some studies indicate that endothelial prostacyclin production may be deficient in cases of restenosis. Therefore, various investigators have considered pharmacologic supplementation of prostacyclin for restenosis prevention. Knudtson et al evaluated the short-term use of prostacyclin in a randomized clinical trial of 286 patients and failed to show a statistically significant difference between the drug and placebo in preventing angiographic restenosis.9 Similarly, Gershlick et al, in a randomized, placebo controlled trial of 135 patients, found that epoprostanol (prostacyclin PGI2), was unable to inhibit platelet aggregation or significantly reduce angiographic restenosis at 6-month follow-up after PTCA.10 In another randomized trial involving 311 patients, ciprostene, a stable analog of prostacyclin, was found to reduce clinical markers of restenosis (repeat PTCA, coronary bypass surgery, MI, or death) (p ⫽ 0.004). Angiograms of 86% of the patients who completed the protocol were retrospectively analysed, and confirmed reduction in angiographic restenosis (p ⫽ 0.025).11 However, larger trials with prospective angiographic follow-up are required to evaluate the efficacy of ciprostene. Omega-3 fatty acids, which have been extensively studied, act by inhibiting TXA2 production and inhibiting leukotriene formation by competitively interfering with arachidonic acid metabolism. They also have the
100
beneficial effects of reduction of triglyceri